Adenoviral gene therapy combined with (selective) chemotherapy for the treatment of cancer by Oosterhoff, D.
  
 
Adenoviral gene therapy combined with 
(selective) chemotherapy for the 
treatment of cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dinja Oosterhoff 
 The research described in this thesis was performed within the framework of 
the Oncology Graduate School Amsterdam (OOA) at the Department of 
Medical Oncology (head: prof.dr G. Giaccone), VU University Medical Center, 
Amsterdam, The Netherlands. The research was financially supported by an 
educational grant from Aventis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publication of this thesis was financially supported by Ortho-Biotech, Pfizer B.V. 
and the Oosterhoff support group. 
 
 
Cover: Staining of carboxylesterase-2 in colon cancer cells infected with the 
conditionally replicating adenovirus Ad.∆24.E3-sCE2. Photo: G.L. Scheffer, 
R.R. Otsen. 
 
 
 
Printed by Ponsen en Looijen, Wageningen 
 
ISBN: 90-9019423-1 
 
 Copyright by Dinja Oosterhoff, 2005 
  
 
 
 
 
 
VRIJE UNIVERSITEIT 
 
 
 
 
 
Adenoviral gene therapy combined with (selective) 
chemotherapy for the treatment of cancer 
 
 
 
 
 
 
ACADEMISCH PROEFSCHRIFT 
 
ter verkrijging van de graad van doctor aan 
de Vrije Universiteit Amsterdam, 
op gezag van de rector magnificus 
prof.dr.T.Sminia, 
in het openbaar te verdedigen 
ten overstaan van de promotiecommissie 
van de faculteit der Geneeskunde 
op vrijdag 17 juni 2005 om 13.45 uur 
in de aula van de universiteit, 
De Boelelaan 1105 
 
 
 
door 
 
 
Dinja Oosterhoff 
 
geboren te ’s-Gravenhage 
 
 
 promotor:  prof.dr. H.M. Pinedo 
copromotoren:   dr. W.R. Gerritsen 
   dr. V.W. van Beusechem 
 Der Blick des Forschers fand nicht selten mehr, als er zu 
finden wünschte. 
 
Gotthold Ephraim Lessing (1729-1781) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
voor mijn ouders 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CONTENTS 
 
 
Chapter 1 General introduction          9 
  Partly published in Journal of Experimental Therapeutics 
  and Oncology 2004, 4: 37-57 
 
 
Chapter 2 Secreted and tumor targeted human carboxylesterase    61 
for activation of irinotecan 
British Journal of Cancer 2002, 87: 659-665 
 
    
Chapter 3 Adenoviral vector mediated expression of a gene    75 
  encoding secreted, EpCAM targeted carboxylesterase-2  
sensitizes colon cancer spheroids to CPT-11 
British Journal of Cancer 2005, 92: 882-887 
 
 
Chapter 4 Gene-Directed Enzyme Prodrug Therapy for     87 
  Osteosarcoma: sensitization to CPT-11 in vitro and  
in vivo by adenoviral delivery of a gene encoding  
secreted carboxylesterase-2 
  Molecular Cancer Therapeutics 2003: 765-771 
 
Chapter 5 Gene-Directed Enzyme Prodrug Therapy with  103 
carboxylesterase enhances the efficacy of the  
conditionally replicating adenovirus Ad∆24  
Gene Therapy, advance online publication, 2005 
 
 
Chapter 6 The conditionally replicative adenovirus Ad∆24-p53      119
  and oxaliplatin act synergistically against colon  
carcinoma 
 
 
Chapter 7 Summary and future perspectives           131 
 
 
Chapter 8 Samenvatting voor niet-wetenschappers            143 
 
     
Dankwoord                             149 
 
 
Curriculum Vitae                                      153 
  
 
 
 
 
 
 
Chapter 1 
 
 
General introduction  
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Partly published in Journal of Experimental Therapeutics 
and Oncology 2004, 4: 37-57 
Chapter 1 
 10 
General introduction 
 11
INTRODUCTION 
 
Cancer is the second most common cause of death in the Western world. In the year 
2000, in the Netherlands 69000 cases of cancer were diagnosed, of which 35500 in males 
and 33500 in females. Because 10 percent of the cases were diagnosed in patients 
already known to have some form of cancer, the number of new cancer patients 
approximated 62000. In the same year, 38000 patients died of cancer, which is more than 
25% of the total number of deaths. The most common type of cancer was breast cancer, 
followed by colorectal cancer (13 percent of all cases in both sexes), lung cancer and 
prostate cancer. In this thesis, the main focus will be on colorectal cancer. Approximately 
30% of all patients with colorectal cancer have metastatic disease at diagnosis, and 50% 
of early-stage patients will eventually develop metastatic or advanced disease.  
The paucity of effective agents in the treatment of colorectal cancer in the past 
resulted in extensive investigation of 5-fluorouracil (5-FU) and 5-FU-based combinations. 
This agent has been developed in many different schedules of administration. Modulation 
of 5-FU anticancer effects with leucovorin became one of the standard treatment regimens 
for metastatic colorectal cancer. Additional pharmacological strategies to enhance the 
effectiveness of 5-FU included combination therapy with methotrexate, cisplatin, N-
[phosphonacetyl)-L-aspartic acid (PALA) and interferon. Despite these attempts, no 
survival advantage was established until the development of the newer cytotoxic drugs 
CPT-11 and oxaliplatin.  
Chemotherapy with cytotoxic drugs has demonstrated to be effective in prolonging 
survival and time to disease progression in patients with metastatic colorectal cancer 1. 
Additionally, improvement in convenience of drug administration has been achieved with 
the development of oral fluoropyrimidines for the treatment of metastatic colorectal cancer. 
However, the success of chemotherapy is still limited by several drawbacks, including 
insufficient drug concentrations in the tumor, systemic toxicity, lack of selectivity for tumor 
cells over normal cells, and the appearance of drug-resistant tumor cells. A number of 
strategies have been used to overcome these problems, including alternative formulations, 
resistance modulation, toxicity modifiers and gene therapy.   
Gene therapy involves the insertion of a gene into somatic cells in a way that 
sufficient quantities of the therapeutic gene will be expressed. The basic concept of human 
gene therapy has a history of more than 30 years 2. Since the early days of recombinant 
DNA technology, the introduction of foreign DNA for therapeutic intervention has been a 
major goal and this has led to the development of a variety of gene therapy strategies.  
One promising area for improving tumor selectivity using an gene therapy strategy 
is Gene-Directed Enzyme Prodrug Therapy (GDEPT). GDEPT, also known as suicide 
gene therapy, is a two-step approach. In the first step, a gene encoding a drug-activating 
enzyme is expressed specifically in tumor cells. In the second step, a non-toxic prodrug, a 
substrate of the enzyme that is now expressed in the tumors, is administered to the 
patient. The net gain is that a systemically administered prodrug can be converted to high 
local concentrations of an active anticancer drug in the tumor, resulting in increased 
efficacy of the chemotherapeutic drug while decreasing the side effects of the drug. To be 
successful, both enzymes and prodrugs should meet certain requirements for this 
strategy. The enzyme should be a protein that is only expressed in low concentrations in 
human tissues so that without GDEPT the majority of prodrug is not converted into the 
toxic drug. The protein must achieve sufficient expression in the tumors and have high 
catalytic activity. The prodrug should be a good substrate for the expressed enzyme in 
tumors, but should not be activated by endogenous enzymes in normal human tissues. In 
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case the prodrug-converting enzyme is an intracellular enzyme, the prodrug should be 
able to cross the tumor cell membrane for intracellular activation, and the cytotoxicity 
differential between the prodrug and its corresponding activated drug should be as high as 
possible.  
The disadvantage of this approach is that the prodrug-converting enzyme will not be 
localized throughout a solid tumor mass. Up to date, the transduction efficiency of all 
available vector systems is inadequate. Vector tropism and the high pressure and limited 
blood supply in the central region of a tumor hamper efficient transduction of all tumor 
cells. Therefore, clinically successful GDEPT relies heavily on the so-called bystander 
effect, which will increase the anti-tumor effect. The bystander effect, initially described by 
Moolten et al. 3 can be defined as an extension of the killing effects of the active drug to 
untransfected, neighboring cells.  This implies that even if only a small percentage of the 
target cells are genetically modified and express the therapeutic gene, tumor eradication 
may still be achieved.  The bystander effect is crucial for a successful GDEPT strategy, 
since with the protocols currently adopted in clinical trials, the transfection efficiency is 
unlikely to be greater than 10%. A bystander effect can be achieved via two ways. First of 
all, it might be achieved by diffusion of the active drug to adjacent non-expressing tumor 
cells. Secondly, one can increase the bystander effect by secretion of the prodrug 
converting enzyme from transduced tumor cells, so that the enzyme can penetrate through 
a solid tumor mass. If hereafter the prodrug is administered, it will be activated 
extracellularly throughout the tumor, leading to toxicity to untransduced neighboring cells. 
To prevent leakage of the secreted enzyme into the circulation that could lead to unwanted 
side effects, the secreted enzyme could be targeted to tumor antigens (Figure 1). 
Evidence in animal models suggests that a systemic immune response may also play an 
important role in inducing bystander killing 4. The presence of an intense inflammatory 
infiltrate has been described in regressing tumors of immunocompetent animals treated 
with GDEPT systems 5-9. 
In this Introduction chapter, replication deficient as well as conditionally replication 
competent adenoviral vectors as vehicles to deliver therapeutic genes to tumor cells will 
be discussed. Furthermore, GDEPT with different enzyme prodrug models will be 
discussed, where the focus is on the use of GDEPT with the enzyme carboxylesterase 
(CE) for tumor specific conversion of the prodrug CPT-11 for the treatment of colorectal 
cancer.   
General introduction 
 13
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic presentation of GDEPT with a gene encoding a secreted, tumor targeted 
enzyme. This gene is cloned into an adenoviral vector that is used to infect tumor cells. The 
infected cells will express and secrete the fusion protein. The secreted fusion protein will diffuse 
through the tumor and will bind to antigen expressing neighboring cells. If hereafter the non-toxic 
prodrug is administered, it will be converted to the active drug extracellularly, after which the 
generated drug can further diffuse through a tumor and kill the tumor cells. 
 
 
GENE-DIRECTED ENZYME PRODRUG THERAPY (GDEPT) 
 
GDEPT with thymidine kinase to activate ganciclovir 
Many GDEPT systems have been described in the past decade. The most extensively 
studied enzyme prodrug models are the herpes simplex virus thymidine kinase 
(TK)/Ganciclovir (GCV) and the cytosine deaminase (CD)/5-fluorocytosine (5-FC) 
combinations. GCV is an antiviral drug that is phosphorylated by TK and then by cellular 
kinases to produce GCV triphosphate, which disrupts DNA synthesis during S-phase, 
leading to cell death. In the last 15 years, more than 600 papers have discussed the 
potentiality of TK/GCV for cancer gene therapy. Preclinical studies using adeno- and 
retroviral vectors were performed in many different animal models and successful results 
were reported for established rodent liver metastases 5, murine hepatocellular carcinomas 
9, rodent glioblastomas 10, human head and neck carcinomas 11, human mesotheliomas 12 
and several other tumor types. One of the main drawbacks of this enzyme prodrug model 
is that the highly charged triphosphate is insoluble in lipid membranes. This impairs the 
diffusion of the drug and makes cell-to-cell contacts necessary for bystander killing. 
Nevertheless, preclinical studies showed that tumor regression could be achieved when 
only 10% of the tumor cells expressed TK 5,13. This phenomenon has been proposed to 
result from transfer of activated GCV through gap junctions 14-17 or exchange of apoptotic 
vehicles 13,18. It is likely that a major part of the in vivo bystander killing is mediated by the 
host immune system. TK/GCV treatment resulted in infiltration of CD4+ and CD8+ T-cells 
and macrophages as well as increased expression of cytokines 6,19. An immune-related 
anti-tumor response could also account for the ‘distant bystander effect’. GCV treatment of 
head and neck squamous cell carcinoma xenografts in nude mice resulted not only in the 
eradication of TK expressing tumors, but also in delayed regression of untransduced 
tumors in the contra-lateral flanks 20, which was abrogated in SCID mice. 
Prodrug Drug
Adenoviral vector
Tumor cell
Fusion protein
Tumor antigen
Chapter 1 
 14 
On the basis of many animal studies, the first gene therapy trials using TK/GCV to 
treat ovarian cancer was approved in 1991, and since then several other clinical studies 
have been undertaken. An overview of clinical trials performed with GDEPT is shown in 
table 1. With TK and GCV, gene therapy trials of brain tumors 21-27, metastatic melanoma 28 
and prostate carcinoma 29,30 have been performed. Delivery of the gene has been done by 
injecting TK-containing replication deficient adenoviruses or retroviral vector-producing 
cells. In these phase I clinical trials, only moderate toxic events were reported, which were 
mostly resolved at the termination of the therapy. Moderate therapeutic responses were 
observed in some of the patients. In a phase I/II study for recurrent glioblastoma, injection 
of retroviral producing cells in the surgical cavity margins after tumor debulking followed by 
intravenous GCV resulted in the absence of recurrence in four of 12 patients at four 
months and in one patient at 2.8 years after treatment 26. Relatively poor responses could 
be due to insufficient gene transfer and limited distribution within the tumor mass.  
There are numerous ways of ameliorating treatment efficacy, notably through the 
improvement of gene delivery and a better understanding of the molecular mechanism of 
the bystander effect. Significant benefits could also arise from the introduction of new 
nucleoside analogues with a higher affinity for TK and fewer side effects than GCV 31-34 and 
of TK mutants engineered to increase specificity and activity towards the prodrug 35,36.  
 
 
GDEPT using cytosine deaminase to activate 5-FC 
The system consisting of CD and 5-FC is based on the production of a toxic nucleotide 
analogue. The enzyme CD is found in certain bacteria and fungi, but not in mammalian 
cells, and catalyzes the hydrolytic deamination of cytosine to uracil. It can therefore 
convert the non-toxic prodrug 5-FC into 5-fluorouracil (5-FU), which is then transformed by 
cellular enzymes to potent pyrimidine antimetabolites. 5-FU is widely used in cancer 
chemotherapy and is a drug often given to patients with colorectal cancer. Administration 
of 5-FU causes a lot of side effects and high dose levels are required for tumor response. 
The CD gene used for GDEPT has been cloned from Escherichia coli 37 and has been 
shown in a number of in vitro studies to enhance mammalian cell sensitivity to 5-FC up to 
2000 fold 37,38. In vivo anti-tumor activity has been demonstrated in several animal models, 
including fibrosarcomas 39, carcinomas 40-43, gliomas 44 and metastatic lesions of different 
origin 7,45. One of the main advantages of CD/5-FC enzyme prodrug therapy is that no cell-
to-cell contact is required for the bystander effect, since 5-FU can diffuse in and out cells 
by non-facilitated diffusion. Experiments conducted in vitro demonstrated that 1-30% of 
cells expressing CD could generate sufficient 5-FU to completely inhibit growth of all cells 
41,44. 
A phase I trial involving local injection of a plasmid containing the CD gene, 
regulated by the tumor selective erbB-2 promoter and systemic 5-FC administration in 
breast cancer patients demonstrated the safety of this approach 46. In 11 of 12 patients CD 
expression was demonstrated, whereas in 4 patients tumor regression was observed, 
whereas two of them did not even receive the prodrug.  
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Table 1: Clinical trials with GDEPT 
 
Prodrug system Tumor type        Phase  Description   
    
TK/GCV Malignant glioma  Ι  replication deficient adenovirus,
      intratumoral injection 22,47  
     
Malignant brain tumors Ι-ΙΙ  retroviral vector producer cells,
       intracerebral injection 21,23-27,48
  
 
Malignant glioma  ΙΙΙ  replication deficient retrovirus,
       intratumoral injection 49  
  
Prostate cancer  Ι  replication deficient adenovirus,
     intraprostatic injection 29,50 
  
   Prostate cancer  Ι-ΙΙ  replication deficient adenovirus,
         combined with radiotherapy and  
hormonal therapy 51,52 
      
   Hepatic metastases  Ι  replication deficient adenovirus,
   from colorectal cancer   intratumoral injection 53  
 
    
   Metastatic melanoma  Ι-ΙΙ  retroviral vector producer cells,
         injected in tumor nodules 28 
    
Mesothelioma   Ι  replication deficient adenovirus,
       intratumoral injection, combined
       with corticosteroids 54,55 
      
CD/5-FC  Breast cancer   Ι  plasmid construct, CD driven by  
the Erb-2 promoter, intratumoral 
injection 46 
  
Hepatic metastases  Ι  replication deficient adenovirus, 
from colorectal cancer   intratumoral injection 56 
 
CD/5-FC +TK/GCV Prostate cancer  Ι  replication competent  
adenovirus, intraprostatic 
injection 57   
 
Ntr/CB1954  Liver tumor or colon  Ι  replication deficient adenovirus,
   metastases in liver    intratumoral injection 58 
      
Chapter 1 
 16 
Specific gene expression and prodrug activation offers the possibility of combining 
Gene-Directed Enzyme Prodrug Strategy systems to enhance the antitumor activity of the 
single treatments without increasing systemic toxicity. Delivery of the CD-HSV-TK fusion 
gene followed by GCV and 5-FC treatment sensitized gliosarcoma, mammary carcinoma 
and prostate tumor cells to the prodrugs 59-62. The combination of these two suicide genes 
has also been shown to sensitize the tumor cells to irradiation 61,63. 
  
 
Enzyme prodrug therapy with CE and CPT-11 
A last enzyme prodrug model that will be discussed is the use of the enzyme CE to 
activate the prodrug CPT-11. The prodrug and the prodrug-converting enzyme will each 
be discussed in more detail in the following sections. 
 
 
CPT-11 
CPT-11 (irinotecan or 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) 
is a water-soluble semi-synthetic derivative of the natural alkaloid camptothecin, a 
relatively new anti-neoplastic agent. Camptothecin was originally isolated from the 
Chinese/Tibetan ornamental tree Camptotheca acuminata, commonly known as the 
‘Chinese tree of joy’. CPT-11, of which the molecular structure is shown in figure 2, was 
first discovered and synthesized in Japan in 1983 and is a chemotherapeutic agent that 
causes S-phase-specific cell killing by inhibition of topoisomerase I (topo I) in the cell. 
Topoisomerase I relaxes supercoils of DNA arising during DNA replication and 
transcription and repair recombination 64. The mechanism of action of topo I can be divided 
into several steps. First, the enzyme binds to the double stranded DNA. Subsequently, the 
enzyme cleaves and reseals the phosphodiester backbone of DNA, which allows passage 
of another singe-or double stranded DNA through the nicked DNA. Finally, the cleaved 
DNA strand is ligated for subsequent replication or transcription. CPT-11 act by binding 
non-covalently to the DNA-Topo I cleavable complex and interferes with DNA religation. 
Probably, CPT-11 interacts with both the enzyme and the DNA, resulting in stabilization of 
the cleavable complex and accumulation of single-strand breaks in the DNA. These single 
strand breaks are by themselves not sufficient to cause cell death. However, upon their 
collisions with the advancing replication forks, the formation of a double-strand DNA break 
occurs, leading to irreversible arrest of the replication fork and cell death 65. The collision of 
the complex with the replication fork also results in G2 arrest/delay by signaling the 
presence of DNA damage to an S-phase checkpoint mechanism 66. At higher 
concentrations of CPT-11, non S-phase cells can also be killed. The mechanism of non-S-
phase cell killing appears to be related to transcriptionally mediated DNA damage and 
through apoptosis 67.  
CPT-11 has demonstrated anti-tumor activity in immune deprived animals bearing 
human tumor xenografts and is approved for use in the treatment of metastatic colorectal 
cancer in humans 68-74. Furthermore, CPT-11 is currently being tested for its efficacy in a 
wide range of tumors, including non-small-cell lung cancer, rhabdomyosarcoma and 
neuroblastoma. Initial approval in the United States was as second-line treatment for 
metastatic colorectal cancer 75 and more recently it has been approved for use in 
combination with 5-FU/Leucovorin as a first-line treatment for this disease 76,77. Likewise, 
phase II studies on advanced esophageal and gastric cancer showed encouragingly high 
response rates 78. The major toxicities of CPT-11 in clinical use are myelosuppression and 
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diarrhea. The drug can cause either acute diarrhea or a delayed diarrhea syndrome, which 
is possibly related to the accumulation of the active metabolite of CPT-11 in the bowel 79. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Molecular structure of the prodrug CPT-11 that can be converted into the active drug 
SN-38 by the enzyme carboxylesterase 
 
 
CPT-11 is a prodrug since it needs to be activated to the drug SN-38 (7-ethyl-10-
hydroxycamptothecin) by cleavage of the bulky dipiperidino side chain at the carbon 
position 80,81 and this conversion mainly takes place in the liver and the small intestine. 
CPT-11 undergoes extensive hepatic metabolism as shown in figure 3. Two major human 
liver CEs, CE1 and CE2 82 can hydrolyze CPT-11 to generate the active drug SN-38. 
Oxidative metabolism of CPT-11 by cytochrome P450 isoenzymes results in formation of 
two major metabolites, APC (7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] 
carbonyloxycamptothecin) and NPC (7-ethyl-10-[4-(1-piperidino)-1-amino] 
carbonyloxycamptothecin) 83,84. In vitro studies have demonstrated that among the 
cytochrome P450 enzymes, only CYP3A4 can oxidize CPT-11 to APC or NPC 85. SN-38 is 
inactivated by glucuronidation to form SN-38 glucuronide (SN-38G). Several uridine 
diphosphate glucuronysyltransferase (UGT) isoforms were studied, and UGT1A1 was 
found to be at least 10 times more active than other isoforms 86. In vitro studies 
demonstrate that NPC as well as APC can be metabolized by CE to produce SN-38 83,87. 
Butyrylcholinesterases can also convert CPT-11 to SN-38, although the exact contribution 
that these enzymes play in drug metabolism remains unclear 88. 
N
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Figure 3: Schematic presentation of the metabolism of CPT-11. CPT-11 is oxidized by CYP3A4 to 
form APC and NPC. NPC, APC and CPT-11 are metabolized by CEs to form SN-38. SN-38 is 
inactivated by UGT1A to SN-38 glucuronide. 
 
 
Following intravenous administration of CPT-11 to humans, low concentrations of 
SN-38 are observed in the plasma of patients 89, ranging from 1% to about 5% prodrug 
converted to the active drug for most schedules of administration. One study further 
demonstrated that the percentage of CPT-11 converted to SN-38 decreased as the drug 
dose increased, indicating limited availability of the enzyme responsible for this 
conversion. Thus, increasing the dose of CPT-11 does not lead to an additional 
therapeutic benefit 90. In light of the curative potential of CPT-11 when sufficient plasma 
levels can be reached 72, the potential for tumor specific expression of active CEs to 
increase SN-38 levels in tumor cells and dramatically increase the therapeutic index merits 
further investigation. 
 
 
Carboxylesterases 
CEs belong to a large family of serine-active hydrolases with a 60 kDa subunit mass and 
have a characteristic β-α-β esterase fold and catalytic acid. Humans express CEs in the 
liver 91,92, plasma 93, small intestine 94, brain 92,95, stomach 95,96, colon 95, macrophages 97 and 
monocytes 98. CEs are classified in four major groups by amino acid sequence alignment 
99, CES1, CES2, CES3 and CES4, and several subgroups. In general, CEs exhibit about 
80% sequence identity within a CES group. All the isoenzymes are responsible for the 
hydrolysis of many exogenous compounds, the consequences of which include both 
inactivation of drugs and activation of prodrugs. Human liver CE activates the prodrugs 
CPT-11 and lovostatin 100 and conversion of a prodrug of prostaglandin F2α has been 
reported 101. A significant number of drugs and endogenous compounds are substrates of 
CEs, including dipivefrin hydrochloride 102, carbonates 103, cocaine 104, haloperidol 105 and 
steroids 95. The most abundant and well-studied human enzymes are CE1 (GI: 119576) 
and CE2 (GI: 4504565) that belong to classes CES1 and CES2 respectively. The mRNA 
of both isoforms is highly expressed in liver. Both CE1 and CE2 are also expressed in 
colon, heart, intestine, testis and kidney tissue. The implications for drug metabolism are 
that both enzymes are important for systemic clearance of esters from blood through the 
liver. Since CE1 is more abundantly expressed in the kidneys it seems to have a more 
pronounced role than CE2 in clearance via the kidney, whereas CE2 is more important 
than CE1 for clearance of orally administered drugs through the small intestine and colon. 
CPT-11
SN-38
NPC APC
CE
CE
CYP3A4 CYP3A4
SN-38-glucuronide
UGT1A
CE
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Although substrate specificity of these isoenzymes is overlapping, they do show substrate 
preference 106. Human CE1 prefers substrates with a smaller alcohol moiety and larger 
acyl substitutes such as meperidine or methylphenidate, whereas CE2 prefers large 
alcohol and small acyl moieties such as CPT-11 or heroin. The N-terminus of nascent CE2 
contains a 19-residue signal peptide that directs the protein to the endoplasmatic reticulum 
107. These amino acids are, however, not present in the mature protein. The four C-terminal 
amino acids HXEL, of which the X can be any amino acid, anchor the protein within the 
endoplasmatic reticulum. Deletion of these amino acids results in secretion of the enzyme 
from the cell. The secreted enzyme is functional, catalyzing the metabolism of both simple 
and complex CE substrates 108.                   
 
 
GDEPT with CE/CPT-11 
Three different CEs have been studied in the context of selective activation of CPT-11, i.e. 
human liver CE1 and CE2 and rabbit CE (rCE). In context of conversion of CPT-11, CE2 
has a 64-fold higher catalytic efficiency than CE1 82. This was unexpected, because until 
today rCE is the most efficient CPT-11 converting enzyme, and CE1 demonstrated to have 
greater than 81% similarity to rabbit CE, whereas CE2 only shares about 40% homology. 
In in vitro assays, the IC50 values for CPT-11 in human tumor cell lines expressing rCE 
were 8-80 fold lower than for plasmid-transfected control cells 109-112. Similar to the results 
obtained with cell lines, stably rCE expressing human tumor xenografts were sensitized to 
CPT-11, since complete, long-term regression was observed following administration of 
CPT-11 to xenograft bearing mice 112.  
Several studies have been performed using CPT-11 in combination with different 
CEs in a GDEPT approach. Kojima et al. described the construction of a replication 
deficient adenoviral vector containing the human liver CE1 gene driven by the CMV 
promoter 113,114. In vitro results showed that several tumor cell lines infected with this virus 
express CE1 and in the presence of CPT-11 tumor growth was effectively suppressed. 
However, on many other tumor cell lines only minimal effects were observed. This 
underscored the notice that the success of a GDEPT approach for CPT-11 requires an 
enzyme with a high efficiency of converting CPT-11 to SN-38. rCE was found to be 100-
1000 fold more efficient in converting CPT-11 than human liver CE1 and was 12-55 fold 
more efficient in sensitizing transfected cells to CPT-11 112. Therefore, an adenoviral vector 
expressing rCE was constructed and transduction of human tumor cells led to sensitization 
to CPT-11 115. This virus, Ad-rCE, has been used for the selective eradication, or purging, 
of neuroblastoma cells from bone marrow or peripheral stem cells autologous stem cell 
rescue. Ad-rCE showed to selectively transduce tumor cells in mixtures of 
hematopoietic/neuroblastoma cells. Administration of CPT-11 subsequently, resulted in 
cytotoxicity specifically to neuroblastoma cells. For GDEPT applications of solid tumors, 
however, the disadvantage of rCE is that expression of a nonhuman protein in patients 
may lead to an immunological response and subsequent enzyme inactivation. A human 
enzyme with higher affinity and higher efficiency than CE1 may overcome these 
limitations. Since it was shown that human CE2 has a higher affinity and a higher 
conversion velocity for CPT-11 than CE1 82, in this thesis we investigated if CE2 could be a 
candidate to employ in a GDEPT approach to treat human colon caner tumors. 
As stated previously, to achieve efficient kill of all tumor cells, a bystander effect is 
required, whereby CPT-11 is cleaved to SN-38 that not only kills the tumor cells in which 
CE is formed, but also neighboring tumor cells that do not express CE. Although SN-38 is 
able to freely pass the cell membrane and might thus exert cytotoxic effects on 
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neighboring cells, we hypothesized that extracellular conversion of CPT-11 would lead to 
an increased bystander effect compared to intracellular prodrug conversion. A 
disadvantage of a secreted enzyme, however, might be that the enzyme is capable of 
leaking away from the transduced tumor cells into the circulation, resulting in conversion of 
prodrug outside of the tumor area and thus negatively affecting tumor selectivity of 
GDEPT. A way to prevent leakage of the enzyme from the tumor may be secretion of a 
fusion protein consisting of an scFv antibody and CE by transduced tumor cells. Such a 
fusion protein will bind specifically to tumor cells, thereby preventing leakage into the 
circulation and reducing the chance that side effects occur. 
 
 
A TARGET MOLECULE FOR THE FUSION PROTEIN: EPITHELIAL CELL 
ADHESION MOLECULE 
 
In order to achieve the highest specificity of enzyme prodrug therapy one could target the 
prodrug-converting enzyme specifically to tumor cells by constructing fusion proteins 
consisting of the enzyme and the binding part of an antibody. Like the prodrug converting 
enzyme, the target antigen and the targeting antibody must meet certain requirements. 
First, the target antigen should be expressed preferentially on tumor cells. In the most 
optimal situation, healthy cells do not express the target antigen whereas it is highly 
expressed in tumor cells. The antigen should be localized on the tumor cell surface or 
should be secreted into the extracellular matrix of the tumor, but no shedding in the blood 
should occur. An example of an interesting tumor antigen meeting these requirements is 
the Epithelial Cell Adhesion Molecule (EpCAM). 
EpCAM has first been identified as a tumor-specific antigen on several carcinomas 
of different origin. Several independent studies generated different antibodies against this 
tumor specific molecule expressed on carcinomas. Because the c-DNA has been 
independently cloned by a number of groups 116-119, the molecule is known by many 
different names, i.e., the human pan-antigen epithelial glycoprotein EGP40, CO-171A 
antigen, KSA1/4, ESA, GA733-2, MOC31 and so forth. In the early 1990s, the reports on 
the carcinoma antigens were combined and it became clear that the described molecules 
were virtually identical. 
EpCAM is a type I transmembrane glycoprotein and consists of an extracellular 
domain containing two epidermal growth factor-like repeats and a short intracellular 
domain of 26 amino acids in which 2 binding sites for α-actinin are present for linkage to 
the cytoskeleton 120. It is a relatively small protein that is highly conserved during evolution 
and mediates calcium-independent homotypic cell-cell adhesions. Studies in murine 
fibroblasts transfected with EpCAM revealed that the molecule is associated with 
proliferation 121,122. Upon (over)expression of EpCAM, cadherin associations dissociate, 
which leads to accumulation of detergent soluble E-cadherin/β-catenin complexes, and to 
a decrease in total cellular α-catenin 123. This suggests that during cell division, the strong 
tight E-cadherin mediated cellular adhesion is abrogated, while the weaker intercellular 
adhesion mediated by EpCAM still holds the cell in place 124. After the proliferative phase, 
EpCAM expression declines and higher levels of E-cadherin mediate intercellular 
adhesions and direct cellular differentiation. 
EpCAM is normally expressed at low levels at the basolateral membrane of the 
majority of epithelial tissues, except in adult squamous epithelium and some specific 
epithelial cell types, such as hepatocytes. Overexpression of EpCAM, as well as de novo 
expression was observed in colon carcinoma and in squamous carcinoma of the uterine 
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cervix 125,126. Immunohistochemical staining of dysplastic colon cells showed 
overexpression of EpCAM not only on the basolateral membrane, but apical staining was 
observed as well. The association of EpCAM expression with metastases is less clear. 
One would expect to find higher EpCAM expression in metastasized cells, because these 
cells are more likely to escape the epithelium than well-differentiated cells anchored by E-
cadherin mediated junctions. Momburg et al. demonstrated that micrometastasis 
originating from carcinomas could be detected with EpCAM antibodies 127. However, in 
nodal metastasis originating from head and neck squamous carcinomas, EpCAM 
expression was found to be reduced compared to the primary tumor 128. In contrast, 
Chaubal et al. concluded that EpCAM gene expression could be used as a tool to identify 
disseminated tumor cells 129,130. 
This overexpression offers possibilities to target EpCAM for cancer immunotherapy 
or adenoviral gene therapy. Colorectal cancer has been targeted with the monoclonal 
antibody CO17-1A and anti-idiotypic antibodies mimicking the CO17-1A epitope. An 
improved survival was accompanied by a prolonged systemic immune reaction to the 
antibody 131. Presently, its anti-tumor effect is being studied as monotherapy after resection 
of stage II colon cancer, and in combination with chemotherapy in patients with stage II or 
III rectal cancer 132. Patients with resected Dukes’ C colorectal carcinoma were treated with 
monotherapy in an adjuvant setting with edrecolomab, the murine monoclonal antibody 
that binds with low affinity to EpCAM 133. This study showed that the antibody administered 
after surgery prevented the development of distant metastasis in approximately one-third 
of patients. The therapeutic effect was maintained after 7 years of follow-up.  
EpCAM antibodies have also been used to target adenoviral vectors specifically to 
tumor cells. By construction of a chemical conjugate or a bispecific scFv antibody that is 
on one side directed to the adenoviral fiber and on the other side to the target antigen 
EpCAM, adenoviruses were retargeted to cancer cells expressing EpCAM 134,135. As well on 
gastric cancer cell lines as on primary gastric cancer cells an improved ratio of tumor 
transduction over normal epithelium transduction was accomplished by the EpCAM 
targeted vectors 136. All these studies demonstrate that EpCAM is a very interesting protein 
to target newly developed anti-cancer strategies specifically to tumor cells.  
 
 
ADENOVIRUSES 
 
Adenoviruses (Ads), belonging to the family Adenoviridae, were first cultured and reported 
as unique viral agents in 1953 137. Ads are associated with the common cold and they 
cause respiratory, intestinal and eye infections in humans. There are more than 50 distinct 
human Ad serotypes and of these, types 2 and 5 have been extensively characterized and 
have served as valuable tools for the study of the molecular biology of DNA replication, 
transcription, and protein synthesis in mammalian cells. 
 The Ad particle is non-enveloped and is a regular icosahedron with a diameter of 
70-90 nm. The capsid is composed of 252 capsomeres, with 240 forming the 20 triangular 
facets and 12 forming the 12 vertices. Each capsomere present on the facet is surrounded 
by 6 neighbors and is hence called a hexon  (Figure 4) The 12 vertex capsomeres have 
only 5 neighbors and are called pentons 138. Protruding from each penton is a structure 
called fiber, whose length varies with the serotype. At its distal end, the fiber bulges out to 
form a globular knob domain, which mediates the attachment of the virion to the cellular 
receptor. 
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 The Ad is a DNA virus with a genome consisting of a linear double-stranded DNA 
molecule of approximately 36000 nucleotides and the entire genome sequences are 
known (139, GenBank accession number BK000408). The genome has a virus-coded 
terminal protein at each 5’ end of the linear genome 140 and inverted terminal repeats. The 
genome is functionally divided into two major overlapping regions, early and late, based on 
time of transcription after infection. The region E1 is active immediately upon entry of the 
viral genome into the nucleus and it encodes proteins that regulate all of the other early 
functions 141,142. The E2 region encodes proteins involved directly in adenoviral DNA 
replication, whereas the E3 region encodes proteins involved in reducing the antiviral 
immune response 143 and in effective lysis of the cell after viral replication has completed 
144,145. The E4 region encodes proteins with multiple functions such as control of viral 
replication, DNA replication and shut-off of host protein synthesis, The late genes, initiated 
8-h post infection, encode most of the viral structural proteins, including capsid proteins, 
hexon, penton and fiber, all transcribed from the major late promoter. 
 
  
 
 
Figure 4:  A schematic representation of the adenovirus showing the major proteins of the capsid: 
hexon, fiber and penton. 
 
 
Ad5 enters the cell by attachment of its fibers to the 46-kDa specific cell surface 
receptor coxsackievirus and Ad receptor (CAR) 146. Once bound to the cell surface, the 
virus is internalized via receptor-mediated endocytosis. Receptors that facilitate 
internalization include the integrins αvβ3 and αvβ5. It then migrates within the plasma 
membrane to clathrin-coated pits that form endosomes. After release of the virion, it is 
transported to the nucleus via nuclear targeting signals where the various transcriptional 
regions are expressed. 
 Ads have been widely used to express foreign proteins and to transfer and express 
therapeutic genes. They have a number of advantages in that they have a broad host 
range and can infect proliferating and quiescent cells. Ad genomes do not integrate into 
the host genome, making them safe vectors for mediating transient transgene expression. 
Ad vectors can easily be purified to high titers. With mounting interest in gene therapy, 
many types of Ad vectors have been developed. Most studies performed to date have 
used the first generation (E1 and E3 deleted) or second-generation (E1, E3 and E4 or E2 
deleted) type 5 Ad vector. The use of replication deficient Ad vectors as gene delivery 
vehicles has reached clinical trials.  
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CONDITIONALLY REPLICATING ADENOVIRUSES (CRAds) 
 
Replication-defective Ad gene delivery vectors have so far shown modest anti-tumor 
efficacy because of poor transduction and penetration capacity in solid tumor masses. To 
overcome this limitation, one could use transgenes encoding secreted proteins, but also 
conditionally replicating adenoviruses (CRAds) were developed and explored as novel 
anti-cancer agents. CRAds replicate only in cancer cells and destroy these cells through 
the natural process of adenoviral replication. In addition, the generated progeny viruses 
released from infected and lysed cancer cells may infect neighboring tumor cells. Via 
several rounds of replication and cell lysis, the tumor will ultimately be destroyed. The 
selective replication of CRAds in cancer cells, the prevention of replication in normal cells, 
the efficacy of CRAds in clinical trials and various ways to increase CRAd efficacy will be 
discussed. 
 
 
Mechanisms of selective replication of CRAds in cancer cells 
The replication cycle of adenoviruses consists of an early and a late phase, separated by 
the onset of DNA replication. A major function of the adenoviral early genes is to provoke 
the infected cell to enter cell cycle and progress to S-phase. In the S-phase the virus can 
take advantage of the cellular DNA replication machinery to replicate its own genome 
efficiently. For the induction of cell cycle progression, inactivation of the cellular 
retinoblastoma (pRb) and p53 tumor suppressor proteins is required (illustrated in figure 
5A). These actions are brought about by proteins encoded by the Ad E1 region. The E1A 
gene is the first to be transcribed and encodes proteins that bind members of the cellular 
pRb family 147. This interaction results in release of the pRb bound transcription factor E2F, 
which is then free to activate transcription of E2F-responsive genes, involved in stimulating 
cell cycle progression.  
To circumvent premature cell death during viral replication, the viral E1B-55kD protein 
binds to and inhibits p53, while the E1B-19kD protein functions as a viral homologue of the 
anti-apoptotic factor bcl-2 148-150. The remaining early regions encode proteins involved in 
viral DNA synthesis (E2), modulation of host immune response and cell lysis (E3), and 
regulation of viral gene expression, mRNA transport, DNA replication and apoptosis (E4). 
The late gene products encode viral structural proteins and proteins involved in virion 
assembly. 
CRAds are made by modifying the Ad genome such that essential early functions 
are abrogated in non-malignant cells but not in cancer cells, or by deleting early viral 
functions that are essential for replication in non-malignant cells and are redundant in 
cancer cells.  
 
 
Limiting viral replication by deletions in viral genes  
One approach to restrict viral replication specifically to tumor cells is by introducing genetic 
modifications that abrogate viral functions that are essential for replication in normal cells 
but are redundant in cancer cells. In most cases, this involves deletions in the E1 region 
(Fig. 5B and C).  
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The by far most extensively studied CRAd is the mutant dl1520 (also known as 
ONYX-015) that contains a 827-base pair deletion in the E1B-55kD gene and a point 
mutation at nucleotide 2022, which results in abrogation of E1B-55kD expression (5). One 
of the functions of E1B-55kD is to bind the tumor suppressor protein p53 151,152.  This 
binding inhibits p53 transcriptional activity and promotes the degradation of p53 153. E1B-
55kD expression during the early phase of adenovirus replication temporarily inhibits p53-
induced apoptosis to prevent premature cell death. dl1520 cannot inactivate p53 and the 
Figure 5: Schematic representation of the
interaction between early adenovirus proteins
and host cell proteins during replication of wild
type adenovirus in normal cells (A) and CRAds
carrying deletions in essential genes in normal
cells (B) or in cancer cells (C). (A) E1A binds to
pRb, causing dissociation of E2F. Free E2F
can activate several cell cycle regulatory
genes. This allows S-phase entry and virus
replication in otherwise quiescent cells.
Another function of E1A is to bind p300/CBP.
This increases pRb binding affinity and
decreases p53 transactivation functions.
E1B55kD can bind directly to wild type p53 and
prevents it from inducing apoptosis or cell
cycle arrest. (B) Mutant E1A proteins incapable
of binding pRb cannot induce S-phase and
thus not promote adenoviral replication.
Similarly, in normal cells with functional p53,
p53-binding deficient E1B55kD fails to prevent
induction of apoptosis or cell cycle arrest
leading to impaired viral replication. (C)
Replication of mutant viruses in malignant
cells. The boxes represent cellular pathways
that are frequently dysfunctional in cancer
cells. For example, the Rb pathway is defective
in cancer either through pRb deficiency,
hyperphosphorylation or sequestration. As a
result, E2F is continuously available for
induction of S-phase progression and viral
replication. Therefore, a deletion in the viral
E1A gene that abrogates pRb binding does not
hamper viral replication. The p53 pathway is
also often dysfunctional in tumor cells (p14arf
deficiency, mdm2 amplification, p53 mutation).
Inhibition of p53 by E1B55kD to prevent
premature cell death by p53-induced of
apoptosis is therefore not necessary in cancer
cells.  
General introduction 
 25
virus was therefore expected to replicate only in cells lacking functional p53 154. In most, if 
not all, cancers p53 is dysfunctional. Over 50% of cancers contain an inactivating mutation 
in p53 itself 130, whereas in the remaining cases p53 is efficiently degraded as a 
consequence of p14ARF deficiency, MDM2 amplification or viral protein expression; or p53 
is sequestered in the cytoplasm 155-157. Therefore, dl1520 should be widely applicable in 
cancer therapy. Originally, dl1520 was reported to selectively replicate in and kill cells with 
mutations in the p53 gene 154. Other reports, however, demonstrated a broader utility. For 
example, Heise et al. demonstrated that although normal human cells were highly 
resistant to dl1520, the virus replicated efficiently in numerous carcinoma cell lines with 
either mutant or normal p53 gene sequences 158. Two other reports also showed that the 
ability of dl1520 to replicate efficiently did not correlate with p53 status 159,160. It was later 
shown that dl1520 could replicate in p53 wild type cancer cells with lost p14ARF expression 
and that reintroducing p14ARF into these cells suppressed replication 161,162. Hence, the 
current view on dl1520 specificity is that this CRAd replicates in cells with dysfunctional 
p53, irrespective of the genetic defect causing this dysfunction.  
Recently, Geoerger et al. reported in subcutaneous glioma xenograft models that 
intratumoral injections of dl1520 yielded significant tumor growth delay compared to 
control animals. Interestingly, wild type p53 status appeared to correlate with increased 
anti-tumor activity of dl1520 163. This finding was in agreement with the observation that the 
adenovirus life cycle is more rapid in p53 wild type cells, due to more effective cell lysis 
164,165. It disagreed, however, with the finding that the rapid adenovirus-induced lysis 
requires formation of a complex between p53 and E1B-55kD 166, because E1B-55kD is 
lacking in dl1520 infected cells.  Hence, the interplay between adenovirus replication and 
p53 remains enigmatic. 
An important disadvantage of dl1520 is that as a consequence of E1B55kD 
deletion, its oncolytic capacity is severely attenuated compared to wild type adenovirus. 
E1B55kD has important viral functions other than p53 inhibition, including promotion of 
viral mRNA transport and host cell protein synthesis shutoff.  Therefore, more recently, a 
CRAd was constructed carrying a subtle single amino acid substitution in E1B-55kD that 
abolishes p53 binding, but leaves all other functions intact 167. This CRAd replicated in 
cancer cells as efficiently as wild type adenovirus. Unfortunately, the paper did not report 
on selectivity of this CRAd for tumor cells. 
Another type of CRAd based on a dysfunctional p53 pathway was developed by 
Ramachandra et al.168. This CRAd, 01/PEME, expresses a specific E2F antagonist, 
consisting of the pRb transrepression domain fused to the DNA binding domain of E2F, 
driven by a p53-responsive promoter. Furthermore, a deletion was introduced in E1A that 
abrogates sequestration of the p53 transcriptional co-activator p300/CBP. In cells with 
functional p53, 01/PEME expresses the E2F antagonist to inhibit S-phase entry and 
adenovirus E1A and E2A expression. 01/PEME did indeed not replicate in normal cells 
and replicated as efficiently as wild type adenovirus in cancer cells. In human xenograft 
tumor models, 01/PEME showed significantly enhanced efficacy compared to dl1520. 
A different class of CRAds with abrogated viral function is based on mutations in 
E1A proteins that abolish binding to members of the Rb family of pocket proteins. pRb 
functions to modulate the cell cycle by regulating progression from G1 into S-phase. E1A 
binds to pRb and this results in release of the transcription factor E2F from pre-existing 
cellular E2F-pRb complexes. E2F can subsequently activate the adenovirus E2 promoter 
as well as several cell cycle regulatory genes. This allows S-phase entry and virus 
replication in otherwise quiescent cells.  Inactivation of the Rb family by E1A proteins and 
the binding domains involved were recently reviewed 169. Paradigm examples of pRb-
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binding deficient CRAds are Ad∆24 and dl922-947 that, although originally reported 
differently, both contain the same 24-bp deletion in the CR2 domain of the E1A gene, 
resulting in an E1A protein lacking amino acids 122 to 129 170,171. Although this has not 
been reported for these CRAds, the ∆24 mutation is expected to also abolish binding to 
the Rb family members p107 and p130. Because Ad∆24 and dl922-947 are defective in 
sequestering pRb from E2F, their replication depends on E2F being released through 
other means. This is the case in most, if not all cancer cells through pRb deficiency, pRb 
hyperphosphorylation, or pRb sequestration by cellular or viral proteins associated with 
malignancy. Therefore, while Ad∆24 and dl922-947 should be unable to replicate in 
quiescent normal tissues, their replication in cancer cells would not be hampered. Fueyo 
et al. demonstrated that Ad∆24 could replicate in and lyse both dividing and non dividing 
tumor cells with great efficiency whereas growth-arrested normal fibroblasts and cancer 
cells with restored pRb activity were resistant to the virus in vitro. Heise et al. showed that 
dl922-947 was effective against a range of cancer cells in vitro and in vivo.  Its potency 
was superior to that of dl1520 and in some cancer types even to that of wild type 
adenovirus. However, they also found that, although dl922-947 was attenuated effectively 
in quiescent normal cells, it did replicate in proliferating normal cells 171. This was, perhaps, 
not entirely unexpected as E2F is temporarily available free from pRb during normal 
regulated cell cycle progression.  
In order to further increase the selectivity of dl922-947, Johnson et al. described the 
construction of the CRAd ONYX-411, that carries the dl922-947 mutation and expresses 
E1A and E4 under control of the human E2F-1 promoter 172. This promoter is itself a 
transcriptional target of E2F. Thus, ONYX-411 is restricted to a single pathway defect (i.e., 
abundant free E2F) by a dual mechanism. This CRAd exhibited improved selectivity in 
vitro and reduced systemic toxicity in animal models in vivo.  
Howe et al. increased the specificity of CRAds dependent on pRb pathway defects 
by combining two E1A deletions, i.e., Addl1101 and Addl1107 173, creating E1Addl01/07 
that lacks binding capacity for p300/CBP and pRb 174. E1Addl01/07 should, therefore, be 
incapable of releasing E2F from pRb and of activating E2F by p300/CBP mediated 
acetylation. E1Addl01/07 was found defective for induction of cytopathic effects in dividing 
non-malignant cells compared to wild type adenovirus and the two single mutant viruses. 
Furthermore, in several different tumor models in vivo, the virus was effective in inhibiting 
tumor growth and extending the survival of the tumor bearing mice. Balagué et al. 
constructed the CRAd CB016 specifically for use against neoplasms associated with 
human papilloma virus (HPV), such as cervical cancers. CB016 combines the Ad∆24 
mutation with a large deletion in the E1A gene encompassing the CR1 region, thereby 
inhibiting binding of E1A to p300/CBP, pRb and p107 175. The large deletion is assumed to 
also diminish transactivation of early adenovirus promoters by E1A proteins. In HPV 
associated cancers, HPV encoded E7 protein should complement for the lost E1A 
functions. Compared to wild type adenovirus and to Ad∆24, CB016 showed delayed 
replication in normal keratinocyte raft cultures. In contrast, CB016 replicated in and killed 
HPV E6/E7 expressing keratinocytes effectively.  
Very recently, a novel method was described for tumor selective replication of 
CRAds, based on an activated Ras pathway in cancer cells (Fig. 6) 176. A common 
response of cells against a virus infection involves the interferon pathway. Interferon 
induces the expression of protein kinase R (PKR), a double stranded RNA-activated 
serine/threonine kinase. During adenoviral infection, viral dsRNAs resulting from bi-
directional transcription of the two strands of the adenovirus genome can bind and activate 
PKR. Activated PKR phosphorylates eIF-2α, leading to inhibition of protein synthesis 
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resulting in abrogation of viral replication. As a defense mechanism against this cellular 
antiviral response, adenoviruses produce virus associated (VA) RNAs that can also bind 
PKR, acting as PKR antagonists. Ad5 expresses two VA RNAs, of which VAI is the 
strongest PKR antagonist. In cancer cells, however, the interferon pathway is often 
defective. Furthermore, oncogenic Ras induces an inhibitor of PKR 177. Based on this, it 
was hypothesized that in cancer cells with an activated Ras pathway, PKR inactivation by 
adenovirus VA RNA is redundant. Cascallo et al. demonstrated that VAI mutant 
adenovirus dl331 indeed exhibited reduced replication in cells with a normal Ras pathway, 
whereas introducing oncogenic Ras into these cells restored the replication of dl331 to 
wild type level. Accordingly, dl331 had anti-tumoral efficacy in vivo when administered 
intratumorally into xenografts of Ras-activated pancreatic cancer cells, with potency similar 
to wild type adenovirus. In contrast, in pancreatic tumor xenografts carrying wild type Ras, 
dl331 was less oncolytic than wild type adenovirus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Schematic representation of the replication of wild type adenovirus in normal cells (A) 
and CRAds with deletions in Virus Associated (VA) RNAs in normal cells (B) or in cancer cells (C). 
In infected cells, adenoviral dsRNA transcripts are formed that can bind and activate protein kinase 
R (PKR). Via phosphorylation of eIF-2α (eIF-2α-P), activated PKR inhibits viral replication. As a 
defense mechanism, the virus produces VA RNAs that act as PKR antagonists (A). VA mutant 
virus cannot bind PKR and is therefore expected not to replicate in normal cells (B). Cancer cells, 
however, often have activated Ras that induces a PKR inhibitor, thereby allowing replication of the 
VA mutant adenovirus to ensue (C). 
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Overall, genuine selective replication of CRAds has not been demonstrated yet. An 
explanation is that adenovirus exploits multiple pathways to promote viral and cellular DNA 
replication, with several virus proteins being capable of complementing each other. For 
example, E4orf6/7 was shown to displace pRb from E2F in the absence of E1A (34). 
Therefore, development of truly tumor selective CRAds will require introducing multiple 
mutations into the adenovirus genome. In this respect, Fukuda et al. recently presented a 
doubly restricted CRAd carrying mutant E1A and a deletion of E1B-55kDa, thus 
simultaneously targeting pRb and p53 pathway defects. This new CRAd replicated in and 
killed cancer cells as efficiently as a CRAd carrying only the E1B-55kDa deletion, but 
exhibited milder cytotoxicity 178. 
 
 
Limiting viral replication by tumor or tissue specific expression of essential 
adenovirus proteins 
Another way to limit viral replication to cancer cells is by transcriptionally regulating the 
expression of essential viral genes by using tumor or tissue specific promoters (fig. 7A and 
B). Several tissue specific CRAds have been developed in which the essential gene E1A 
is placed under the control of an exogenous promoter that is preferentially active in tumor 
cells. The first CRAd of this type was CN706 (later renamed CV706) that specifically 
replicates in prostate-specific antigen (PSA) expressing tumor cells 179. In CN706, a 
minimal promoter derived from the human PSA gene drives expression of E1A. As 
intended, E1A was expressed at high levels in CN706-infected human PSA-producing 
LNCaP prostate cancer cells but not in CN706-infected PSA-negative prostate cancer 
cells. Consequently, CN706 replicated in LNCaP cells, but not in several other human 
cancer cell lines that did not express PSA. In vivo, LNCaP subcutaneous solid tumors 
growing in nude mice were destroyed by a single injection of CN706. To increase the 
specificity of CN706, two next generation CRAds were constructed that contained two 
different prostate-selective promoters to drive expression of E1A and E1B, i.e., the PSA 
promoter and the promoter/enhancer of the hK2 gene or the rat probasin promoter 180,181. 
These double-selective CRAds CV739 and CV764 exhibited an even higher therapeutic 
index of toxicity on PSA-positive prostate cancer cells over cells from other tissues. 
Neither CN706 nor CV764 could, however, eliminate distant pre-existent LNCaP xenograft 
tumors in mice following administration via the tail vein.   In contrast, the CV739-derivative 
CV787 that retained the entire E3 region, which was lacking in the above-described 
CRAds exhibited 10-100 fold increased efficacy in vitro and in vivo 181. Six weeks after an 
intravenous injection of CV787, prostate tumors growing in mice were reduced in size to 
less than 5% of their original size.  
Matsubara et al. developed another CRAd, Ad-OC-E1a, that specifically replicated 
in both PSA expressing and non-expressing prostate cancer cells by using a non-
collagenous bone matrix osteocalcin (OC) promoter to drive expression of E1A. OC is 
expressed in several solid tumors, including osteosarcoma and ovarian, lung, brain, and 
prostate cancers. All the prostate cancer cell lines tested, as well PSA expressing as non-
expressing cell lines, were sensitive to Ad-OC-E1a induced cell lysis in vitro. Systemic 
administration of Ad-OC-E1a was effective against androgen-independent prostate cancer 
skeletal xenografts. Following repeated CRAd administration, tumors were eliminated 
completely 182.  
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Figure 7:  Schematic representation of the selective replication of CRAds in tumor cells by using a 
tumor specific promoter or by selective stabilization of mRNA . By regulating the expression of an 
essential viral gene, in particular E1A, via a tumor specific promoter (TSP) expression leading to 
replication will occur in malignant cells (B), but not in normal cells (A).  
Selective stabilization of mRNAs of essential viral genes by introducing an AU-rich element (ARE) 
derived from the 3’UTR of one of many unstable mammalian mRNAs into their 3’UTR is illustrated 
in panels C and D. Several ARE-binding proteins (ABPs) were identified that have either a 
negative or a positive effect on mRNA stability. One of the ABPs that stabilizes their target mRNA 
is Hu-antigen R (HuR). HuR is depicted here by way of example, because it is known to be 
activated by p38/MAPK, which is frequently activated in tumor cells. In normal cells, HuR is not 
phosphorylated and activated, and can thus not bind to the ARE, leading to rapid mRNA 
degradation by the exosome, an enzymatic polyprotein complex that degrades mRNA. CRAds with 
the ARE sequence in the E1A 3’UTR will therefore not replicate in normal cells (C). In tumor cells 
with activated p38, HuR is activated (HuR-P) and can bind to the ARE thereby preventing mRNA 
degradation (D). The exact mechanism of mRNA stabilization is, however, not elucidated 
completely. An overview on current knowledge and hypotheses concerning this topic was recently 
given by Bevilacqua et al 183. 
 
 
Similar strategies have been explored to develop CRAds that specifically replicate 
in other types of cancer, like hepatocellular carcinoma using the α-fetoprotein promoter 
184,185, breast cancer using the DF3/MUC1 gene promoter 186 or estrogen responsive 
element from the pS2 gene promoter 187, melanoma using a tyrosinase enhancer/promoter 
construct 188-190, ovarian cancer using the IAI.3B promoter 191 or a truncated version of the 
L-plastin promoter 188 and lung cancer using the surfactant protein B promoter 192. All these 
CRAds showed preferential replication in their target cells and demonstrated anti-tumor 
activity in preclinical models.  
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However, for many different human malignancies, tissue specific promoters have 
not been characterized yet. Moreover, the promoters used in these studies are primarily 
tissue-specific rather than tumor-specific. CRAds relying on these promoters might thus 
cause toxicity to normal tissues. To overcome this, general features that discriminate 
cancer cells from non-malignant cells have been explored to develop cancer specific 
CRAds.  
Brunori et al. developed a colon cancer specific CRAd by taking advantage of the 
constitutive activation of the wnt pathway invariably seen in this type of cancer 193. 
Activation of the wnt pathway leads to transactivation of promoters containing Tcf binding 
sites. Therefore, Tcf binding sites were placed in the adenoviral E1B and E2 promoters 
resulting in decreased CRAd replication in non-permissive cell lines, whereas replication 
was comparable to wild type adenovirus in many colon cancer cell lines. Additionally 
inserting Tcf binding sites in the E1A promoter resulted in further improved specificity for 
colon cancer cells 194.  
A common characteristic of all solid tumors is that they create an environment with 
low oxygen tension, hypoxia, due to their aberrant vasculature. The transcription factor 
hypoxia inducible factor (HIF) is expressed under hypoxic conditions, leading to 
expression of a number of genes needed for adaptation to the low oxygen situation via 
binding of HIF to hypoxia responsive elements (HREs) in the promoter of these genes. 
Hernandez-Alcoceba et al. described the construction of the CRAd AdEHT2, in which a 
minimal artificial promoter that contains HREs and estrogen responsive elements controls 
E1A expression 195. AdEHT2 showed a good activation of E1A expression by hypoxia in 
different cancer cell lines or by estrogens in estrogen receptor expressing cell lines and 
this correlated with increased CRAd cytotoxicity. Cuevas et al. constructed a CRAd in 
which E1A expression is directed by an artificial minimal promoter containing nine tandem 
copies of the HRE and expression of E4 is controlled by the E2F-1 promoter 196. This virus 
was as effective as wild type virus in eliminating cancer cells with increased HIF activity, 
and was severely attenuated in HIF-defective tumor cells and normal cells in vitro. 
Furthermore, intratumoral injection in renal cell carcinoma xenografts resulted in a 
significant reduction of tumor growth 196. 
Another general characteristic of tumors is high expression of telomerase reverse 
tanscriptase (TERT). TERT is the catalytic subunit of the enzyme telomerase and is the 
rate-limiting determinant of enzymatic activity of human telomerase. Telomerase is a DNA 
polymerase, which directs the synthesis of TTAGGG (telomere) at the ends of 
chromosomes to compensate for telomere shortening during cell division. Telomerase is 
active in fetal development and becomes dormant in post-mitotic tissue soon after birth. 
High telomerase activity in tumor cells is one of the reasons for their immortality and 
telomerase is active in most human malignancies. CRAds based on this general feature of 
tumors could therefore be efficacious against a wide variety of tumors. The study by 
Hernandez-Alcoceba described above also included introduction of the TERT promoter 
into the E4 region of AdEHT2. This CRAd, however, replicated in telomerase positive and 
negative cells, probably because E1A gene expression activated the E4 gene directly (51). 
Other studies, however, described more successful use of the TERT promoter to regulate 
expression of E1A (53, 54). Huang et al. reported that a TERT-specific CRAd replicated in 
TERT positive cells as efficiently as wild type adenovirus, whereas replication was 
severely hampered in TERT-negative cells. In vivo, local administration into human 
hepatocellular carcinoma xenografts in nude mice resulted in significant inhibition of tumor 
growth as compared to control treated animals. In the study by Wirth et al. a smaller 
fragment of the TERT promoter was used to drive expression of E1A. Whereas the CRAd 
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replicated efficiently in several cancer cell lines, neither viral replication nor E1A 
expression was observed in human hepatocytes. To achieve higher levels of E1A 
expression, Kim et al. constructed a CRAd with a modified TERT promoter containing 
additional c-Myc and Sp1 binding sites. This virus induced cell killing as potently as the 
control virus in vitro and in vivo, but was approximately 100-1000 fold less cytotoxic to 
normal cells in vitro (Kim et al., 2003). 
Many tumors have increased levels of the transcription factor E2F, either because 
of a deregulated Rb pathway or because of E2F gene amplification. Several CRAds have 
been developed that replicate specifically in cells with active E2F by placing the E1A gene 
under the E2F promoter. These CRAds replicated as efficiently as wild type virus in a 
panel of cancer cells, whereas normal cells were not capable of supporting CRAd 
replication 197,198. 
A last general feature of solid tumors is that their growth requires new blood vessel 
formation. Targeting CRAds towards tumor vessels instead of tumor cells has the potential 
of depriving the tumor of its oxygen and nutrient supply and the advantage of a better 
delivery to the entire tumor. A number of genes, including Flk-1 and endoglin, were shown 
to be overexpressed in angiogenic endothelial cells. Savontaus et al. constructed two 
CRAds, AdFlk-1 with E1A under the control of the Flk-1 enhancer/promoter, and Ad.Flk-
Endo that additionally has the E1B gene under the endoglin promoter. Both CRAds 
replicated efficiently in human umbilical vein endothelial cells, with replication of Ad.Flk-
Endo being severely hampered in Flk-1 and endoglin negative cells 199. 
For the design of CRAds with specific promoters it is important to consider that 
insertion into the adenovirus genome may affect selective expression of the gene, due to 
the presence of dominant transcriptional activators, as was observed for the ERBB2 
promoter 200. When delivered in a plasmid, selective expression of the transgene in ERBB2 
expressing cells was observed, but this selectivity was lost when the expression cassette 
was delivered by replication deficient adenoviral vectors. Selective expression can, 
however, be retained by insulating the expression cassette from adenovirus expression 
elements by inserting transcription stop signals 201,202. 
Recently, a novel method was described for development of CRAds based on 
selective mRNA stabilization in cancer cells (Fig. 7C and D) 203. The expression of many 
proteins involved in early responses to certain physiological conditions, such as hypoxia, 
radiation exposure, inflammation and cell proliferation is regulated partly at the level of 
mRNA stability. The 3’ UTRs of the mRNAs encoding these proteins contain destabilizing 
AU-rich elements (AREs), whose action is reversed under stress 204,205. In tumor cells, 
continuous intracellular proliferative signals predominate, establishing conditions for 
selective stabilization of early-response-mRNAs. PTGS2, also known as COX2, is induced 
in different types of tumors and has been associated with a poor prognosis. PTGS2 is 
induced partly by mitogen-activated protein kinase (MAPK)-dependent selective mRNA 
stabilization. MAPKs are downstream effectors of RAS-mediated transformation and 
receptor tyrosine kinase phosphorylation that are common in cancer. Ahmed et al. 
described the construction of the CRAd Ad-E1A-COX, in which a fragment encompassing 
AREs from PTGS2 was introduced into the E1A 3’UTR. This resulted in destabilization of 
E1A mRNA and decreased E1A expression in normal cells. In contrast, Ad-E1A-COX was 
preferentially oncolytic in human tumor cells with high levels of active phosphorylated 
MAPK (P-MAPK) in vitro. Moreover, in vivo this CRAd was as effective as wild type virus in 
tumors with high P-MAPK activity, but generated no significant cytotoxic effects in tumors 
with low P-MAPK activity 203. 
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LIMITED EFFECTS OF CRADS USED AS SINGLE AGENTS IN CLINICAL 
TRIALS  
 
The safety and anti-tumor efficacy of dl1520 has been tested in several clinical trials in 
different types of tumors and using different administration routes. Following intratumoral 
injection, dose-limiting toxicities were not observed and maximally tolerated doses (MTDs) 
were not reached. The most common treatment associated toxicities were grade I-II flu-like 
symptoms, which did not correlate with viral dose 206-210. Increases in neutralizing anti-
adenovirus antibodies were commonly observed, but, importantly, these high neutralizing 
antibody titers did not appear to prevent CRAd replication in tumors 206. In terms of 
therapeutic efficacy of CRAds as single agent, the most encouraging data were obtained 
by Nemunaitis et al. in 37 patients with recurrent head and neck cancer that were injected 
intratumorally or peritumorally with dl1520. A significant tumor regression was observed in 
21% of evaluable patients, whereas no signs of virus were present in normal surrounding 
tissue, despite direct injection 206,211. In one study, dl1520 was administered 
intraperitoneally 212. Although also here the MTD was not reached, abdominal pain 
secondary to inflammation was common and in one patient dose-limiting. Intravascular 
administration of dl1520 to patients with colorectal carcinoma metastatic to the liver 213,214 
or to patients with end-stage refractory carcinoma metastatic to the lung 215 was well 
tolerated at doses up to 2x1013 particles. Evidence of viral replication was observed in 
patients treated at high virus doses 214,215. Also in these trials, the most common toxicities 
were mild flu-like symptoms. None of the studies with systemic dl1520 administration 
documented objective responses.  
A phase I trial was also conducted with the CRAd CV706, that specifically replicates 
in PSA expressing prostate cancer cells 216. Intra-prostatic CV706 injections appeared to 
be safe, because no CRAd-related grade III or IV toxicities were observed. The most 
common side effects were local pain and genitourinary symptoms. In this study, all 
patients demonstrated a dose-dependent reduction in PSA levels, suggesting CRAd 
efficacy.  
Most importantly, clinical trials with CRAds have shown that administration of these 
viruses is a safe procedure without the manifestation of severe side effects. The lack of 
clinically significant toxicity in the liver is of particular importance, because most of the 
systemic administered adenoviruses end up in the liver. Unfortunately, no objective 
responses were documented with single agent therapy. Given this high degree of safety 
but inadequate efficacy, second generation viruses with greater potency will have to be 
engineered. In addition, combination therapies are being considered. These potential 
improvements will be discussed in the next sections. 
 
 
INCREASING THE EFFICACY OF VIROTHERAPY BY COMBINING 
CRADS WITH CONVENTIONAL THERAPIES 
 
Given their limited efficacy in clinical trials, it is unlikely that CRAds will have a future as 
single agents in cancer treatment. In addition, conventional chemotherapy and 
radiotherapy have already significant, though incomplete, efficacy against many cancers. 
Therefore, patients entering clinical trials for new anti-cancer agents are usually not 
withheld conventional treatment. Furthermore, there is also a theoretical basis for additive 
or perhaps even supra-additive anti-cancer effects of CRAds combined with chemotherapy 
or radiotherapy. These considerations have directed investigations into the combination of 
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CRAds with conventional therapies. These studies have confirmed improved anti-tumor 
efficacies of combination treatments in vitro, in vivo and in clinical trials.  
Chemotherapy has been combined with dl1520 and with liver- and prostate-specific 
CRAds. Heise et al. combined intratumoral dl1520 injection with cisplatin treatment and 
intravenous dl1520 infusion with 5-FU treatment in subcutaneous nude mouse carcinoma 
xenograft models 158. Both combinations resulted in significantly increased responses 
compared to chemotherapy alone. This was extended by synergy observed between 
dl1520 and cisplatin plus 5-FU in three different cancer xenograft models 217. Furthermore, 
in lung cancer cell lines and primary cultures dl1520 worked synergistically with paclitaxel 
and cisplatin 218.  Interestingly, synergy required that dl1520 was administered prior to or 
simultaneously with the drug. Although an explanation for this observation is currently 
lacking, it suggested that virus replication enhanced sensitivity to drugs rather than 
chemotherapy enhancing viral oncolysis. A mechanism potentially contributing to 
adenovirus-mediated chemosensitization is E1A expression, which has been shown to 
induce p53 expression 149 as well as to render cells more sensitive to chemotherapy in a 
p53 independent manner 219.  Another possible result of adenovirus replication is the 
induction of chemosensitizing cytokines including TNF 220. Li et al. described the 
combination of a hepatocellular carcinoma specific CRAd and doxorubicin treatment 221. In 
vitro and in vivo, synergistic effects were observed which in the latter experiment resulted 
in complete elimination of subcutaneous Hep3B tumors four weeks after a single 
intravenous administration of both compounds. Similarly, Yu et al. tested the combination 
of CV787 with the chemotherapeutic drugs paclitaxel or docetaxel on prostate cancer cells 
222. In vitro and in vivo, a synergistic anti-cancer effect was observed on PSA-expressing 
prostate cancer cells when CV787 was combined with either of the two taxanes. PSA-
positive prostate cancer cell specificity was retained in the combination treatment. In these 
experiments, the CRAd was administered simultaneously with or before or after taxane 
addition. Synergy was documented in all cases. Thus, the importance of correct 
scheduling reported for dl1520 was not confirmed for CV787 plus chemotherapy. Some 
insight into a possible mechanism for synergy of CRAd plus chemotherapy came from the 
observation that cells treated with the combination exhibited a greater burst size of CV787 
compared to viral treatment alone. This suggested that the drugs speeded up the CRAd 
life cycle. A possible explanation for this effect is that many anticancer drugs, including 
etoposide, gemcitabine, topotecan and dexamethasone can increase adenovirus infection 
by increasing expression of the primary adenovirus receptor Coxsackie Adenovirus 
Receptor (CAR) on the cell surface 223. This does, however, not provide a complete 
explanation, because paclitaxel was found not to induce CAR expression.   
To date, dl1520 has been combined with chemotherapeutic drugs in four reported 
clinical trials. Khuri et al. described the results of a phase II trial in which dl1520 was 
injected intratumorally in combination with intravenous cisplatin and 5-FU in patients with 
recurrent squamous cell cancer of the head and neck 224. In 19 of 30 (63%) evaluated 
patients an objective response was documented, with 8 patients showing a complete 
response and 11 a partial response, which was better than the responses seen in multi-
center, randomized trials with 5-FU/cisplatin alone. No correlation was observed between 
response and baseline tumor size, baseline neutralizing antibody titer, p53 gene status or 
prior treatment. The treatment was well tolerated; as for single-agent CRAd treatments, 
injection site pain and flu-like symptoms were seen. Nemunaitis et al. treated patients with 
lung metastases, with intravenous dl1520 injection and carboplatin and paclitaxel 
concurrently. Two patients showed tumor stabilization for more than 6 months 215. Reid et 
al. combined dl1520 infusion into the hepatic artery with 5-FU and leucovorin. At high viral 
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doses, several anti-tumor responses were documented 214. Finally, Hecht et al. injected 
pancreatic carcinomas with dl1520 under ultrasound guidance eight times over a two-
month period, the last four injections combined with intravenous gemcitabine. While no 
objective responses were demonstrated after the first four CRAd injections, the 
combination treatment gave 10% objective partial regressions 225. Although one should 
obviously be careful in comparing the outcome of different clinical studies, it seems fair to 
conclude that the efficacy obtained with CRAds plus chemotherapy is among the most 
promising results seen with CRAds so far. This warrants further development of this type 
of combination treatment. 
Several reports have demonstrated the successful combination of cytolytic 
adenoviral therapy with radiotherapy (RT) in vitro and in vivo. Rogulski et al. tested the 
combination of dl1520 and RT on the colon carcinoma cell line RKO (p53 wild type) and 
the derivative cell line RKO.p53.13 that expresses an inactivating mutant of p53 226. In vivo 
experiments with subcutaneous xenografts demonstrated that in the parental cell line 
combination treatment with RT and dl1520 resulted in a tumor growth delay identical to 
that obtained with RT alone, consistent with the assumption that dl1520 is not effective in 
p53 wild type cells. In contrast, treatment of RKO.p53.13 tumors with dl1520 and RT 
produced an anti-tumor effect that was significantly greater than that achieved with either 
monotherapy. In contrast to these findings, a recent report by Georger et al. describes 
additive effects of dl1520 with RT in p53 mutant as well as in p53 functional subcutaneous 
human glioma xenografts in vivo 227. Investigations into the potential mechanism of 
combined treatment effects did not provide a clear answer, but ruled out that irradiation 
increased adenovirus infection or replication. Induction of necrosis and apoptosis did not 
seem to play a major role either. Furthermore, Toth et al. found increased activities of 
CRAds with RT in cancer cell lines and could rule out radiation-induced replication as the 
possible mechanism 228. These findings partially conflicted with another study using 
replication deficient adenoviruses, where it was found that irradiation enhanced virus 
uptake into cancer cells 229. 
The PSA selective CRAd CV706 was shown to act synergistically with RT in LNCaP 
cells in vitro and in vivo 230. In this study, in contrast to the observations described by 
Geoerger et al., increases in necrosis and apoptosis and a decreased blood vessel density 
were found in combination treated tumors. As was reported by the same group for the 
combination of CV787 with chemotherapy, CV706 plus RT combination increased viral 
burst size and did not affect the prostate specificity of the virus. Lamfers et al. 
demonstrated that the combination of RT and Ad5-∆24RGD in primary glioma cell cultures 
resulted in cytotoxicity effects ranging from additive to supra-additive. To achieve the 
same therapeutic response in vivo, a 10-fold lower dose of Ad5-∆24RGD was needed 
when it was combined with RT 231. Taken together, it can be concluded that, although the 
mechanism remains unclear, perhaps because the two components are independent, the 
combination of CRAd with RT is promising for further preclinical and clinical evaluation. 
 
 
POSSIBLE WAYS TO MAKE CRADS MORE EFFECTIVE  
 
Targeting CRAds towards tumor cells 
Almost all CRAds designed so far were derived from human adenovirus serotype 5 (Ad5). 
The infection of host cells by Ad5 is a two-step process. The first step is a high-affinity 
interaction of the knob domain of the adenovirus fiber protein with the cell surface receptor 
CAR 146,232. Subsequent internalization, via receptor-mediated endocytosis, involves 
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interactions between the Arg-Gly-Asp (RGD) sequences of the adenovirus penton base 
proteins with cellular αvβ3 and αvβ5 integrin receptors. Unfortunately, many tumors exhibit 
limited levels of CAR expression 233-238, whereas CAR is abundantly expressed on many 
normal cell types. Douglas et al. demonstrated that CAR deficiency on tumor cells restricts 
the oncolytic potency of CRAds in vitro and in vivo 239. Therefore, CAR deficiency emerges 
as a major limiting factor for effective use of CRAds for cancer gene therapy. A logical 
approach to circumvent inefficient CAR-mediated CRAd infection is by redirecting CRAd 
entry (i.e., targeting) via alternative cell surface molecules abundantly expressed on 
cancer cells. Modification of Ad tropism has so far primarily been studied in the context of 
replication deficient adenoviral vectors, but several strategies are now also being explored 
to target CRAds (Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Schematic representation of different approaches to target CRAds to tumor cells. During 
native infection, adenovirus serotype 5 enters the cell following high-affinity binding to the cellular 
receptor CAR. Replacing the tropism-determining fiber knob domain of Ad5 with that of a different 
adenovirus serotype results in a virus with a modified tropism and improved transduction efficiency 
on several tumor types. Infectivity enhanced CRAds have also been constructed by inserting 
peptide motifs in the virus capsid that can bind to receptors on cancer cells. Furthermore, bispecific 
targeting moieties have been incorporated in CRAds.  These molecules can bind on one side to 
the adenoviral fiber and on the other side to a tumor antigen. 
 
 
It has been known for long that various human adenovirus serotypes bind to distinct 
cell receptors (e.g.240). In addition, it appeared possible to replace the tropism-determining 
fiber knob domain of Ad5 with that of a different adenovirus serotype (e.g.241,242). 
Replication deficient Ad5/Ad3 chimeric viruses, i.e., vectors encapsidated in Ad5 virions 
carrying fibers consisting of the Ad5 tail and shaft domains and the Ad3 knob domain 
encompassing the receptor binding site, exhibited a modified tropism and improved 
transduction efficiency on several tumor types, including ovarian cancer, squamous cell 
carcinoma of the head and neck (SCCHN) and B-cell lymphomas 243-245. Ad3 has an 
unidentified receptor distinct from that of Ad5 and therefore a different tissue tropism. 
Haviv et al. exploited Ad5/Ad3 chimeric fibers to target replication competent adenoviral 
vectors towards renal cell carcinoma cells deficient in CAR expression 246. Ad5/3 virus 
successfully infected and replicated in renal cell carcinoma cancer cells that were resistant 
CAR                  viral receptor         Tumor antigen     Tumor antigen
Normal infection Pseudotyping Insertion of a ligand Bispecific targeting moiety
                 Alternative
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to Ad5 infection. Kawakami et al. made the same comparison on SCCHN cells.  They 
found a modest enhancement of infection of SCCHN cells by Ad5/3 compared to Ad5, but 
a much higher virus progeny production and oncolytic activity of the chimeric virus. Hence, 
the pseudotyping affected multiple steps of the adenovirus replication cycle, including 
post-infection processes 247. Very recently, the first pseudotyped CRAd Ad5/3-∆24 was 
reported. On primary ovarian cancer spheroids, this virus exhibited improved oncolysis 
compared to the control virus Ad5-∆24. Moreover, in an intraperitoneal model of 
disseminated ovarian cancer, a single injection of Ad5/3-∆24 increased the survival of 
tumor bearing mice significantly compared to injections with control viruses 248. 
Obviously, the utility of pseudotyping is limited by the natural diversity of adenovirus 
receptor recognition. Defined targeting of cancer cell specific surface molecules requires 
synthetic design of targeted adenoviruses. For this, single- and two-component systems 
are being explored. 
The design of single-component targeted adenovirus vectors by incorporating 
targeting ligands into adenovirus capsid proteins has been widely explored and was 
reviewed before 249. The most extensively studied capsid protein modifications are peptide 
extension of the fiber protein carboxy-terminus and peptide insertion into the flexible fiber 
HI-loop. These modifications do not abrogate binding to CAR and do thus expand rather 
than target adenovirus entry. However, it should be possible to combine them with capsid 
protein mutations known to abolish native tropism 250 to construct truly targeted viruses.  
In CRAds, two different targeting ligand incorporation strategies have been studied 
so far. Shinoura et al. described the construction and evaluation of the E1B-55kD deleted 
CRAd AdV-E1AdB-F/K20 carrying a stretch of 20 lysine residues at the COOH terminus of 
the fiber to allow CRAd binding to heparan sulfate cellular receptors. The infection and 
replication efficiency of AdV-E1AdB-F/K20 on glioma cells was greatly enhanced and its 
anti-tumor effect was much stronger compared to the parental control virus 251. Suzuki et 
al. constructed Ad5-∆24RGD, an infectivity-enhanced variant of Ad∆24 that contains a 
cyclic RGD peptide motif in the fiber HI-loop. Ad5-∆24RGD exhibited enhanced 
propagation and oncolytic effect compared to the control virus Ad∆24 in vitro and in vivo 
252. Oddly, both Shinoura et al. and Suzuki et al. evaluated the oncolytic potency of their 
infectivity-enhanced CRAds only on CAR-positive tumor models. More recently, however, 
Ad5-∆24RGD was tested on CAR-deficient rhabdomyosarcoma, ovarian carcinoma and 
glioma cells 231,238,253,254. Ad5-∆24RGD was found very effective in killing cancer cells in vitro 
and in vivo, the latter resulting in significant improvement in survival of tumor-bearing 
animals. Ad5-∆24RGD was reported to be more oncolytic than the parental virus Ad∆24. 
However, the importance of targeting for effective CRAd treatment could not be 
established, because Ad∆24 lacks the E3 region, while Ad5-∆24RGD carries an intact E3 
region that includes the gene for Adenovirus Death Protein (ADP), which is involved in 
lysis of the infected cell 255. Therefore, in a follow-up study, Suzuki et al. constructed 
Ad∆24 CRAds with and without E3 region and with and without RGD targeting sequence 
256. This allowed delineation of the effects exerted by the individual modifications. It was 
found that the superior potency of Ad5-∆24RGD was primarily due to the incorporation of 
the E3 region, but contribution of the infectivity-enhancement to the anti-cancer effect was 
also confirmed.   
Targeting by adenovirus capsid protein modification is bound by the structural 
demands on the incorporated ligand. So far, this approach has been limited to the use of 
small or flexible peptides. The versatility of tumor specific CRAd entry could potentially be 
much expanded if more complex ligands, such as antibodies, could be used. However, 
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such molecules have so far not been successfully incorporated as a structural component 
of the adenovirus capsid. In addition, the nuclear assembly of adenoviruses may preclude 
correct post-translational modification of protein moieties that are normally processed 
through the secretory pathway. For this reason, complex binding ligands including 
antibodies have so far only been successfully employed in two-component targeting 
strategies, where they were bound to the adenovirus fiber indirectly via a second protein 
moiety 134,233,257,258. Also for CRAds it has been reported that infection of tumor cells in the 
presence of such a bispecific molecule is more efficient 259,260. However, in such two-
component strategies, the targeting moiety is not part of the CRAd genome and is thus 
lost upon viral replication. As a solution to this limitation, recently two Ad∆24 derived 
CRAds containing an expression cassette for a bispecific-targeting molecule were 
described.  Hemminki et al. 261 utilized the targeting moiety sCAR-EGF, consisting of the 
extracellular domain of CAR fused to the Epidermal Growth Factor (EGF) that binds with 
specificity to the EGF receptor (EGFR) and we used 425-S11, a bispecific single chain Fv 
antibody fragment directed on one side to the adenovirus fiber and on the other side to 
EGFR 262. As expected, Ad∆24-425S11 exhibited increased infection efficiency and 
replication on 2-D monolayers and 3-D tumor spheroids of CAR deficient cancer cells 262. 
Surprisingly, incorporation of sCAR-EGF into the Ad∆24 backbone did not at all increase 
the oncolytic potency of the virus, but abrogated its cell killing potency 261. The unexpected 
results with Ad∆24-sCAR-EGF appear to have been caused by the particular targeting 
ligand that was used. EGF is an active mitogen, with diverse regulatory functions related 
to cell growth, communication and development. Through an unknown mechanism, sCAR-
EGF expression negatively influenced viral oncolysis as well as its own production 261. 
Conversely, the anti-EGFR scFv that was used to construct Ad∆24-425S11 and that 
enhanced Ad∆24 oncolytic potency is an EGFR antagonist that binds to and neutralizes 
the receptor and has therefore no or perhaps even an inhibitory effect on cell processes 
related to EGFR signaling. These observations underscore the importance of thorough 
selection of the appropriate targeting moiety in designing targeted CRAds.  
To generate a genuine tumor-targeted CRAd, it might perhaps be possible to 
combine the two-component targeting approach with mutations in the adenoviral genome 
to abrogate binding of the CRAd to CAR and integrins 263,264. Such an approach is, 
however, not possible with targeting moieties based on sCAR, since such molecules bind 
specifically to the CAR-binding site in the fiber knob.  
 
 
Combining CRAds with Gene-Directed Enzyme Prodrug Therapy 
GDEPT has been investigated extensively using replication deficient adenoviral vectors. 
The demonstrated synergy between CRAds and chemotherapy warranted studies into 
combinations of CRAds with the more selective GDEPT. Several investigators have 
attempted to enhance the anti-cancer efficacy of CRAds by incorporating TK into the 
CRAd genome and adding GCV. Wildner et al. constructed an E1B-55kD deleted CRAd 
expressing TK 265. Intratumoral injection of this CRAd into human melanoma, cervical 
cancer or colon cancer xenografts in nude mice, followed by GCV treatment resulted in 
increased survival of the mice compared to viral treatment without prodrug administration 
or compared to replication deficient TK virus combined with GCV treatment 265,266. 
Importantly, the combination of TK expressing CRAd plus GCV was only more effective 
than the CRAd alone when GCV was administered 3 days after CRAd injection. 
Simultaneous treatment was not beneficial, suggesting that GDEPT could interfere with 
CRAd replication. The same group also compared the efficacy of another HSV-TK 
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expressing E1B-55kD deleted CRAd with that of two other E1B positive TK expressing 
viruses in a subcutaneous lung cancer model and in an intraperitoneal ovarian cancer 
model 267. In the subcutaneous model, GCV administration improved the oncolytic potency 
of the E1B-55kD deleted CRAd, but not of the other two much more potent viruses. 
Moreover, in the intraperitoneal model, the addition of GCV reduced instead of prolonged 
survival compared to virus treatment alone for all three viruses. Subsequent studies with 
TK expressing replication competent adenoviruses in a subcutaneous head and neck 
squamous cell carcinoma model 268,269 and subcutaneous and intraperitoneal lung cancer 
models 269 each showed that addition of GCV did not improve oncolytic potency. Thus, in 
all these models TK GDEPT appeared ineffective or even counterproductive in 
combination with replicating adenoviruses, despite the fact that in several experiments the 
first GCV injection was postponed until one week after virus injection. In contrast to these 
observations, Nanda et al. found that although TK/GCV treatment completely abrogated 
adenovirus replication when administered concomitantly, it significantly enhanced the 
oncolytic potency of an adenovirus in vitro and in vivo when GCV administration was 
started only one or two days after virus injection 270. Apparently, there is a delicate balance 
between TK/GCV induced cell death and TK/GCV reduced cell kill by impaired viral 
replication. This makes TK/GCV GDEPT rather unattractive for use in combination with 
CRAds.  
Another extensively studied GDEPT system utilizes the E.coli cytosine deaminase 
(CD) enzyme that converts 5-FC into the toxic drug 5-FU. Several studies have been 
performed in which a fusion gene consisting of CD and TK was inserted into a replication 
competent adenoviral vector, because double CD/TK suicide gene therapy is more 
efficacious than either GDEPT alone 271. Freytag et al. constructed the E1B-55kD deleted 
CRAd FGR (subsequently renamed Ad5-CD/TKrep) expressing the CD/TK fusion gene 272. 
FGR was quite effective in killing cancer cells in vitro when combined with either prodrug, 
which effect could be further augmented by irradiation. Interestingly, these effects 
occurred at prodrug concentrations that effectively inhibited adenovirus replication, i.e., 
under combinations where the CRAd functioned as a GDEPT expression vector rather 
than an oncolytic agent. This suggests that the assumed CRAd plus GDEPT combination 
effect was in fact an adenovirus protein plus GDEPT effect. This fits quite well with the 
known synergy between adenovirus E1A expression and chemotherapy 219 and explains 
why the GDEPT/CRAd combination seems to work best for rather weak CRAds that may 
act more or less as replication deficient E1A expression vectors. In vivo studies with FGR 
in subcutaneous cervical carcinoma tumors and treatment with the two prodrugs resulted 
in a remarkable reduction in tumor volume compared to mice treated with virus only, or in 
combination with one prodrug, suggesting synergistic interactions between the suicide 
systems. Combining the double suicide systems with RT could even further enhance the 
efficacy of this approach 271. However, in two in vivo prostate cancer models, the addition 
of double prodrug therapy did not improve tumor control beyond that of FGR viral therapy 
273. Nevertheless, these results led to a phase I study for the treatment of locally recurrent 
prostate cancer in 16 patients 57. The virus was delivered intraprostatically followed 2 days 
later with 5-FC and GCV treatment. Escalation up to 1012 viral particles and two weeks of 
GV and 5-FC treatment did not result in dose limiting toxicities and the MTD was not 
defined, indicating that this approach can be safely applied to humans. Forty-four percent 
of the evaluated patients showed a decrease in PSA level indicative of tumor regression of 
more than 25%, with 19% exhibiting a more than 50% reduction. Two patients were 
negative for adenocarcinoma by biopsy 1 year after the treatment.   
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A last GDEPT system that was very recently explored in CRAds uses the CE 
enzyme that activates the prodrug CPT-11 into the toxic drug SN-38. Stubdal et al. 
incorporated the rabbit CE gene into the dl1520 genome. In vitro, in the presence of CPT-
11 CE-expressing dl1520 derived viruses exhibited increased toxicity on a colon 
carcinoma cell compared to dl1520. In subcutaneous colon cancer xenografts growing in 
nude mice treatment with CE-expressing CRAds and CPT-11 enhanced the survival of 
these mice 274. 
All together, results from preclinical and clinical studies indicate that CRAd plus 
GDEPT combination treatment is showing signs of improved efficacy warranting further 
investigation. However, careful evaluation of CRAd efficacy enhancing versus abrogating 
activities of enzyme/prodrug systems is required to select synergistic CRAd/GDEPT 
combinations. Since the aim of such endeavors is to enhance the efficacy of CRAd 
potency, in our view these investigations should focus on testing GDEPT systems in the 
context of the stronger CRAd types.  
 
 
Insertion of therapeutic genes into the CRAd genome  
Finally, CRAds could be developed into more powerful anticancer agents by inserting 
therapeutic genes into their genome (summarized in figure 9). There are two good reasons 
to express a transgene in a CRAd. First, the gene product can be used to enhance the 
inherent oncolytic property of the CRAd to realize its full anti-cancer potential. Second, the 
CRAd can be used as a very potent expression vector for an anti-cancer therapeutic. This 
concept has enormous potential, as the expression cassette for the therapeutic agent is 
amplified over 1000-fold in each infected cell.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Schematic representation of different strategies to increase the anti-tumor efficacy of 
CRAds by incorporation of therapeutic genes. See text for details. 
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The first approach aims to enhance the inherent cancer cell killing potency of the 
CRAd. Besides entry of CRAds into tumor cells, lysis of infected cells is another critical 
step that determines the efficacy of CRAd-based therapy. The E3-encoded ADP promotes 
lysis of infected cells and is expressed at very late stages of viral infection 144,255. By 
comparing the CRAd CV787 with intact E3 region to the otherwise identical CRAd CV739 
lacking E3, the important contribution of E3 proteins to the anti-tumor efficacy in vitro and 
in vivo was demonstrated 181. CRAds overexpressing ADP were reported to lyse and 
spread from cell to cell more rapidly than wild type adenovirus, resulting in improved in 
vivo anti-cancer effect 275. Suzuki et al. compared E3-positive and E3-negative variants of 
Ad∆24 and the integrin targeted derivative Ad5-∆24RGD 256. The presence of the E3 
region enhanced the spreading ability of the CRAd resulting in superior oncolytic potency 
compared with E3 negative CRAds in vitro and in vivo. The mechanism through which 
ADP enhances the viral spread is not elucidated yet. However, the effect of ADP is clearly 
not tumor selective. Therefore, investigators have sought to achieve increased tumor 
selective cell lysis by insertion of therapeutic genes other than ADP. These studies have 
focused on cell death pathways that are defective in cancer cells. Mi et al. demonstrated 
that insertion of a dominant-negative I-κB that sensitizes cells to Tumor Necrosis Factor 
(TNF)-induced apoptosis in an adenovirus enhanced viral release when apoptosis was 
induced after virion assembly was completed 276. In contrast, premature cell death during 
viral DNA replication compromised virus production, emphasizing the importance of careful 
timing of apoptosis induction. One way to accomplish this is to express a pro-apoptotic 
gene that is regulated during replication by the CRAd itself. In this regard, two studies 
have explored the effects of inserting p53 into the genome of a CRAd 277 or replication 
competent adenovirus 278 to improve viral burst specifically in tumor cells. We described 
the construction of Ad∆24-p53 in which a constitutive p53 expression cassette was 
inserted in place of the E3 region 277. Ad∆24-p53 exhibited enhanced oncolytic potency 
compared to the control vector Ad∆24 on a vast majority of tested cancer cell lines.  As 
expected, the observed effects were most pronounced on p53 deficient cells. However, 
there was no significant correlation found with the p53 functional status of the cell. 
Exogenous p53 expression also augmented CRAd potency in several cell lines where this 
was less expected, because these cells express p53-inhibiting proteins or p53 dominant-
negative mutants. Recently, we confirmed that Ad∆24-p53 is also more potent than its 
parent in killing primary cancer cells from many different patient specimens and in 
inhibiting tumor growth in three different cancer xenograft models in vivo 279lts). Sauthoff et 
al. expressed p53 during the late replication phase of an adenovirus without E3 region 278. 
They found that the p53-expressing virus in comparison to a wild type adenovirus 
expressing ADP was more cytotoxic to cancer cells but less cytotoxic to normal cells, 
suggesting that this modification may contribute to improving CRAd selectivity. 
The second approach combines CRAd treatment with anti-cancer gene therapy. 
The CRAd/GDEPT treatment discussed above is an example of this approach. In addition, 
several other cancer therapeutic genes have been evaluated in the context of CRAds. For 
example, CRAds have been used to deliver therapeutic genes that activate the immune 
system. Interferon plays an important role in a multitude of immunological processes, 
among them the upregulation of MHC class I and class II.  Human breast cancer cells 
transduced with the interferon gene failed to grow when transplanted into nude mice. 
Therefore, Zhang et al. constructed a replication competent adenoviral vector carrying the 
human interferon gene in the E3 region 280. Two cell lines grown as tumors in nude mice 
completely or partially regressed after injections with this virus, with wild type adenovirus 
being less effective. Kurihara et al. constructed a breast cancer specific CRAd expressing 
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TNF, known to have selective anti-tumor activity 186. Nude mice bearing subcutaneous 
breast cancer xenografts were treated with this virus or with the control virus expressing 
GFP instead of TNF. Treatment with the TNF-CRAd but not with the control virus was 
associated with regression to barely palpable tumors that sustained long-term. Bristol et al. 
constructed a CRAd in which GM-CSF, a potent inducer of specific, long-lasting anti-
tumoral immunity, was incorporated into the viral genome and its expression was 
controlled by the adenoviral E3 promoter 281. In two xenograft models, in which the CRAd 
was injected intratumorally, GM-CSF was detected in serum and tumor extracts, resulting 
in a significantly enlarged anti-tumor response compared to untreated mice or mice treated 
with replication deficient adenovirus. Compared to a replication competent control virus 
that lacks the GM-CSF expression cassette, in one of the tumor models a significant 
difference in tumor growth was observed. Very recently, two genes in the E3 region of a 
CRAd were replaced with TNF and monocyte chemotactic protein-3, respectively 282. The 
effect of this virus on the immunological response remains to be determined.  
Another strategy to enhance the efficacy of CRAds is by inducing cell killing through 
induction of fusion of tumor cells to form large multinucleated syncytia by fusogenic 
membrane glycoproteins (FMG). The formation and subsequent disintegration of syncytia 
is also immunostimulatory 283. Li et al. showed that an adenovirus expressing the fusogenic 
envelope protein of human immunodeficiency virus (HIV) induced syncytium formation in 
infected cell cultures expressing HIV receptors. Importantly, syncytium formation elevated 
adenovirus production and release 284. Recently, Ahmed et al. demonstrated that 
virotherapy in combination with injection of a plasmid encoding the Gibbon Ape Leukemia 
Virus (GALV) hyperfusogenic envelope FMG effectively treated large established tumors 
at doses of plasmids or virus that alone were ineffective 285. Inserting the GALV-FMG into a 
CRAd genome seems therefore an interesting option. Many other useful transgenes, that 
inhibit cell proliferation, migration, invasion, or blood vessel formation, can be envisaged, 
but have so far not been evaluated in replicating adenoviruses. For some therapeutic 
transgenes, it may be required that expression is temporally regulated, to avoid 
interference with CRAd replication. Several ways to express transgenes only during the 
late phase of replication were reported. For example, Sauthoff et al. used an Internal 
Ribosome Entry Site to link transgene expression to the fiber expression unit 278 and 
Hawkins and Hermiston replaced the ADP open reading frame with the transgene coding 
sequences 286. Thus, methods are in place to also use transgenes that may not only be 
detrimental to cancer cells but also to the virus. 
All together, enhancing the oncolytic potency of CRAds by inserting genes 
encoding therapeutic proteins that are specifically active in tumor cells is very useful for 
further development of CRAds into clinically applicable tools for the treatment of cancer. 
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OUTLINE OF THE THESIS 
 
The major goal of this thesis was to improve the efficacy of chemotherapy with CPT-11, an 
approved anti-cancer agent for treatment of colorectal cancer, by selective activation of 
the prodrug at the site of the tumor. In the general introduction in Chapter 1 background 
information is given on enzyme prodrug therapy with replication deficient adenoviral 
vectors, with emphasis on the carboxylesterase (CE)/CPT-11 system.  
GDEPT with CPT-11 and CE to convert the prodrug CPT-11 into the toxic drug SN-
38 has several advantages not offered by other enzyme prodrug models. First, CPT-11 
has demonstrated considerable anti-tumor activity as a single agent, indicating an intrinsic 
sensitivity of several types of solid tumors to this drug. Second, xenograft experiments 
showed that CPT-11 has a steep dose-response curve, suggesting that even a relatively 
modest increase in drug activation in tumor cells could produce remarkable increases in 
anti-tumor activity. Third, the molecular target of SN-38 is topoisomerase I, an essential 
enzyme, in which no resistance-conferring mutations have been identified in tumors of 
patients undergoing treatment with camptothecins. Fourth, since the basis for substrate 
specificity of most human CEs is known, more suited prodrugs based on existing or new 
classes of anti-tumor agents, or enzymes with a higher specific activity for CPT-11, could 
be designed. Fifth, SN-38 freely passes through cell membranes, thereby increasing the 
likelihood that a bystander effect might occur. 
Although CPT-11 therapy is effective against colon cancer, only 5% of 
intravenously administered CPT-11 is converted into SN-38. With GDEPT, it is possible to 
increase the levels of CE at the site of the tumor, resulting in increased conversion of the 
prodrug into the drug. This should lead to increased efficacy of the chemotherapy whereas 
toxicity is reduced. 
In this thesis, we focus on developing adenoviral vectors with expression cassettes 
encoding different forms of the prodrug converting enzyme CE for the treatment of 
colorectal cancer. We envisioned that expression of a secreted form of human liver CE2 
could increase the bystander effect, since extracellularly formed SN-38 might more easily 
diffuse through a solid tumor mass, resulting in toxicity to untransduced neighboring cells. 
A secreted, tumor-targeted form could, furthermore, prevent leakage of the enzyme into 
the circulation, thereby decreasing the possibility that of side effects occur. To investigate 
this, we describe in Chapter 2 the construction and characterization of secreted and 
secreted, targeted forms of human liver CE2. Secreted CE2 was obtained by deletion of a 
cellular C-terminal retention signal and introduction of a secretion signal. The targeted 
fusion protein consisted of the secreted form and a scFv antibody directed to the tumor 
antigen Epithelial Cell Adhesion Molecule (EpCAM). Delivery of these enzymes to the 
tumor can be achieved by transduction of tumor cells with these cDNA constructs. To that 
end, the genes encoding secreted or secreted, EpCAM targeted CE2 were cloned into 
replication deficient adenoviral vectors. The construction of the replication deficient 
adenoviral vector containing the gene encoding the targeted fusion protein is described in 
Chapter 3. In 3-dimensional colon cancer spheroids, we determine the penetration 
capacity of the fusion protein and the therapeutic efficacy of this replication deficient 
adenovirus in combination with CPT-11 treatment. In Chapter 4, the construction of a 
replication deficient adenoviral vector expressing the secreted form of CE2 is described 
and the utility of this virus in combination with CPT-11 for the treatment of osteosarcoma 
cell lines or primary cell cultures in vitro and in vivo is evaluated.  
Another way to overcome the poor penetration capacity of the adenoviral vectors is 
by using conditionally replicating adenoviruses (CRAds) that selectively replicate in tumor 
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cells. The general introduction in Chapter 1 also gives an overview on the working 
mechanisms of conditionally replicating adenoviruses (CRAds), the efficacy of CRAds in 
clinical trials and possible ways to improve the efficacy of CRAds. An example of such a 
CRAd is Ad5-∆24.E3. In Chapter 5, we describe the construction of an Ad5-∆24.E3 
derivative expressing the secreted form of CE2 and its applicability for the treatment of 
colon cancer in combination with chemotherapy with CPT-11. In Chapter 6, we compare 
in colon cancer cell lines the oncolytic potency of the CRAd Ad5-∆24 with its derivative 
Ad5∆24-p53 that expresses functional p53 upon infection. Furthermore, we investigate 
whether the efficacy of Ad5∆24-p53 could be further improved by treatment with sub-toxic 
dose of the chemotherapeutic drug oxaliplatin.  
Finally, in Chapter 7, the results are summarized, discussed and put in current 
perspective. 
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SUMMARY 
 
Irinotecan (CPT-11) is an anticancer agent for the treatment of colon cancer. 
CPT-11 can be considered as a prodrug, since it needs to be activated into 
the toxic drug SN-38 by the enzyme carboxylesterase (CE). An approach to 
achieve tumor specific activation of CPT-11 is to transduce the cDNA 
encoding CE into tumor cells. A secreted form of CE may diffuse through a 
tumor mass and may activate CPT-11 extracellularly. This could enhance the 
anti-tumor efficacy by exerting a bystander effect on untransduced cells. In 
addition a secreted targeted-targeted form of CE should prevent leakage of 
the enzyme from the site of the targeted into the circulation. We have 
constructed a secreted form of human liver CE-2 by deletion of the cellular 
retention signal and by cloning the cDNA downstream of an Ig kappa leader 
sequence. The protein was secreted by transfected cells and showed both 
enzyme activity and efficient CPT-11 activation. To obtain a secreted, 
targeted-targeted form of CE2 the cDNA encoding the human scFv antibody 
C28 directed against the epithelial cell adhesion molecule EpCAM, was 
inserted between the leader sequence and CE-2. This fusion protein showed 
CPT-11 activation and specific binding to EpCAM expressing cells. 
Importantly, in combination with CPT-11 both recombinant CE proteins 
exerted strong antiproliferative effects on human colon cancer cells. They are, 
therefore, promising new tools for gene directed enzyme prodrug therapy 
approaches for the treatment of colon carcinoma with CPT-11. 
 
 
INTRODUCTION 
 
Conventional chemotherapy lacks specificity for tumor cells. This results in 
dose-limiting side effects and insufficient concentrations of the drugs in the 
tumor, through which efficacy is limited and drug resistant cellular 
subpopulations may emerge. These problems may be overcome by 
expressing an enzyme that is capable of converting a non-toxic prodrug into a 
toxic drug specifically in tumor cells. This so-called gene-directed enzyme 
prodrug therapy (GDEPT) or suicide gene therapy aims to increase the 
concentration of the drug in the tumor while reducing the systemic toxicity. 
The gene encoding the prodrug-activating enzyme is delivered to the tumor 
cells by, for example, an adenoviral vector, followed by systemic 
administration of the prodrug. In this regard, several prodrug-converting 
enzymes have been extensively studied, such as the herpes simplex virus 
thymidine kinase enzyme that converts ganciclovir (GCV) into the active 
compound GCV-P and bacterial cytosine deaminase that activates 5-FC to 
the anticancer drug 5-FU 1,2.  
A prodrug for the treatment of colon carcinoma is irinotecan (CPT-11 or 
7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin). CPT-11 is 
converted by carboxylesterases (CE) into the toxic drug SN-38 (7-ethyl-10-
hydroxycamptothecin) by cleavage of the bulky dipiperidino side chain at the 
carbon position 3,4. CPT-11 has demonstrated anti-tumor activity in immune 
deprived animals bearing human tumor xenografts 5-8 and is approved for use 
in the treatment of metastatic colorectal cancer in humans. Although SN-38 
can be detected in the plasma of cancer patients only minutes after the 
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administration of CPT-11 9, 90% of the administered CPT-11 is not converted 
to SN-38 10. 
CEs are a ubiquitously expressed class of enzymes. High levels of 
enzyme activity are found in human liver and lung 11. Different isoforms of 
human CE have been described. CE1 is found in liver only, whereas CE2 is 
also found in the intestines and CE3 is found in brain cells 12,13. Furthermore, 
it has been shown that human alveolar macrophages release a serine 
esterase that is identical to liver CE1 14. 
Several studies have been performed using CPT-11 in combination 
with human CE1 in a GDEPT approach. Kojima et al. described the 
construction of a replication deficient adenoviral vector containing the human 
liver CE1 gene driven by the CMV promoter 15,16. In vitro results showed that 
several tumor cell lines infected with this virus express CE1 and in the 
presence of CPT-11 tumor growth was effectively suppressed. However, on 
many other tumor cell lines only minimal effects were observed. This 
underscored the notice that the success of a GDEPT approach for CPT-11 
requires an enzyme with a high efficiency of converting CPT-11 to SN-38. The 
rabbit CE was found to be 100-1000 fold more efficient in converting CPT-11 
than human liver CE1 and was 12-55 fold more efficient in sensitizing 
transfected cells to CPT-11 17. Therefore, an adenoviral vector expressing 
rabbit CE was constructed and transduction of human tumor cells led to 
sensitization to CPT-11 18.  The disadvantage of rabbit CE, however, is that 
expression of a nonhuman protein in patients may lead to an immunological 
response and subsequent enzyme inactivation. A human enzyme with higher 
affinity and higher efficiency than CE1 may overcome these limitations. It was 
shown that human CE2 has a higher affinity and a higher conversion velocity 
for CPT-11 than CE1 19. Therefore, we envisaged that CE2 would be a 
candidate to employ in a GDEPT approach to treat human tumors. 
To achieve efficient kill of all tumor cells, a bystander effect is required, 
whereby CPT-11 is cleaved to SN-38 that not only kills the tumor cells in 
which CE2 is formed, but also neighboring tumor cells that do not express 
CE2. We hypothesized that extracellular conversion of CPT-11 would lead to 
a larger bystander effect than intracellular conversion and, furthermore, that a 
fusion protein consisting of secreted CE2 fused to a tumor specific scFv 
antibody will be retained in the tumor thereby preventing leakage of the 
enzyme into the circulation and therefore further reducing unwanted side 
effects.  
In this study we describe the construction of a secreted form of CE2 
(sCE2) by deletion of a C-terminal cellular retention signal and by adding the 
Ig kappa leader sequence. Furthermore, a secreted targeted form of human 
CE2 (C28-sCE2) was constructed by fusing sCE2 to a human scFv directed 
against Epithelial Cell Adhesion Molecule (EpCAM). The binding specificity 
and enzyme activity of the secreted form of CE2 and the fusion protein and 
their ability to sensitize human tumor cell lines to CPT-11 is determined and 
compared to wild type intracellularly expressed human CE2 (CE2). 
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MATERIAL AND METHODS 
 
Chemicals 
Pwo polymerase, PCR buffer and dNTPs were obtained from Roche (Almere, 
The Netherlands). Restriction enzymes were purchased from New England 
Biolabs (Beverly, MA) and Life Technologies (Breda, The Netherlands). The 
kits used for DNA isolation, purification and extraction from agarose gel were 
from Qiagen (Hilden, Germany). The substrate p-nitrophenyl-acetate was 
purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). The prodrug 
CPT-11 and the drug SN-38 were obtained from Rhône-Poulenc Rorer (Vitry-
sur-Seine, France). 
 
 
Cell lines 
The COS-7 and the human colon cancer SW1398 cell lines were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies, Paisley, UK) 
supplemented with 5% (COS-7) or 10% heat-inactivated fetal calf serum (Life 
Technologies), 50IU/ml penicillin (Life Technologies) and 50µg/ml 
streptomycin (Life Technologies) in a humidified atmosphere containing 5% 
CO2 at 37°C. 
 
 
Construction of psCE2 and pC28-sCE2 
The pBluescript vector containing the CE2 open reading frame 20 was 
digested with EcoRI and the CE2 encoding fragment was ligated into the 
EcoRI linearized eukaryotic expression vector pcDNA3 (Invitrogen, 
Groningen, The Netherlands). This construct was called pCE2. To construct a 
secreted form of CE2 (psCE2), two primers (sense 5' 
GACGCGGCCCAGCCGGCCCAGGACTCAGCCAGTCCCATCC 3' and antisense 5' 
GACTCGAGCGGCCGCTCTCTCTTCAGGCTCCTCGAGC 3') were designed to 
introduce an SfiI restriction site (italic) at the beginning of the sequence 
encoding the mature protein and a NotI restriction site (italic) before the 
retention signal, as shown in figure 1. After performing the PCR, the SfiI/NotI 
digested fragment was isolated, purified, and ligated into the eukaryotic 
expression vector pSTCF, containing a myc- and 6 his-tag and the Ig kappa 
leader sequence that directs proteins to the secretory pathway 21. 
The human anti-EpCAM scFv C28 was derived from scFv UBS-54, 
which was isolated from a semi-synthetic phage antibody display library 22, 
and was a kind gift of Dr. T. Logtenberg (Crucell, Leiden). An SfiI/NotI 
fragment encoding the scFv C28 was isolated from a pHEN vector, and 
cloned into the eukaryotic expression vector pSTCF. A flexible (Gly4Ser)2 
linker was introduced downstream of C28, as described previously 23.  To 
allow insertion of sCE2 downstream of the (Gly4Ser)2 linker, a PCR was 
performed to obtain a DNA fragment encoding a secreted form of CE2 starting 
from the mature CE2 protein and ending just before the cellular retention 
signal. Both primers used in the PCR (sense 5' 
GTGTGCGGCCGCCAGGACTCAGCCAGTCCCATC 3' and antisense primer as 
described above) contained a NotI site (italic). The PCR product was digested 
with NotI and inserted into the NotI sites of the vector containing C28 with the 
(Gly4Ser)2 linker to obtain pC28-sCE2. 
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Expression of CE2, sCE2 and C28-sCE2 fusion protein 
COS-7 cells (2.106) were transfected with 2 µg pCE2, psCE2 or pC28-sCE2 
by Lipofectamine Plus reagent (Life Technologies) according to instructions of 
the manufacturer. Cells were grown in 3.5 ml DMEM containing 5% FCS and 
antibiotics. After 48 h, supernatants were removed and cells were harvested 
by trypsinization. Cellular lysates were obtained by three times freeze thawing 
in 350 µl PBS. For cytotoxicity assays and HPLC analysis proteins present in 
supernatants of transfected COS-7 cells were 10X concentrated using a 
Biomax-10 centrifugal filter (Millipore, Bedford, USA). Supernatants and 
cellular lysates were analyzed for the presence of functional CE enzyme or 
C28-sCE2 fusion protein by Western blotting, esterase activity assay and 
cytotoxicity assays. Binding of proteins in supernatants of COS-7 cells 
transfected with pC28-sCE2 or psCE2 to EpCAM positive cells was 
determined by FACS analysis. 
 
 
Western blot analysis 
Proportional amounts of supernatant or cellular lysate from COS-7 cells 
transfected with pCE2, psCE2 or pC28-sCE2 were dissolved in sample buffer 
24 with 5% 2-mercaptoethanol and heated at 95°C for 5 min. Samples were 
electrophorezed through a denaturing 10% sodium dodecyl sulphate-
polyacrylamide gel and protein bands were electroblotted onto PVDF protein 
membrane (BioRad). Proteins were detected using anti-myc antibody 9E10 25 
and HRP-conjugated rabbit anti-mouse IgG (Dako) or with rabbit-anti-CE2, an 
antibody directed to the C-terminal retention signal of CE which was a kind gift 
of Dr. Yan, University of Rhode Island 26, and HRP-conjugated swine anti-
rabbit IgG (Dako). Blots were developed with enhanced chemo luminescence 
reagent (Lumilight Plus, Roche). 
 
 
Esterase activity assay 
Supernatants or cellular lysates of transfected COS-7 cells were incubated 
with 200 µl 100 mM Tris-HCl pH 8.0 containing 100 mM pNpAc, a substrate 
for CE. After mixing, conversion to p-Nitrophenol was measured at a 
wavelength of 415 nm during 10 minutes using an ELISA plate reader 
(BioRad, Veenendaal, The Netherlands).  
 
 
FACS analysis  
EpCAM expressing SW1398 cells were trypsinized for 5 min at 37°C, washed 
with DMEM, counted and resuspended in PBS. A total of 5×105 cells was 
incubated for 1 h on ice with 50 µl supernatant of COS-7 cells transfected with 
pC28-sCE2. As a negative control, supernatants of untransfected COS-7 cells 
or cells transfected with psCE2 were used. After washing 3 times with PBS, 
cells were incubated with anti-myc antibody 9E10 in PBS/0.1% BSA, washed 
3 times with PBS, and stained with fluorescein-conjugated rabbit anti-mouse 
IgG (Dako). As a positive control 50 µl (10 µg/ml) of the anti-EpCAM antibody 
323/A3 27 was used. Stained cells were fixed with 1% formaldehyde in PBS 
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and analyzed on a FACScan flow cytometer (Becton Dickinson, Mountain 
View, CA). 
 
 
Immunohistochemistry 
To show binding of C28-sCE2 to EpCAM expressing cells, 1.104 SW1398 
cells were plated and incubated overnight with the concentrated supernatants 
of COS-7 cells transfected with psCE2 or pC28-sCE2. Unbound enzyme was 
removed by washing with culture medium and cells were fixed with 100 µl 
50% MeOH/50% acetone. After washing with PBS, anti-myc antibody 9E10 
was added to the cells for 1 h at 37°C, followed by incubation with rabbit anti 
mouse HRP (1:100 in PBS/0.1%BSA) for 1 h. Hereafter cells were washed 
and 3-amino-9-ethylcarbazole substrate chromogen (Dako, USA) was added. 
The staining was stopped by washing with PBS. Cells were counterstained 
with haematoxylin. 
 
 
In vitro cytotoxicity assay 
SW1398 cells (1.104) were plated in a 96-wells microtiter plate (Bio-one). After 
24 h, concentrated supernatants of COS-7 cells transfected with pCE2, 
psCE2 or pC28-sCE2 was added together with a non-toxic concentration of 
CPT-11 (1µM). Control experiments were performed in which SW1398 cells 
were incubated with DMEM supplemented with 10% FCS, SN-38 or CPT-11 
only. After another 72 h culture the cells were incubated with cell proliferation 
reagent WST-1 (Roche Diagnostics) for 1 h at 37°C. The absorbency was 
measured at a wavelength of 450 nm. The antiproliferative effects were 
determined and expressed as percentages of growth as compared to 
untreated control growth, which was set to 100%. 
 
 
RESULTS 
 
Construction of CE2, sCE2 and C28-sCE2 
The cDNA coding for human CE2 20 was inserted into the eukaryotic 
expression vector pcDNA3, creating pCE2 (fig. 1). Using PCR we amplified a 
CE2 cDNA fragment encoding the mature protein without the last four amino 
acids encoding the cellular retention signal HTEL. This fragment was inserted 
into the pSTCF vector, which contains the Ig kappa leader that directs the 
protein in the secretory pathway and a myc- and 6xhis-tag 21. The resulting 
construct encoding a secreted form of CE2 (sCE2) was designated psCE2 
(fig.1). The cDNA fragment coding for sCE2 was also inserted into the pSTCF 
vector in frame with the anti-EpCAM scFv C28, creating pC28-sCE2 (fig. 1). 
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Figure 1: Schematic representation of the CE2, sCE2 and C28-sCE2 expression 
cassette. The CE2 cDNA is inserted as an EcoRI fragment into pcDNA3. The 
encoded protein contains its wild type N-terminal signal peptide and a C-terminal 
cellular retention signal sequence HTEL. The structural elements of pSTCF include 
the strong cytomegalovirus (CMV) promoter, IgG kappa leader sequence, and a C-
terminal myc- and His-tag (mycHis) for easy detection and purification. sCE2, without 
retention signal, is inserted as a SfiI/NotI fragment into pSTCF. 
The anti-EpCAM scFv C28 is inserted as a SfiI/NotI fragment. The gene 
encoding CE2 is inserted as a NotI/NotI fragment, after the (Gly4Ser)2 linker is 
inserted in the NotI and ApaI restriction sites. 
 
 
Expression and characterization of CE2, sCE2 and C28-sCE2 
COS-7 cells were transfected with pCE2, psCE2 or pC28-sCE2 and 
expressed proteins in supernatant and cellular lysates were analyzed by 
Western blotting, FACS analysis, esterase activity assay and cytotoxicity 
assays. To assess the size of the expressed proteins and determine the 
amount of secreted protein, SDS-PAGE was performed followed by Western 
blotting and detection with anti-myc antibody for sCE2 and C28-sCE2 or anti 
CE2 antibody for CE2 (figure 2). The CE2 protein appeared to remain 
intracellular since it was only detected in the cellular lysate (fig. 2, lane 1) of 
transfected COS-7 cells. Like CE2, the sCE2 monomers migrated with an 
apparent molecular weight of 75 kDa. As expected, the majority of sCE2 was 
detected in the supernatant of transfected COS-7 cells, proving that deletion 
of the C-terminal retention signal and fusing the Ig kappa leader, indeed 
directed the protein into the secretory pathway (fig. 2, lane 5). The C28-sCE2 
fusion protein, with an apparent molecular weight of 100kDa, was also found 
mainly in the supernatants of transfected COS-7 cells (fig. 2, lane 6). 
Functional enzyme activity of CE2, sCE2 and C28-sCE2 was 
demonstrated by an esterase enzyme activity assay (figure 3). In cells 
transfected with pCE2 esterase activity remained intracellular, while in cells 
transfected with psCE2 or pC28-sCE2 almost all activity was detected in the 
culture medium. These results confirmed the results of the Western blotting 
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experiments, since the relative amounts and the activities of CE2 proteins in 
cells and supernatants of transfected COS-7 cells were comparable. 
 
 
 
 
 
 
 
Figure 2: Western blot analysis of the cellular lysates and supernatants of COS-7 
cells transfected with pCE, psCE2 or pC28-sCE2. sCE2 and C28-sCE2 were 
detected using an antibody directed against the myc-tag and CE2 was detected with 
an antibody directed against the C-terminal cellular retention signal. In lanes 1, 3 and 
4 cellular lysates (c) and in lanes 2, 5 and 6 supernatants (s) of COS-7 cells 
transfected with pCE2 (lanes 1,2), psCE2 (lanes 3,4) and pC28-sCE2 (lanes 5,6) 
respectively are shown. The CE proteins migrated with an apparent molecular weight 
of 75 kDa whereas the fusion protein had a molecular weight of 100 kDa. As 
expected, CE2 mainly remained intracellular while sCE2 and C28-sCE2 were 
secreted by transfected COS-7 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: CE-activity in cellular lysates and supernatants of COS-7 transfected with 
pCE2, psCE2, pC28-sCE2. Cellular lysates or supernatants of transfected COS-7 
cells were incubated with 1mM pNpAc and conversion was measured during 10 
minutes. sCE2 and C28-sCE2 show enzymatic activity and are efficiently secreted by 
transfected cells, because most of the enzyme activity is found in the supernatant. 
 
 
Binding of the C28-sCE2 fusion protein to EpCAM was demonstrated 
by FACS analysis of EpCAM expressing SW1398 colon cancer cells 
incubated with transfected COS-7 supernatants (figure 4A), whereas sCE2 did 
not bind the EpCAM expressing cells. Thus, the C28 moiety of C28-sCE2 
mediated EpCAM binding. Furthermore, SW1398 cells were plated and 
incubated with the transfected COS-7 supernatants for 24 h. Hereafter, cells 
were stained with anti-myc antibody to detect bound fusion protein. C28-sCE2 
was detected at the membrane of SW1398 cells, shown in figure 4B, whereas 
cells incubated with sCE2 were not stained.   
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Figure 4: Binding of C28-sCE2 to the EpCAM expressing human colon cancer cell 
line SW1398. (A) FACS analysis of SW1398 cells that highly express EpCAM, with 
the supernatants of COS-7 cells transfected with psCE2 or pC28-sCE2. As a positive 
control the 323A3 antibody (bold line), directed to EpCAM was used. Binding was 
visualized with mouse anti-myc antibody and fluorescein-conjugated rabbit anti-
mouse IgG. The fusion protein C28-sCE2 (dotted line) is able to bind to SW1398 
cells, whereas sCE2 is overlapping the PBS control (solid line). (B) Cells were 
incubated for 24 h with supernatants of transfected COS-7 cells. Hereafter, cells 
were stained with anti-myc antibody to show binding of sCE2 or C28-sCE2 to 
EpCAM. Cells were counterstained with haematoxylin. Only cells incubated with C28-
sCE2 (right) show binding of the fusion protein to the cellular membrane, whereas 
sCE2 incubation did not show bound protein (left). 
 
 
Prodrug activation and antiproliferative effects 
Concentrated supernatants of COS-7 cells transfected with pCE2, psCE2 or 
pC28-sCE2 were analyzed for CPT-11 conversion using HPLC. Supernatants 
were incubated with CPT-11 for 22 h at 37°C. It was found that both sCE2 
and C28-sCE2, which were secreted in the culture medium of transfected 
cells, were able to activate the prodrug CPT-11, since the drug SN-38 was 
formed (data not shown).  
 
 
 
CPT-11 conversion by secreted and targeted CE 
 71
To show the effect of CPT-11 conversion into SN-38 by CE2, sCE2 and C28-
sCE2 on the viability of colon cancer cells, the EpCAM-expressing colon 
carcinoma cell line SW1398 was incubated overnight with the concentrated 
supernatant of COS-7 cells transfected with pCE2, psCE2 or pC28-sCE2. 
After incubation, culture medium or a non-toxic concentration (1 µM) of CPT-
11 was added. In figure 5 it is shown that the supernatants of COS-7 cells 
transfected with sCE2 or C28-sCE2 render SW1398 cells susceptible to CPT-
11. Incubation with supernatants of pCE2 transfected COS-7 cells and CPT-
11, which do not secrete CE, or incubation with sCE2 or C28-sCE2 
supernatant only, did not show augmented toxicity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Cytotoxicity assay with the EpCAM expressing cell line SW1398 incubated 
with 1 µM CPT-11 and concentrated supernatants of COS-7 cells transfected with 
pCE2, psCE2 or pC28-sCE2 or with supernatants only. Results are shown as % of 
killed cells compared to untreated control cells, which were set to 0 % kill. Incubation 
with sCE2 or C28-sCE2 supernatants and the non-toxic concentration of CPT-11 
result in growth inhibition comparable to incubation with 1 µM SN-38, whereas 
incubation with CPT-11 or supernatant only is not toxic. 
 
 
DISCUSSION 
 
CPT-11 is a prodrug for the treatment of colon cancer. One enzyme that 
converts CPT-11 into the toxic drug SN-38 is CE. By increasing the 
concentration of CE at the site of a tumor via a GDEPT approach, the 
conversion of CPT-11 to SN-38 will be enhanced at the site of the tumor, 
leading to tumor specific cytotoxicity. Human liver CE1 and rabbit CE have 
been employed in a GDEPT approach in combination with CPT-11. Although 
rabbit CE appeared to convert CPT-11 very effectively 17, an enzyme of 
human origin is preferred for in vivo applications to treat patients. Human CE1 
showed a low conversion velocity and a low hydrolysis rate for CPT-11 in 
comparison with CE2 19. Therefore, in this study we used the human liver CE2 
enzyme to sensitize human tumor cells to CPT-11.  Because current gene 
transfer technology does not allow expression of transgenes in all cells of a 
targeted tumor in vivo, a bystander effect is required, in order to achieve 
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efficient tumor reduction.  Extracellularly produced SN-38 should not only kill 
the tumor cells in which CE2 is formed, but also neighboring tumor cells that 
do not express CE2. To investigate whether extracellular conversion of CPT-
11 would lead to a larger bystander effect than intracellular conversion, we 
constructed a secreted form of CE2 (sCE2). Furthermore, we hypothesized 
that a fusion protein consisting of sCE2 fused to a tumor specific scFv 
antibody would be retained in the tumor thereby preventing leakage of the 
enzyme into the circulation and therefore further reducing unwanted side 
effects. An example of a tumor-associated antigen is EpCAM. This molecule 
is an attractive target for enzyme prodrug therapy, since it is highly expressed 
on the cell surface of most carcinomas, including colon tumors. Furthermore, 
EpCAM is highly expressed on distant metastasis 28. Therefore, we 
constructed a fully human fusion protein consisting of sCE2 fused to a human 
scFv antibody directed to EpCAM (C28-sCE2). Intratumoral expression of this 
protein in cancer patients is expected to be less immunogenic than expression 
of non-human fusion proteins. 
The secreted and the targeted protein were detected in the supernatant 
of transfected COS-7 cells and the secreted proteins exhibited comparable 
enzymatic activities as determined by conversion of pNpAc. Comparing the 
secreted proteins to intracellular wild type CE2, it was observed that 
transfecting COS-7 cells with pCE2 resulted in a much lower total amount of 
CE-activity than cells transfected with psCE2 or the fusion protein C28-sCE2. 
Whether this is due to a greater amount of protein or a higher enzyme activity 
of sCE2 when compared with CE is not clear. C28-sCE2 showed enzyme 
activity and specific binding to EpCAM expressing cells as determined by 
FACS analysis and immunohistochemistry on SW1398 cells, whereas sCE2 
did not bind these cells. Furthermore, using HPLC analysis it was shown that 
the secreted as well as the targeted form of CE2 were able to efficiently 
convert CPT-11 into SN-38.  Experiments with SW1398 colon carcinoma cells 
that were incubated with secreted or targeted protein and a non-toxic 
concentration of CPT-11 showed complete growth inhibition of these cells.  
In conclusion, we constructed a secreted form of CE2 that was capable 
to convert the prodrug CPT-11, leading to enhanced toxicity of CPT-11 to 
colon cancer cells. This construct holds promise in GDEPT approaches since 
transduction of tumor cells with psCE2 will most likely result in high 
concentrations of sCE2 throughout the whole tumor. Therefore, CPT-11 will 
be converted to SN-38 very efficiently throughout the tumor, resulting in a 
larger bystander effect than intracellular conversion of CPT-11. The C28-
sCE2 fusion protein is as active as sCE2, and therefore this construct is as 
useful as sCE2 for GDEPT, but the theoretical advantage of C28-sCE2 is that 
the targeting moiety will prevent leakage of the construct into the circulation. 
However, from this study it can not be concluded that C28-sCE2 will have this 
additional advantage as compared to sCE2 .To prove this hypothesis, in vivo 
experiments are necessary in which sCE2 and C28-sCE2 are expressed in 
colon carcinoma xenografts followed by CPT-11 administration.  
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SUMMARY 
 
CPT-11 is an anticancer agent in use for the treatment of colon cancer. In 
order to be fully active, CPT-11 needs to be converted into SN-38 by the 
enzyme carboxylesterase. In humans, only a minority of CPT-11 is converted 
to SN-38. To increase the anti-tumor effect of CPT-11 by Gene-Directed 
Enzyme Prodrug Therapy, we constructed a replication deficient adenoviral 
vector Ad.C28-sCE2 containing a fusion gene encoding a secreted form of 
human liver carboxylesterase-2 targeted to the surface antigen EpCAM that is 
highly expressed on most colon carcinoma cells. By targeting 
carboxylesterase-2 to EpCAM, the enzyme should accumulate specifically in 
tumors and leakage into the circulation should be minimized. Ad.C28-sCE2 
transduced colon carcinoma cells expressed and secreted active 
carboxylesterase that bound specifically to EpCAM expressing cells. In 
sections of 3-dimensional colon carcinoma spheroids transduced with 
Ad.C28-sCE2, it was shown that C28-sCE2 was capable of binding 
untransduced cells. Most importantly, treatment of these spheroids with non-
toxic concentrations of CPT-11 resulted in growth inhibition comparable to 
treatment with SN-38. Therefore, Ad.C28-sCE2 holds promise in gene therapy 
approaches for the treatment of colon carcinoma. 
   
 
INTRODUCTION 
 
Conventional chemotherapy is not specific for tumor cells and therefore its 
administration is limited by side effects. These side effects might potentially be 
overcome by targeting chemotherapy specifically to tumor cells by Gene-
Directed Enzyme Prodrug Therapy (GDEPT). In GDEPT, a gene encoding a 
prodrug-converting enzyme is delivered to the tumor by, for example, an 
adenoviral vector. If the prodrug is administered it will be specifically 
converted to the active drug at the site of the tumor. This should increase the 
efficacy and decrease the side effects of chemotherapy. CPT-11 (irinotecan or 
7-ethyl-10[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) is an 
anticancer agent that is approved for first line treatment of metastatic colon 
cancer. In order to be fully active, CPT-11 needs to be activated into the 
active compound SN-38 (7-ethyl-10-hydroxycamptothecin) by 
carboxylesterase (CE) enzymes 1,2. Although SN-38 is detected in the plasma 
of cancer patients only minutes after administration of CPT-11 3, 90-95% of 
the prodrug is not converted to SN-38 4. A way to improve the anti-tumor 
effect of CPT-11 may be to use CPT-11 and CE in a GDEPT approach. 
Adenoviral mediated expression of rabbit CE showed to efficiently sensitize a 
panel of tumor cell lines to CPT-11 5. A human enzyme, however, has the 
advantage over a non-human enzyme that it will not lead to an immune 
response against the enzyme and subsequent enzyme inactivation. Kojima et 
al. described the construction of a replication deficient adenoviral vector 
containing the cDNA encoding human liver CE isoform 1 (CE1) 6.  Cell lines 
transduced with this virus and treated with CPT-11, however, showed only 
minimal anti-tumor effects. The liver CE isoform 2 (CE2) has a higher affinity 
and a higher conversion velocity of CPT-11 compared to CE1 7. Therefore, we 
envisaged that human liver CE2 would be the best candidate to employ in a 
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GDEPT approach to treat human colon cancer. Given the fact that current 
gene transfer technologies do not allow transduction of all tumor cells, a 
bystander effect is warranted to achieve effective kill of untransduced tumor 
cells. To improve the bystander effect of adenoviral vector mediated GDEPT 
approaches, secreted and surface-tethered prodrug converting enzymes have 
been investigated 8,9,10,11. We envisioned that a targeted, secreted form of 
CE2, consisting of the secreted form of CE2 (sCE2) fused to a tumor specific 
scFv antibody would provide an enlarged bystander effect and would 
furthermore theoretically prevent leakage of the protein into the circulation, 
thereby reducing systemic side effects.  Previously, we constructed a fusion 
protein in which sCE2 was fused to the human scFv antibody C28 which is 
directed to the tumor antigen Epithelial Cell Adhesion Molecule (EpCAM) 12. 
This fusion protein has potential utility for GDEPT of colon cancer, because 
EpCAM is highly overexpressed in colon cancer cells including distant 
metastases 13. Here, we describe the construction of a replication deficient 
adenoviral vector containing the cDNA encoding the fully human fusion 
protein C28-sCE2. In a 3-D tumor spheroid model in vitro, we could 
demonstrate that the secreted fusion protein bound non-transduced cells and 
caused efficient killing of colon cancer cells in the presence of CPT-11.   
 
 
MATERIALS AND METHODS 
 
Cells and culture conditions  
The colon cancer cell lines SW1398 and Colo205 and the ovarian cancer cell 
line A2780 (all cell lines were kindly provided by Dr. E. Boven, VUMC, 
Amsterdam, The Netherlands) were maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% Fetal Calf Serum (FCS), 50 IU/ml 
penicillin and 50 µg/ml streptomycin (Invitrogen, Breda, The Netherlands), at 
37°C in a 5% CO2 humidified atmosphere. The 293-cell line (ATCC, 
Manassas, VA) was maintained in DMEM supplemented with 10% FCS, 50 
IU/ml penicillin, 50 µg/ml streptomycin and 2mM L-glutamine (Invitrogen).  
 
 
Formation of colon cancer spheroids 
96-well plates (Greiner, Alphen aan den Rijn, The Netherlands) were coated 
with 2% agarose (Roche, Almere, The Netherlands) in PBS. Colon cancer 
SW1398 or Colo205 cells were plated (1.104 cells/well) and rotated overnight 
at 140 rpm in a Heidolph Unimax incubator. By plating equal amounts of cells 
in each well and rotating them overnight, spheroids of similar sizes are 
formed. This allows direct comparison of different treatment modalities. After 
rotation, the formed spheroids were grown in a 5% CO2 humidified 
atmosphere at 37°C for 3 days before use in transduction experiments.  
 
 
Construction of Ad.C28-sCE2  
The adenoviral vector Ad.C28-sCE2 was constructed using the AdEasy 
System 14. The plasmid pSTCF-C28-sCE2, containing the secreted, EpCAM-
targeted CE2 (C28-sCE2) open reading frame 12 with a myc-6His tag at the C-
terminus, was digested with PmeI and NheI and the C28-sCE2 open reading 
Sensitization of spheroids to CPT-11 
 79
frame was ligated into the XbaI and EcoRV linearized transfer vector 
pAdTrack-CMV. This construct contains a gene encoding Green Fluorescent 
Protein (GFP) under the CMV promoter. Subsequently, the plasmid was 
digested with PmeI and cotransformed into E. coli BJ5183 cells with 
adenoviral backbone plasmid pAdEasy-1 to construct pAdEasy-C28-sCE2. 
After linearization of this recombinant vector with PacI, the plasmid was 
transfected into the 293 adenovirus packaging cell line. Virus was further 
propagated in 293 cells according to standard techniques. For all experiments 
AdGFP 15 was taken along as a negative control. 
 
 
Western blot analysis 
Equivalent amounts of supernatant or cellular lysate from SW1398 cells 
transduced with Ad.C28-sCE2 were dissolved in sample buffer 16 with 2-
mercaptoethanol and heated to 95°C for 5 min. Samples were 
electrophorezed through a denaturing 10% sodium dodecyl sulphate-
polyacrylamide gel and protein bands were electroblotted onto a PVDF protein 
membrane (BioRad, Veenendaal, The Netherlands). Proteins were detected 
using anti-myc antibody 9E10 17 and HRP-conjugated rabbit anti-mouse IgG 
(DakoCytomation, Heverlee, Belgium). Films were developed with enhanced 
chemoluminescence (Lumilight Plus, Roche). 
 
 
Esterase activity assay  
To evaluate the esterase activity of proteins expressed by SW1398 cells 
transduced with Ad.C28-sCE2, cellular lysates or supernatants were 
incubated with 200 µl 100 mM Tris-HCl pH =8.0 containing 1 mM p-
nitrophenyl-acetate (pNpAc) (Sigma Aldrich, Zwijndrecht, The Netherlands), a 
substrate for CE. Conversion to pNp at room temperature was measured 
during 10 minutes using an ELISA plate reader (BioRad) at a wavelength of 
415 nm. 
 
 
Immunohistochemistry  
Spheroids were harvested at different time points after transduction (day 1, 4 
or 5) in TissueTek (Sakura Finetek, Zoeterwoude, The Netherlands) and 
cryostat sections of 7-10 µM were made and stored at -80°C. After drying, 
sections were fixed with 4% formaldehyde in PBS for 30 minutes, washed with 
PBS and treated with 0.2% Triton-X-100 in PBS. After washing, the sections 
were incubated for 1h with the anti-myc antibody 9E10. As a positive control, 
anti-EpCAM antibody 323A3 (kindly provided by Centocor, Leiden, the 
Netherlands) was taken along and as negative controls PBS/0.1% BSA and 
anti-glucuronidase 18 were used. After incubation, sections were washed with 
PBS and incubated with rabbit-anti-mouse-HRP or goat-anti-rabbit-HRP 
(1:100 in PBS/0.1% BSA, both from DakoCytomation). After incubation for 1 
h, sections were washed with PBS and stained with AEC (DakoCytomation) 
and sections were counterstained with haematoxylin. 
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In vitro cytotoxicity assays  
Three days after formation of colon cancer spheroids, the spheroids were 
transduced with 1.107 plaque-forming units Ad.C28-sCE2 in 100 µl culture 
medium. Control spheroids were transduced with AdGFP or cultured in 
medium. After 7 days, 100 µl culture medium was added containing a range of 
CPT-11 (Aventis, Strasbourg, France). After a further 7 days, cell viability was 
determined by WST-1 (Roche Diagnostics) conversion at 37°C. Data are 
expressed as percentages compared to untransduced, untreated control 
spheroids.  
 
 
RESULTS 
 
Construction and characterization of Ad.C28-sCE2  
The open reading frame of EpCAM-targeted carboxylesterase C28-sCE2 with 
C-terminal mycHis-tag was inserted in place of the E1 region of an adenovirus 
vector next to a GFP expression cassette to create Ad.C28-sCE2 (Figure 1A).  
SW1398 colon cancer cells were transduced with Ad.C28-sCE2 or control 
virus AdGFP at MOI 100 and after 6 days expression of C28-sCE2 in 
supernatant and cellular lysate was analyzed by Western blotting. Figure 1B 
shows that the majority of the 110 kDa C28-sCE2 protein was detected in the 
supernatant of Ad.C28-sCE2 transduced cells, confirming efficient secretion. 
Enzyme activity of C28-sCE2 was demonstrated by an esterase enzyme 
activity assay (figure 1C). Binding of C28-sCE2 to EpCAM expressing cells 
was shown by immunohistochemistry (figure 1D). The EpCAM positive cell 
line Colo205 and the EpCAM negative ovarian cancer cell line A2780 were 
incubated with the supernatant of SW1398 cells transduced with Ad.C28-
sCE2 or AdGFP. As can be seen in figure 1D, C28-sCE2 specifically bound to 
the cellular membranes of EpCAM expressing cells 
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 Diffusion of C28-sCE2 in multicellular colon cancer tumor spheroids 
Colo205 spheroids were transduced with Ad.C28-sCE2 and cryosections 
were made 1, 4 and 5 days later. Sections were stained with an anti-myc 
antibody to localize the C28-sCE2 fusion protein. Figure 2 illustrates that on 
day 1 after transduction only the outer rim of the spheroid stained slightly 
positive for C28-sCE2. Sections of spheroids harvested at later time points 
after transduction showed presence of C28-sCE2 in deeper layers of the 
spheroid. A higher magnification of the anti-myc staining at day 5 after 
transduction (figure 2B) suggests that C28-sCE2 had bound untransduced 
neighboring cells since only the cellular membrane of these cells stained 
positive. Thus, C28-sCE2 penetrated into and accumulated in the tumor mass 
surrounding Ad.C28-sCE2 transduced cells.    
 
 
CPT-11 activation and antiproliferative effects in Ad.C28-sCE2 
transduced cells  
Colon cancer spheroids transduced with Ad.C28-sCE2 or AdGFP were 
subjected to CPT-11 treatment for 7 days. Figure 3 demonstrates the viability 
of the spheroid as measured by WST-1 conversion. Ad.C28-sCE2 transduced 
Colo205 and SW1398 colon cancer spheroids were sensitized to CPT-11, 
since CPT-11 treatment to these spheroids was as toxic as treatment with its 
activated analogue SN-38. 
 
 
 
Figure 1: Schematic structure of the replication deficient adenovirus Ad.C28-sCE2 
and characterization of Ad.C28-sCE2 transduced SW1398 cells by Western blot 
analysis, esterase activity assay and immunohistochemistry. (A) Schematic structure 
of the replication deficient adenovirus Ad.C28-sCE2. The C28-sCE2 expression 
cassette includes the CMV promoter, an IgGκ leader sequence for secretion and a 
C-terminal myc- and His-tag for detection and purification. The adenovirus also 
contains the gene encoding GFP under the CMV promoter. (B) Western blot analysis 
of cellular lysates (lane 1 and 2) and supernatants (lane 3 and 4) of SW1398 cells 
transduced with Ad.C28-sCE2 (lane 1 and 3) or AdGFP (lane 2 and 4) at MOI 100. 
C28-sCE2 was detected using an antibody directed to the myc-tag. (C) CE-activity in 
cellular lysates and supernatants of SW1398 cells transduced with Ad.C28-sCE2 or 
AdGFP at MOI 100. Cellular lysates or supernatants were incubated with 1mM 
pNpAc and conversion was measured during 10 minutes. C28-sCE2 showed 
enzymatic activity and was efficiently secreted by transduced cells, since most of the 
activity was detected in the supernatant. (D) Binding of C28-sCE2 to the EpCAM 
expressing cell line Colo205. Colo205 cells or the EpCAM negative cell line A2780 
were incubated with the supernatant of SW1398 cells transduced with Ad.C28-sCE2 
or AdGFP at MOI 100. After washing, the cells were stained with anti-myc antibody to 
show binding of C28-sCE2. Only the EpCAM expressing Colo205 cells incubated 
with supernatant of Ad.C28-sCE2 transduced SW1398 cells showed a positive 
membrane staining, indicating that the fusion protein had bound specifically to the 
Colo205 cells. Figure 1D is shown at page 82. 
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Figure 3: Cytotoxicity assay on SW1398 and Colo205 colon cancer spheroids. 
SW1398 (A) and Colo205 (B) spheroids were transduced with 1.107 pfu AdGFP or 
Ad.C28-sCE2. Seven days after infection spheroids were subjected to a range of 
CPT-11 concentrations and cultured for a further 7 days. Cell viability of 
untransduced spheroids treated with CPT-11 (closed black circles) or SN-38 (open 
black circles), AdGFP transduced spheroids treated with CPT-11 (open black 
triangles) and Ad.C28-sCE2 transduced spheroids treated with CPT-11 (closed black 
squares) were analyzed by WST-1 conversion measurement. 
 
 
 
 
Figure 2: Immunohistochemistry on sections of Ad.C28-sCE2 transduced Colo205 
spheroids. Colo205 spheroids were transduced with 1.107 pfu Ad.C28-sCE2 and 
harvested at day 1, day 4 and day 5 after transduction. Sections of these spheroids 
were made and stained for myc to detect C28-sCE2. (A) At day 1 after Ad.C28-sCE2 
transduction no positive staining can be detected. At days 4 and 5, several spots 
along the rim of the spheroid are positively stained. (B) A higher magnification of the 
fusion protein staining at day 5 after transduction is shown. Cells with clear staining 
of membranes only (arrows) represent untransduced neighboring cells with bound 
C28-sCE2. 
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DISCUSSION 
 
Targeting chemotherapy specifically to tumor cells with GDEPT is expected to 
increase the anti-tumor effect, while side effects are decreased. A limitation of 
adenoviral vector mediated cancer gene therapy is the poor penetration ability 
of adenoviral vectors into a solid tumor mass. To improve the efficacy of 
adenoviral vector mediated GDEPT approaches, secreted prodrug converting 
enzymes have been studied 8,9. However, secreted enzymes might leak away 
from the site of the tumor. Therefore, cell surface-tethered forms of prodrug 
converting enzymes, such as β-glucuronidase or carboxypeptidase G2, were 
developed to prevent leakage of untargeted enzyme from the tumor, while 
prodrug activation is retained 10,11. Another way to prevent diffusion of the 
enzyme from the tumor is secretion by transduced tumor cells of a fusion 
protein consisting of a scFv antibody and a prodrug-converting enzyme, which 
can subsequently bind to tumor cells 12,19. We hypothesized that the bystander 
effect achieved by such a secreted targeted prodrug converting enzyme might 
be more pronounced than that achieved by a cell surface-tethered form, as 
the targeted form can diffuse and bind to neighboring tumor cells. In this 
study, we investigated the utility of a replication deficient adenoviral vector 
containing the cDNA encoding a secreted, EpCAM-targeted form of human 
liver carboxylesterase-2, Ad.C28-sCE2, to sensitize colon cancer tumors to 
CPT-11. We chose to study Ad.C28-sCE2 in a 3-dimensional in vitro colon 
cancer spheroid model, because the three-dimensional structure of spheroids 
resembles in vivo tumors much closer than two-dimensional cell cultures. 
Furthermore, we wanted to visualize the bystander effect by determining 
secretion of C28-sCE2 and penetration of the fusion protein through a solid 
tumor mass, which can only be studied in a 3-dimensional structure. Grill et al. 
demonstrated that transduction of primary glioma spheroids with a replication 
deficient vector resulted in expression of the transgene in the outer rim of the 
spheroid only. This showed that spheroids are relevant structures to study 
lack of adenovirus penetration into solid tumor masses 20. In the colon cancer 
spheroid model used in this study, we were able to detect the C28-sCE2 
fusion protein bound to untransduced cells several cellular layers away from 
transduced cells. This suggests that C28-sCE2 is capable of diffusing into a 
solid tumor mass.    
From these results we hypothesized that optimal cytotoxicity from CPT-11 
could be expected if the prodrug was administered at least a few days after 
Ad.C28-sCE2 transduction when C28-sCE2 has spread through the spheroid. 
Transduction of colon cancer spheroids with Ad.C28-sCE2 and treatment with 
CPT-11 after 7 days resulted in complete sensitization of these spheroids to 
CPT-11. The toxicity to these spheroids was comparable to SN-38 treatment, 
indicating that CPT-11 is effectively converted into the toxic drug.  
In order to compare a targeted prodrug-converting enzyme with a secreted 
prodrug-converting enzyme it is necessary to perform in vivo experiments. 
However, the high endogenous plasma esterase activity in mice presents a 
challenge in using mouse models to evaluate tumor-specific conversion of 
CPT-11. In mice, more than 50% of the administered CPT-11 is converted to 
SN-38 by plasma esterases 21, whereas in human patients less than 5% of the 
prodrug is activated 4. Hence, the analysis of CE-mediated activation of CPT-
11 in normal mice does not accurately reflect what happens after 
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administration of the drug to humans. Previously, a strain of plasma esterase-
deficient mice was described 21, in which CPT-11 metabolism is comparable 
to that observed in humans. Recently, these mice were crossbred with SCID 
mice (personal communication with Dr. Phil Potter, St. Jude Children’s 
Research Hospital, Memphis, USA) and we are currently testing adenoviral 
vectors expressing EpCAM-targeted sCE2 or untargeted sCE2 in these 
esterase deficient SCID mice bearing colon cancer xenografts. 
In conclusion, we constructed a replication deficient adenoviral vector 
containing a cDNA encoding a secreted, EpCAM targeted form of human liver 
carboxylesterase-2 that was capable of converting the prodrug CPT-11 into its 
activated form, leading to enhanced toxicity of CPT-11 to colon cancer 
spheroids. Therefore, this adenoviral construct holds promise in GDEPT 
approaches for the treatment of patients with EpCAM expressing colon 
cancer.  
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SUMMARY 
 
Despite improvement in the treatment of osteosarcoma there are still many 
patients who cannot benefit from current treatment modalities. This warrants 
exploration of new treatment options. To that end, we investigated Gene-
Directed Enzyme Prodrug Therapy (GDEPT) with the use of human liver 
carboxylesterase-2 (CE2) and the anticancer agent CPT-11. CPT-11 is a 
clinically approved prodrug that needs to be metabolized into the active drug 
SN-38 by carboxylesterases, which occurs rather inefficiently in humans. 
GDEPT aims at high production of CE2 at the tumor site resulting in efficient 
local conversion of CPT-11 into SN-38. We showed that osteosarcoma cells 
transduced with an adenoviral vector containing the cDNA encoding a 
secreted form of CE2 (Ad-sCE2) expressed and efficiently secreted CE2. In 
vitro, transduction of a panel of osteosarcoma cell lines with Ad-sCE2 resulted 
in sensitization up to 2800-fold to CPT-11 treatment. Primary osteosarcoma 
short-term cultures, derived from patients suffering from a classic high-grade 
osteosarcoma, demonstrated increased CPT-11 sensitivity up to 70-fold after 
transduction with Ad-sCE2 in vitro. When mice bearing subcutaneous MG-63 
osteosarcoma xenografts were intratumorally injected with Ad-sCE2 and CPT-
11, this resulted in a significant difference in time to reach 2000 mm3 in tumor 
volume as compared to animals receiving Ad-sCE2 or CPT-11 treatment 
(p<0.05).   
Together, these data suggest that osteosarcoma cells are sensitive for 
the combination of Ad-sCE2 and CPT-11. 
 
 
INTRODUCTION 
 
Osteosarcoma (OS) is the most common primary bone tumor in children and 
young adults 1. Despite recent improvement in the treatment of OS there are 
still too many patients who cannot benefit from current treatment modalities 2. 
The overall survival of primary OS with combined treatment, consisting of 
neoadjuvant chemotherapy and surgery, now varies between 50-65% 3-5. 
Attempts to treat OS with multiple new agents have not increased survival 
rates. Therefore, new treatment options have to be explored for this type of 
disease. 
Camptothecin derivatives have been explored in phase I-II trials 
including patients with OS refractory to standard treatment protocols. In these 
trials partial responses have been observed 6, 7. Pratesi et al. have shown 
complete tumor response and cures in 70% of animals bearing subcutaneous 
U2OS OS. The tumor variant selected for resistance against cisplatin was still 
responsive to camptothecin treatment 8.  
CPT-11 is a semi-synthetic, water-soluble derivative of camptothecin 
that differs from other camptothecin analogues, in that it is a prodrug that 
undergoes de-esterification to the much more potent topoisomerase I inhibitor, 
SN-38 (7-ethyl-10 hydroxycamptothecin) 9. A class of enzymes that converts 
CPT-11 to SN-38 is the human carboxylesterases (CE). CE-activity can be 
detected in human liver, intestines and other sites 10. Although patients do 
express CE, the amount of CPT-11 administered systemically that is 
converted to the active drug SN-38 is in the range of only 5 to 10% 11. 
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Furthermore, the usefulness of CPT-11 is hampered by dose-dependent 
toxicity, primarily diarrhea. A strategy to increase the antitumor effects of CPT-
11, while decreasing the unwanted side effects, is to express the cDNA 
encoding CE specifically at the site of the tumor. After systemic administration 
of CPT-11, this will lead to tumor-specific conversion and therefore tumor-
specific toxicity. This approach is called Gene-Directed Enzyme Prodrug 
Therapy (GDEPT). Another GDEPT approach previously described for OS in 
experimental models utilizes the viral enzyme thymidine kinase (TK) in 
combination with the prodrug acyclovir (ACV). The efficacy of this approach 
was shown in vitro 12 as well as in vivo 13 14. In the latter case, 80% of gene 
therapy treated animals bearing subcutaneous OS xenografts survived, 
whereas survival rates increased to 100% when gene therapy was combined 
with metrotrexate. The advantage of using CE/CPT-11 GDEPT approaches is 
that human isoforms of CE can be used which should not result in an 
immunological response and subsequent enzyme inactivation. Therefore, 
repeated administration should be possible.  
We have screened a panel of human malignant cell lines originating of 
different tissues to explore which cell lines could be sensitized to CPT-11 by 
addition of CE into the culture medium. All osteosarcoma cell lines tested 
became highly sensitive for CPT-11 in the presence of extracellular CE 
(unpublished results). To explore the effect of CPT-11 on osteosarcoma cells 
in a GDEPT approach, we constructed an adenoviral vector containing the 
cDNA encoding secreted human carboxylesterase isoform-2 (Ad-sCE2). A 
secreted form of CE2 might have the advantage that it will likely spread 
through a solid tumor mass, resulting in extracellular conversion of CPT-11. 
This may lead to antitumor effects to untransduced neighboring tumor cells, 
also designated as the ‘bystander effect’.  
In this study, we describe the construction and characterization of the 
Ad-sCE2 adenoviral vector and its ability to sensitize osteosarcoma cell lines 
and primary osteosarcoma cells to CPT-11 in vitro. In addition, we report on 
the usefulness of Ad-sCE2 in human OS xenografts grown in nude mice and 
treated with CPT-11. 
 
 
MATERIALS AND METHODS 
 
Cells and Culture conditions 
MG-63 15 (courtesy of Dr. C. Löwik, Leiden University Medical Center, the 
Netherlands), MNNG-HOS 16, SaOs-2 17, (courtesy of Dr. F. van Valen, 
Westfalische Wilhelms-Universität, Münster, Germany), CAL-72 18 (courtesy of 
Dr. J. Gioanni, Laboratoire de Cancerologie, Faculté de Medicine, Nice, 
France) and HEK293 (ATCC, Manassas, VA) cell lines were maintained in 
Dulbecco’s Modified Eagle Medium supplemented with 10% fetal calf serum 
(FCS), 50 IU/ml penicillin, 50 µg/ml streptomycin and 2 mM L-glutamine (all 
from Gibco BRL, Life Technologies B.V., Breda, The Netherlands), at 37°C in 
a 5% CO2 humidified atmosphere.  
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Patient material 
Fresh tumor material was obtained from patients having a classic high grade 
OS and was brought into culture as described 19. From patient 6, cells were 
cultured before (OS-6) and after (OS-6a) chemotherapy. From patient 1, only 
material after chemotherapy was cultured (OS-1a). All experiments were 
performed in cell cultures at passage 0-5.    
 
 
Construction of Ad-sCE2 
The adenoviral vector Ad-sCE2 was constructed using the AdEasy method 20. 
The plasmid pSTCF-sCE2 containing the secreted CE2 (sCE2) open reading 
frame with a myc-6xHis tag at the C-terminal ending 21, was digested with 
PmeI and NheI and the sCE2 comprising fragment was cloned into XbaI and 
EcoRV digested pAdTrack-CMV. The resulting plasmid was digested with 
PmeI and recombined with adenoviral backbone plasmid pAdEasy-1 in E. coli 
BJ5183 cells to construct pAdEasy-sCE2. After linearization with PacI, the 
plasmid was transfected into the adenovirus packaging cell line HEK293 and 
virus was further propagated in HEK293 cells according to standard 
techniques. Purified virus stocks were prepared by two successive bandings 
on CsCl gradients. Viral particle (vp) titer  and plaque forming unit (pfu) titer 
was determined by OD260 and limiting dilution, respectively. The pfu titer was 
1.5*1012 and the vp/pfu ratio was 18.1. For all experiments the pfu titer was 
used and Ad-GFP was taken along as a negative control 22.  
 
 
Western blot  
Equivalent amounts of supernatant or cellular lysate from SaOs-2 cells 
infected with Ad-sCE2 or Ad-GFP (multiplicity of infection (MOI) 100) were 
dissolved in sample buffer 23 with 5% 2-mercapto-ethanol and boiled at 95°C 
for 5 min. Samples were subjected to electrophoresis through a denaturing 
10% sodium dodecyl sulphate-polyacrylamide gel and protein bands were 
electroblotted onto PVDF protein membrane (BioRad, Veenendaal, The 
Netherlands). Proteins were detected using mouse anti-myc antibody 9E10 24 
and horseradish peroxidase-conjugated rabbit anti-mouse IgG 
(DakoCytomation, Heverlee, Belgium). Blots were developed with enhanced 
chemoluminescence (Lumilight Plus, Roche Diagnostics, Almere, The 
Netherlands). 
 
 
Esterase activity  
Cellular lysates or supernatants of SaOs-2 cells infected with Ad-sCE2 or Ad-
GFP were incubated with 200 µl 100 mM TRIS-HCl pH=8.0 containing 1 mM 
p-nitrophenyl-acetate (pNpAc) (Sigma Aldrich, Zwijndrecht, The Netherlands), 
a substrate for CE. Conversion to paranitrophenol was monitored over a 10-
min period using an ELISA plate reader (BioRad, Veenendaal, The 
Netherlands) at a wavelength of 415 nm at room temperature. 
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In vitro proliferation assay 
OS cell lines and primary OS cell cultures were plated in a 96-wells microtiter 
plate (Greiner Bio-One B.V., Alphen aan den Rijn, The Netherlands) at 5.103 
cells per well in 100 µl. After 24 h, medium was removed and cells were 
infected with Ad-sCE2 at an MOI of 1, 10 or 100 in 50 µl in culture medium 
with 2.5% FCS. After 1 h, virus was removed and 200 µl culture medium with 
or without CPT-11 (Aventis, Strasbourg, France) in a range of concentrations 
was added to separate wells in triplicate. Control experiments were performed 
in which the OS cells were infected with Ad-GFP and treated with CPT-11 or 
cells were only treated with CPT-11 or SN-38 (Aventis). After an incubation 
period of 6 days, growth was determined by incubating the cells with the cell 
proliferation reagent WST-1 (Roche Diagnostics) at 37°C. After 2 h the 
absorbency was measured at a wavelength of 450 nm using an ELISA plate 
reader. The antiproliferative effects of treated cells were expressed as 
percentages of growth from uninfected, untreated control cells. 
 
 
Crystal violet staining 
In a separate assay, cytotoxicity in OS cell lines and primary OS cell cultures 
was measured by crystal violet staining. Cells were treated as described for 
the antiproliferative assay. At the end of the experiment, medium was 
aspirated from cell cultures and adherent cells were fixed with 4% 
formaldehyde in PBS for a 10-minute period at room temperature. After 
fixation, cells were washed and incubated for 15 minutes with 1% crystal violet 
dissolved in 70% ethanol. Hereafter, cells were washed with water, air-dried 
and scanned on a BioRad GS690  scanner. 
 
  
In vivo experiments 
The experimental protocols adhered to the rules outlined in the Dutch Animal 
Experimentation Act (1977) and the published ‘Guidelines on the protection of 
experimental animals’ by the council of the E.C. (1986).  The protocol was 
approved by the committee on Animal Research of the Vrije Universiteit. 
Female athymic nu/nu mice, weighing 25-35 g, obtained from Harlan-CPB 
(Austerlitz, the Netherlands) were housed under pathogen-free conditions and 
were fed ad libitum. Tumor pieces (3x3x3 mm), derived from subcutaneously 
injected MG-63 cells in previous recipients, were implanted under the skin of 
one flank in anesthetized mice. Mice were weighed and tumor size was 
monitored twice a week using digital calipers. The tumor volume was 
calculated from the average of tumor length and width according to the 
formula: 4/3Πr3. The volume doubling time of untreated MG-63 tumors was 
1.6 days. 
In order to determine the highest dosage of CPT-11 that had no effect 
on tumor growth, mice were divided in 4 groups of 3 animals each, when the 
tumor nodules reached 200-300 mm3.  Mice in each group were intratumorally 
injected with 0.143 or 1.43 or 14.3 µg CPT-11 in 25 µl PBS or PBS alone for 7 
consecutive days. Tumors were measured for a period of 3 weeks. 
In the next experiment, mice were divided into three groups when the tumor 
nodules reached 200-300 mm3 (designated as day 0). Tumors were injected 
with 1.109 plaque forming units (pfu) of Ad-sCE2 in 25 µl PBS followed by 
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intratumoral injection with 1.43 µg CPT-11 in 25 µl PBS for 7 consecutive 
days (9 animals). Tumors of control mice received PBS on day 1 followed by 
injection with 1.43 µg CPT-11 for 7 consecutive days (6 mice) or 1.109 pfu of 
Ad-sCE2 on day 1 followed by injection with PBS for 7 days (6 mice). The 
mice were euthanized when the tumors reached a size of ≥2000 mm3.  The 
different treatment modalities were evaluated by comparing tumor growth 
delay (time required to reach 5 times the initial tumor volume) and comparing 
the time for the tumors to reach a volume of ≥2000 mm3, which was regarded 
as the endpoint of the Kaplan-Meier curves. 
Statistical analyses were performed using SPSS (SPSS inc., Chicago, 
USA). The ANOVA test was used to compare the growth delay between the 
different treatment groups. The Kaplan-Meier curves were calculated and 
differences in time for the tumors to reach ≥2000 mm3  between different 
treatment groups were analyzed using the log-rank test. 
 
 
RESULTS 
 
Antiproliferative effects of CPT-11 and SN-38  
To assess the sensitivity of OS cells to CPT-11 and SN-38, IC50 values (the 
concentrations of prodrug or drug that results in 50% growth inhibition) were 
determined. OS cell lines and short-term cultures, derived from tumors of 
patients with classic high grade OS, were subjected to a range of 
concentrations of CPT-11 or SN-38 for 6 days. The IC50 values for CPT-11 
and SN-38 and the ratios of these values are shown in Table 1. The OS cell 
lines tested were 625- to 1200-fold more sensitive to SN-38 than to CPT-11. 
In three primary OS cultures, this varied between 30- to 125-fold. For the 
other 3 short-term primary cultures tested the ratio was at least >33 times, but 
could not be determined exactly since the highest concentration of CPT-11 
used was not toxic to these cells. These results indicate that efficient 
activation of CPT-11 to SN-38 would result in considerable antiproliferative 
effects in OS cells.   
 
 
Construction and characterization of Ad-sCE2 
A secreted form of human liver CE2 (sCE2) was obtained by deletion of the 
cellular retention signal HTEL and by cloning it downstream of an IgGκ leader 
sequence. At the C-terminus a myc-6xHis tag was cloned for easy detection 
and purification. The expression of sCE2 was driven by the cytomegalovirus 
(CMV) promoter 21. The adenovirus vector Ad-sCE2, was constructed by 
inserting the sCE2 expression cassette adjacent to a Green Fluorescent 
Protein (GFP) expression cassette in place of the adenovirus E1 region 
(Figure 1). 
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Table 1: Antiproliferative effects of CPT-11 and SN-38 and for CPT-11 after 
transduction with Ad-sCE2 or Ad-GFP in OS cells. 
* The ratio is expressed as IC50 value for CPT-11 divided by the IC50 value for SN-
38.  
** The degree of sensitization (d.o.s.) is expressed as IC50 value for CPT-11divided 
by the IC50 value for CPT-11 after cellular transduction with Ad-sCE2. 
*** The transduction efficiency of the MNNG-HOS cell line was < 5%, which could 
explain the moderate d.o.s. 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic presentation of the adenovirus Ad-sCE2 that was constructed 
by inserting the sCE2 expression cassette adjacent to a GFP expression cassette in 
place of the adenovirus E1 region. The sCE2 expression cassette includes the CMV 
promoter (CMV), an IgG kappa leader sequence for secretion (L), a C-terminal myc- 
and 6xHis-tag for detection and purification (mycHis) and an SV40 polyadenylation 
signal (PA). 
 
 
SaOs-2 cells were infected with either Ad-sCE2 or control virus Ad-
GFP (MOI 100) and after 6 days supernatant and cellular lysates were 
analyzed for sCE2 expression by Western blot. Figure 2A shows that almost 
all sCE2 was detected in the supernatant of infected cells. Functional activity 
of sCE2 at day 6 after transduction was demonstrated by an esterase activity 
assay (Figure 2B). Again, most of the CE activity was detected in the 
supernatant of SaOs-2 cells infected with Ad-sCE2, confirming the results of 
the Western blot.  
To follow sCE2 secretion in the supernatant of Ad-sCE2 transduced 
cells in time, SaOs-2 supernatants were harvested at day 1 to 6 after 
transduction and a CE activity assay was performed (figure 2C). A gradual 
increase of CE activity in time after transduction was observed. 
pA      GFP           CMV pA    mycHis          sCE2           L           CMV                                  Ad5 DNA 
∆E3v
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Figure 2: Characterization of Ad-sCE2
infected SaOs-2 cells by Western blot
and by esterase activity assay. (A)
Western blot of the cellular lysates and
supernatants of SaOs-2 cells infected
with Ad-sCE2 at MOI 100. As a
negative control, cells were infected
with Ad-GFP at MOI 100. sCE2 was
detected using an antibody directed
against the myc tag. In lanes 1 and 3
cellular lysates (c) and in lanes 2 and 4
supernatants (s) of SaOs-2 cells
infected with Ad-GFP (lanes 1, 2) or
Ad-sCE2 (lanes 3, 4) are shown. sCE2
migrated with an apparent molecular
weight of 75 kDa and almost all protein
was secreted. (B) CE activity in cellular
lysates and supernatants of SaOs-2
cells untransduced or transduced with
Ad-sCE2 or Ad-GFP at MOI 100.
Samples were incubated with 1 mM
pNpAc and conversion was measured
over a 10-minute period. Ad-GFP
infected cells did not show enhanced
CE-activity in cellular lysates and
culture medium compared to mock
infected SaOS-2 cells, whereas Ad-
sCE2 infected cells clearly expressed
the CE enzyme, which was detected
mainly in the supernatant. (C) CE
activity in supernatants of SaOs-2 cells
transduced with Ad-GFP (dotted line) or
Ad-sCE2 (bold line) at MOI 100 at
different time points post infection. In
time, CE activity in supernatants of Ad-
sCE2 transduced cells gradually
increased. 
2C 
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Antiproliferative effects of CPT-11 activation in Ad-sCE2 transduced OS 
cells 
To show improved conversion of the prodrug CPT-11 to the toxic drug SN-38 
by Ad-sCE2 encoded sCE2, OS cell lines or primary OS cells were 
transduced with Ad-sCE2 or Ad-GFP as a control, followed by exposure to 
CPT-11. Six days after transduction, surviving cells were visualized by crystal 
violet staining. Antiproliferative effects were quantified with the WST-1 assay. 
Ad-sCE2 exhibited a dose dependent sensitization to CPT-11 (not shown). 
Figure 3 shows the results obtained for the OS cell line SaOs-2 transduced at 
MOI 100. Ad-sCE2 enhanced the sensitivity of SaOs-2 cells to CPT-11 
approximately 2800-fold, resulting in toxic effects comparable to treatment 
with SN-38 alone. Table 1 summarizes the results of the proliferation assay on 
all OS cell lines and primary OS cell cultures transduced at MOI 100. All OS 
cells tested could be sensitized to CPT-11 following infection by Ad-sCE2, 
ranging from 10- to 2800 fold for OS cell lines, while primary OS cells were up 
to 2 orders more sensitive.  Interestingly, also primary cell cultures from 
patients resistant against cisplatin and doxorubicin treatment, i.e. OS-1a and 
OS-6a, were sensitized to CPT-11 by infection with Ad-sCE2. In general, in 
this experimental setting, where not all cells were transduced with Ad-sCE2, 
CPT-11 prodrug conversion was incomplete, yielding 7-70% cytotoxicity 
compared to SN-38 treatment. 
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Figure 3: Cytotoxicity assay on
SaOs-2 cells infected with  AdsCE2
or Ad-GFP. Cell survival  was
determined with crystal violet
staining (A) or WST-1 proliferation
assay (B). (A) The SaOs-2 cells
were transduced with Ad-GFP or
Ad-sCE2 at MOI 100 as indicated
and treated for 6 days with CPT-11
or SN-38 at the indicated
concentration. Subsequently,
adherent cells were stained with
crystal violet and photographed.
(B) Ad-GFP transduced SaOs-2
cells ( ) did not show further
inhibition of growth when compared
to CPT-11 treated untransduced
cells (∆). Transduction with Ad-
sCE2 in combination with CPT-11
(?) resulted in toxicity comparable
to exposure to SN-38 (▪). Data are
presented as mean of triplicates +/-
SD. 
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To investigate if OS tumors could be sensitized to CPT-11 after transduction 
with Ad-sCE2 in vivo, nude mice bearing well-established subcutaneous MG-
63 tumors of 200-300 mm3 were treated by intratumoral injection with 1.109 
pfu Ad-sCE2 or PBS. Subsequently, tumors were injected on 7 consecutive 
days with 1.43 µg CPT-11, since this was the highest concentration of CPT-11 
that did not by itself result in tumor growth inhibition as compared to PBS 
treatment (data not shown), or with PBS. CPT-11 was injected intratumorally 
since mice, in contrast to humans, have high esterase activity in their plasma 
25. Tumor growth was monitored until a volume of >2000 mm3 was reached. 
Tumors treated with Ad-sCE2 and PBS showed a tumor growth rate (time 
required to reach 5 times the initial tumor volume±SD) of 4.8±1.5 days. For 
tumors treated with PBS and CPT-11 the tumor growth rate was 4.6±1.3 days. 
A significant increase in tumor growth delay was observed for the combination 
treatment with Ad-sCE2 plus CPT-11 (7.1±1.7 days) as compared to Ad-sCE2 
alone (p=0.021) and CPT-11 alone (p=0.011) (data not shown).   
Figure 4 shows in Kaplan-Meier curves the time of the tumors to reach 
a volume of ≥2000 mm3. At a volume of 2000 mm3 the animals had to be 
sacrificed according to animal welfare guidelines for these experiments. Curve 
comparison with log-rank analysis showed a significant delay in time to reach 
>2000 mm3 tumor volume between GDEPT treated animals compared to Ad-
sCE2 or CPT-11 alone (p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Kaplan-Meier curves showing the time for the tumors to reach a volume of 
≥2000 mm3. Curve comparison with log-rank analysis showed a significant difference 
in time to reach ≥2000 mm3 between GDEPT treated animals compared to Ad-sCE2 
or CPT-11 alone (p<0.05). 
 
 
0 5 10 15 20 25 30 35
0.0
0.2
0.4
0.6
0.8
1.0
Ad-sCE2 + PBS
PBS + CPT-11
Ad-sCE2 + CPT-11
days after start of treatment
po
rti
on
 w
ith
 tu
m
or
 v
ol
um
e
≤2
00
0m
m
3
Chapter 4 
 98
DISCUSSION 
 
Despite improvement of the treatment of primary osteosarcoma (OS), the 
overall survival of patients varies between 50-65%. Therefore, new treatment 
modalities are warranted. In several studies using the enzyme-prodrug 
combination of herpes simplex virus thymidine kinase and ganciclovir an anti-
tumor response was observed in OS models. Both local treatment and 
systemic treatment of lung metastasis resulted in long-term survivors 12-14. In 
this study, we investigated the utility of an adenoviral vector containing the 
cDNA encoding a secreted form of human liver CE2, Ad-sCE2, to sensitize 
OS cells to the clinically approved prodrug CPT-11. OS cells transduced with 
Ad-sCE2 indeed secreted functional sCE2. Transduction of OS cells and 
primary cell cultures with Ad-sCE2 sensitized OS cells to CPT-11 in vitro.  
Several isoforms exist from the human enzyme CE. Kojima et al. have 
described the construction of an adenovirus containing the cDNA encoding 
intracellular human liver CE isoform 1 (CE1) 26. Only 3/11 cancer cell lines did 
show a marked (>5 fold) decrease in IC50 value after transduction and CPT-
11 treatment. Humerickhouse et al. demonstrated that human CE2 has a 
higher affinity and a higher conversion velocity for CPT-11 than CE1 27. Based 
on the latter studies, we decided to use CE2 for our studies. Recently, Wierdl 
et al. described the construction of an adenoviral vector containing the cDNA 
encoding a secreted form of rabbit liver carboxylesterase 28, which is probably 
the most efficient isoform of CE 29. Since a non-human enzyme, such as rabbit 
CE, might elicit an immune response in humans and repeated administration 
of Ad-sCE2 is anticipated in clinical applications, we preferred to express a 
secreted form of a human CE in our study.  Therefore, it was decided to use a 
secreted form of human liver CE2 and as we show herein, the adenovirus 
expressing human sCE2 was highly effective in GDEPT with CPT-11 for OS in 
vitro. We put particular emphasis on including primary short-term cultures. 
These primary OS cells were directly brought into culture after the 
tumor(piece) was surgically removed. Experiments were performed between 
passage 1 and 5 of these cultures. Therefore, these cells can be considered 
as reliable primary tumor cells. Although Coxsackie Adenovirus Receptor 
(CAR), expression was very low on these primary cells 19 they could still be 
sensitized to CPT-11 by transduction with Ad-sCE2 at a relatively high MOI.  
Sensitization was not complete, which could be partly attributed to differences 
in transduction efficiency. Interestingly, heavily pretreated primary OS cells 
(OS-1a and OS-6a), which were resistant to doxorubicin and cisplatin, could 
still be sensitized to CPT-11 by Ad-sCE2 infection.  
An in vivo experiment in which MG-63 tumors were infected with Ad-
sCE2 and treated with CPT-11 showed a significant tumor growth delay and a 
significant difference in the time to reach a tumor volume of >2000 mm3 
compared to tumors treated with either CPT-11 or Ad-sCE2 alone. Although 
the results differed significantly between the experimental groups, the in vivo 
treatments did not result in cures. The modest effects in vivo could be 
explained by either low transduction efficiency or a relatively low concentration 
of the prodrug. 
The primary receptor for adenoviral entry CAR is expressed in low 
amounts on the cells surface of the cell line MG-63 19.  During the in vitro 
experiments only 25% of the MG-63 cells were transduced with Ad-sCE2 as 
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determined by GFP expression. It is hypothesized that the MOI used to 
transduce MG-63 tumors in vivo was lower (1.109 pfu of Ad-sCE2/ 200mm3 
tumor). So probably, only a very small percentage of tumor cells was indeed 
transduced by Ad-sCE2 and this might explain the poor therapeutic effect in 
vivo. To improve this, several possibilities can be explored. First of all, the 
efficacy of Ad-sCE2 and CPT-11 treatment in vivo can perhaps be improved 
by redirection of the adenoviral vector to tumor antigens. We previously 
demonstrated that targeting an adenoviral vector towards the Epidermal 
Growth Factor Receptor via a bispecific antibody improved gene transfer to 
OS cells in vitro 19. Another improvement of this approach could be the 
combination of enzyme prodrug therapy with conditionally replicating 
adenoviruses (CRAds). CRAds have shown promising preliminary results in 
clinical trials, especially in combination with chemotherapy. Preliminary 
experiments in which OS cells were transduced with Ad-sCE2 and a CRAd 
and treated with CPT-11 showed increased anti-cancer efficacy as compared 
to viral or enzyme prodrug therapy alone (unpublished results). Finally, we 
expect that a higher dose of CPT-11 could further enhance the efficacy of this 
approach. Unlike humans, however, mice have high esterase activity in their 
plasma, which precludes proper xenograft studies with higher doses of CPT-
11 30.  
In clinical applications of GDEPT for human cancer, the adenoviral 
vector should be injected into the tumor lesion, while CPT-11 is given by the 
intravenous route. In this respect, it is questionable whether the tumor 
concentration of CPT-11 will be sufficient for enhanced SN-38 mediated tumor 
cell damage. This might perhaps be investigated in esterase deficient mice 30. 
High intra-tumor concentrations of CPT-11 in humans, may however also be 
reached in inoperable or recurrent OS injected with Ad-sCE2 after which CPT-
11 is given by intra-arterial infusion, such as in isolated limb perfusion. 
Altogether, our data suggest that the combination of Ad-sCE2 and 
CPT-11 could be further improved and developed into a new treatment 
modality for OS.  
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SUMMARY  
 
Conditionally replicating adenoviruses (CRAds) selectively replicate in and 
thereby kill cancer cells. The CRAd Ad∆24 with pRb-binding deficient E1A 
kills cancer cells efficiently. Arming CRAds with genes encoding prodrug-
converting enzymes could allow for enhanced anti-cancer efficacy by the 
combined effects of oncolytic replication and local prodrug activation. Here, 
we investigated combination treatment of human colon cancer cell lines with 
Ad∆24-type CRAds and Gene-Directed Enzyme Prodrug Therapy (GDEPT) 
using two different enzyme/prodrug systems, i.e. thymidine kinase/ganciclovir 
(TK/GCV) and carboxylesterase (CE)/CPT-11. On all three cell lines tested, 
GDEPT with TK/GCV made CRAd treatment less efficacious. In contrast, 
expression of a secreted form of CE (sCE2) combined with CPT-11 treatment 
markedly enhanced the efficacy of Ad∆24 virotherapy. Based on this 
observation, we constructed an Ad∆24 variant expressing sCE2. In the 
absence of CPT-11, this new CRAd Ad5-∆24.E3-sCE2 was similarly effective 
as its parent in killing human colon cancer cells. Low concentrations of CPT-
11 inhibited Ad5-∆24.E3-sCE2 propagation. Nevertheless, CPT-11 specifically 
augmented the cytotoxicity of Ad5-∆24.E3-sCE2 against all three-colon 
cancer cell lines. Hence, the positive contribution of sCE2/CPT-11 GDEPT to 
colon cancer cytotoxicity outweighed its negative influence on CRAd 
propagation. Therefore, CRAd-sCE2/CPT-11 combination therapy appears 
useful for more effective treatment of colon cancer.  
 
 
INTRODUCTION  
 
Gene therapy with human adenoviral vectors is under investigation as an 
alternative approach to treat cancer. Replication-defective adenoviral gene 
delivery vectors have so far shown only modest anti-tumor efficacy, partly 
because of poor penetration capacity in solid tumor masses. To overcome this 
limitation, conditionally replicative adenoviruses (CRAds) were developed and 
explored as novel anti-cancer agents 1-3. CRAds replicate only in cancer cells 
and destroy these cells through the natural process of adenoviral replication. 
In addition, the generated progeny viruses released from infected and lysed 
cancer cells may infect neighboring tumor cells. Via multiple cycles of lytic 
replication and lateral spread, more pronounced anti-tumor effect is 
accomplished. Unfortunately, however, the efficacy of CRAds as 
monotherapeutic agents in clinical trials has so far been limited 4,5. Treatment 
modalities in which CRAd virotherapy was combined with a conventional 
chemotherapeutic agent such as cisplatin, 5-FU or paclitaxel were 
significantly more effective than treatment with either agent alone 6-8. This 
synergy between CRAds and chemotherapy warranted studies into 
combinations of CRAds with the more selective Gene-Directed Enzyme 
Prodrug Therapy (GDEPT). In GDEPT, tumor cells are transduced with an 
expression vector encoding an enzyme that converts a non-toxic prodrug into 
an active drug. After systemic administration of the prodrug, this will lead to 
local prodrug activation at the tumor site resulting in tumor-specific toxicity. 
Arming CRAds with a prodrug-activating gene might thus result in augmented 
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anti-tumor effects similar to the combined effect of CRAds and chemotherapy, 
but with less systemic toxicity. In addition, the CRAd may be considered as a 
very potent enzyme expression vector as it is amplified in infected cells. 
Higher levels of prodrug-converting enzyme in the tumor should produce 
higher local toxic drug concentrations, thereby causing a more effective 
GDEPT. 
Several prodrug converting enzymes, including carboxylesterase (CE) 
that activates the prodrug CPT-11 into the toxic drug SN-38, Herpes Simplex 
Virus thymidine kinase (HSV-TK) that converts the prodrug ganciclovir (GCV) 
into its active metabolite and nitroreductase that activates CB1954, have 
already been incorporated into the genome of replication competent 
adenoviruses 9-15. Only in some cases, addition of the prodrug increased the 
oncolytic potency as expected 9,10,12. Remarkably, in all successful studies 
E1B deleted CRAds with severely compromised replication capacity were 
used. 
Since then, much more potent CRAds have been constructed. One of 
these is Ad∆24, or dl922-947, that contains a subtle deletion in the E1A region 
that abolishes binding of E1A to members of the Rb family of pocket proteins 
16,17. Because Ad∆24 is defective in sequestering pRb from E2F, its replication 
depends on E2F being released through other means. This is the case in 
most, if not all, cancer cells through pRb deficiency, pRb 
hyperphosphorylation, or pRb sequestration by cellular or viral proteins 
associated with malignancy. Indeed, it was demonstrated that Ad∆24 
replicates in and lyses both dividing and non-dividing tumor cells with high 
efficiency, whereas cancer cells with restored pRb activity were resistant to 
the virus in vitro 16. Although Ad∆24 was not entirely cancer-specific, as it was 
also shown to replicate in proliferating normal cell cultures and in human brain 
explants 17,18, the CRAd did not replicate in growth-arrested normal cell 
cultures 17, suggesting relative safety in normal tissues. The virus was 
effective against a range of cancer cells in vitro and in vivo exhibiting a 
potency superior to that of an E1B deleted CRAd and in some cancer types 
even to that of wild type adenovirus 17. This led us to investigate if combining 
the more powerful Ad∆24 virotherapy with GDEPT using the HSV-TK/GCV or 
CE/CPT-11 paradigms would further increase its anti-cancer efficacy.  
 
 
MATERIAL AND METHODS  
 
Cells and culture conditions 
The colon cancer cell lines SW1398, Colo205 and WiDr and the lung cancer 
cell line A549 were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% Fetal Calf Serum (FCS), 50 IU/ml penicillin and 50 
µg/ml streptomycin (Invitrogen, Breda, The Netherlands), at 37°C in a 5% CO2 
humidified atmosphere. 293 (ATCC, Manassas, VA) and 911 (Introgene, 
Leiden, The Netherlands) cells were maintained in DMEM supplemented with 
10% FCS, 50 IU/ml penicillin, 50 µg/ml streptomycin and 2mM L-glutamine 
(Invitrogen). 
 
GDEPT with CE enhances the efficacy of Ad∆24 
 107
Recombinant adenoviruses 
The replication deficient adenoviral vectors Ad-sCE2 30 and AdCMVHSV-TK 31 
that express cytomegalovirus immediate early promoter-driven secreted 
human liver carboxylesterase-2 (sCE2) and HSV-TK, respectively, have been 
described previously. The conditionally replication competent adenovirus 
Ad∆24 containing a 24 bp deletion in the CR2 domain of the E1A region, 
resulting in selective replication in pRb mutated cells 16, has been described 
previously 32. The CRAd Ad5-∆24.E3 has the same deletion in E1A, but 
retains the entire E3 region 19.  
To construct the Ad∆24 CRAd with an expression cassette for sCE2, the 
CMV-sCE2 expression cassette was amplified from pSTCF-sCE2 33 by PCR 
with sense primer 5’-CAGCATGCTATGGTCGACTCTCAGTACAATCTGCTC-
3’ and antisense primer 5’-AAGCCATAGAGCCCACCGCATCC-3’. The 
resulting fragment was digested with SphI that cuts in the sense primer (italic) 
and four nucleotides adjacent to the antisense primer-annealing site and 
inserted into SphI digested pABS.4 (Microbix, Biosystems, Toronto, Canada) 
to generate pABS.4-sCE2. Functional expression of sCE2 was confirmed 
following transient transfection of the plasmid into COS-7 cells. At 2 days after 
transfection, supernatants were harvested and CE-activity was measured by 
pNpAc conversion as described previously 33. To construct a GATEWAY 
compatible entry vector, pABS.4-sCE2 was digested with NruI and KpnI and 
ligated into EcoRV/KpnI digested pENTR-2B (Invitrogen) creating pENTR-
sCE2. The GATEWAY system compatible adenoviral shuttle vector 
pEndK/DEST-R carrying the DEST cassette in the adenovirus genome 
between the E4 region and the right-hand ITR has been described previously 
34. The sCE2 expression cassette of pENTR-sCE2 was transported into this 
pEndK/DEST-R via an LR Gateway in vitro recombination reaction 
(Invitrogen) according to the manufacturer’s protocol, generating pEndK-
sCE2-R containing the CMV promoter and sCE2 in the rightward orientation 
of the adenoviral genome.  
An Ad5-∆24.E3 derivative CRAd expressing sCE2 was generated by 
homologous recombination in E. coli BJ5183 between Ad5-∆24.E3 viral DNA 
and EcoRV-digested pEndK-sCE2-R to form plasmid pAd5-∆24.E3-sCE2-R. 
This plasmid was digested with PacI to release the full-length adenoviral DNA 
from the plasmid backbone and was transfected into 293 cells. The CRAd 
Ad5-∆24.E3-sCE2 was harvested and further propagated on A549 cells. The 
E1A-∆24 mutation and the sCE2 insertion were confirmed by PCR on the final 
products and functional plaque forming units (PFU) titers were determined by 
limiting-dilution plaque titration on 293 cells according to standard techniques. 
All infections were normalized on the basis of PFU titers. 
 
 
CE-activity in the supernatant of adenovirus infected cells 
SW1398 cells were infected with Ad5-∆24.E3-sCE2 at a multiplicity of 
infection (MOI) of 0.3 or with a range of MOIs of Ad-sCE2. At different time 
points after infection, the supernatants were harvested and analyzed for 
esterase activity. Supernatant aliquots were incubated in 50 mM HEPES (pH 
7.4) containing 3 mM para-nitrophenyl acetate, an esterase substrate, and 
conversion was monitored at 420 nm for 5 minutes on a Bio-Rad microplate 
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reader. Data were expressed as µmol p-nitrophenol produced per milliliter of 
culture media. 
 
 
Ad5-∆24.E3-sCE2 burst size in the presence of CPT-11 
WiDr and Colo205 cells were seeded at 1.105 cells/well in 24 well plates and 
cultured overnight. The next day, the cells were infected with Ad5-∆24.E3-
sCE2 at MOI 0.01 and cultured with or without 1 µM CPT-11. After 5 and 12 
days, cells were harvested in the culture medium and subjected to three 
rounds of freeze/thawing to release viral particles. Titers were determined 
using the Adeno-XTM Rapid Titer Kit (Becton Dickinson) and a modified 
protocol. Briefly, 911 cells were plated (2,5.104 cells/well) in a 96 wells plate. 
The next day, cells were infected in triplicate with serially diluted Ad5-∆24.E3-
sCE2 samples. After 2 days, cells were fixed with methanol and stained with 
mouse anti-hexon antibody, HRP labeled rat anti-mouse antibody and DAB 
substrate. Hereafter, hexon-positive cells were counted in wells from at least 
three virus dilutions and viral titers were calculated from linear regression 
analyses. 
 
 
WST-1 cell viability assay on colon cancer cells treated with adenovirus 
and GDEPT 
Colon carcinoma cells (1.104/well) were seeded in a 96-wells microtiter plate 
(Greiner). After 24h, the medium was replaced with a dual virus mixture 
consisting of Ad-sCE2 or AdCMVHSV-TK at an MOI of 600 with Ad∆24 at a 
MOI of 1 or 10 or Ad5-∆24.E3 or Ad5-∆24.E3-sCE2 at an MOI of 1. 
Simultaneously, a concentration range of the prodrugs CPT-11 (Aventis, 
Strasbourg, France) or GCV (Roche Diagnostics, Almere, The Netherlands) 
was added. After six days of culture, the viability of the cells was determined 
by performing a WST-1 conversion assay. For that, the culture medium was 
removed and replaced by 100 µl 10% WST-1 (Roche Diagnostics) in culture 
medium. After 60-90 minutes incubation at 37°C, the A450 was measured on a 
Bio-Rad microplate reader. WST-1 conversion was expressed as percentage 
of the conversion by uninfected, untreated control cells after subtraction of 
background values in the absence of cells. 
 
 
Crystal violet cytotoxicity assay on CRAd/GDEPT treated colon cancer 
cells 
Cells were seeded at 1.105 cells/well in 24 well plates and cultured overnight. 
The next day, the cells were infected with Ad5-∆24.E3-sCE2 at the indicated 
MOI. Hereafter, cells were cultured with or without 1 µM CPT-11, with 50% 
medium changes every 2-3 days. At day 11 after infection, cells were washed 
with PBS and fixed for 10 minutes at room temperature in 4% formaldehyde in 
PBS. Cells were stained using 1% crystal violet dye in 70% ethanol for 15 
minutes at room temperature. After several washes with water, the culture 
plates were air dried and scanned on a Bio-Rad GS-690 imaging 
densitometer. 
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RESULTS 
 
TK/GCV GDEPT decreases the oncolytic potency of Ad∆24 against colon 
cancer cells 
Human colon cancer cell lines SW1398, WiDr and Colo205 were infected with 
a dual virus mixture consisting of replication deficient AdCMVHSV-TK and the 
CRAd Ad∆24 and treated with the prodrug GCV (Figure 1). In this system, the 
prodrug-converting enzyme is expressed in the context of CRAd replication. 
As controls, cells were treated with GCV only, infected with Ad∆24 and 
treated with prodrug or transduced with AdCMVHSV-TK and treated with 
GCV. After six days of culture, the viability of the cells was determined by 
WST-1 analysis.  
In all three colon cancer cell lines, treatment with GCV had no effect on 
viability, while transduction with AdCMVHSV-TK and GCV treatment was 
cytotoxic at the higher concentrations of GCV, suggesting GCV activation. 
Infection with Ad∆24 induced dose-dependent cell death that was not affected 
by GCV treatment. Sensitivity of the cells to AdCMVHSV-TK/GCV treatment 
was not affected by co-infecting the cells with Ad∆24. However, at 
concentrations of GCV below 10 µM a significant reduction in Ad∆24 oncolytic 
toxicity on AdCMVHSV-TK transduced cells became apparent.  Thus, the 
combination of Ad∆24 replication and HSV-TK/GCV GDEPT did not lead to 
enhanced colon cancer cell death. Instead, at low GCV concentrations, HSV-
TK/GCV GDEPT decreased the anti-cancer effect of Ad∆24. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Exogenous expression of TK combined with GCV treatment decreases the 
oncolytic potency of Ad∆24 against colon cancer cells. Three colon cancer cell lines 
(SW1398, WiDr Colo205) were infected with AdCMVHSV-TK at MOI 600 or with 
Ad∆24 at MOI 1 or 10, or with dual virus mixtures and treated with GCV as indicated. 
After 6 days, the viability of the cells was determined with WST-1 and results are 
expressed as % of the untreated control cells. In all three cell lines, combination 
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treatment consisting of AdCMVHSV-TK, Ad5∆24 and non-toxic concentrations of 
GCV was less effective than Ad∆24 treatment only. At higher concentrations of GCV, 
the efficacy of dual virus mixture was comparable to AdCMVHSV-TK/GCV only. 
 
 
sCE2/CPT-11 GDEPT enhances the oncolytic potency of Ad∆24 against 
colon cancer cells 
Similar combination experiments as described above were done with mixtures 
of replication deficient Ad-sCE2 expressing a secreted variant of human 
carboxylesterase and Ad∆24 plus CPT-11 prodrug (Figure 2). CPT-11 was 
toxic to the cells at concentrations above 1 µM and Ad-sCE2 sensitized the 
cells to CPT-11 at lower concentrations. CPT-11 treatment did not affect the 
oncolytic function of Ad∆24. Co-infection with Ad∆24 and Ad-sCE2 without 
CPT-11 treatment was as toxic as Ad∆24 infection alone. Most importantly, 
Ad∆24 plus Ad-sCE2/CPT-11 treatment showed a CPT-11 dose-dependent 
increase in cytotoxicity. At 0.1 to 1 µM CPT-11, Ad∆24 plus GDEPT was as 
effective or more effective than Ad∆24 virotherapy at a 10-times higher viral 
dose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Exogenous expression of sCE2 in colon carcinoma cells and treatment 
with non-toxic concentrations of CPT-11 enhances the oncolytic efficacy of Ad∆24. 
SW1398, WiDr and Colo205 were infected with Ad-sCE2 at MOI 600 or with Ad∆24 
at MOI 1 or 10, or with dual virus mixtures and treated with CPT-11 as indicated. The 
viability of the cells was determined after 6 days, as described in the legend to figure 
1. Ad∆24-infected cells expressing sCE2 were sensitized to CPT-11 treatment. 
 
 
Next, we conducted similar combination experiments with sCE2/CPT-
11 and Ad5-∆24.E3. In contrast to Ad∆24, Ad5-∆24.E3 contains an intact E3 
region, which encodes the adenoviral death protein that promotes cytolysis 19. 
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In addition, E3 proteins contribute to virotherapy efficacy in vivo 20. 
Consequently, Ad5-∆24.E3 is more potent than Ad∆24. Combination 
experiments showed that the efficacy of Ad5-∆24.E3 could also be further 
improved by expression of sCE2 and treatment with non-toxic doses of CPT-
11 (Figure 3). Hence, in contrast to HSV-TK/GCV GDEPT, sCE2/CPT-11 
GDEPT enhanced the oncolytic potency of strong Ad∆24-type CRAds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: sCE2/CPT-11 treatment enhances the oncolytic efficacy of the CRAd Ad5-
∆24.E3 against colon carcinoma cells.  SW1398, WiDr and Colo205 were infected 
with Ad-sCE2 at MOI 600 or with Ad5-∆24.E3 at MOI 1, or with dual virus mixtures 
and treated with CPT-11 as indicated. The viability of the cells was determined after 
6 days, as described in the legend to figure 1. Cells expressing sCE2 and infected 
with Ad5-∆24.E3 were sensitized to CPT-11. 
 
 
Construction and characterization of sCE2 expressing CRAd Ad5-
∆24.E3-sCE2  
Based on the observations described above, we decided to construct an Ad5-
∆24.E3 derived CRAd expressing sCE2, which is schematically shown in 
figure 4A. Insertion of the sCE2 expression cassette into the adenoviral 
genome, creating a virus with an approximate 108% wild type genome size, 
did not affect propagation efficiency (not shown). Proper expression of sCE2 
by the new CRAd Ad5-∆24.E3-sCE2 was tested by infecting SW1398 cells at 
low MOI and measuring CE-activity in the supernatant of infected cells at 
different time points after infection. As expected, extracellular CE-activity 
increased in time, as the CRAd replicated and spread in the culture (Figure 
4B). In the same experiment, SW1398 cells were transduced with the 
replication deficient adenovirus Ad-sCE2 at various MOIs.  As can be seen in 
figure 4C, a more than 300-fold higher MOI of the replication deficient vector 
was needed to obtain comparable CE-activity in the supernatant at day 5 after 
transduction.  
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To analyze the effect of sCE2/CPT-11 enzyme prodrug therapy on viral 
replication, Colo205 and WiDr cells were infected with Ad5-∆24.E3-sCE2 at 
low MOI and the viral titer was determined 5 and 12 days later.  As can be 
seen in figure 5, CPT-11 treatment decreased the viral output from Ad5-
∆24.E3-sCE2 infected cells up to 300-fold. Virus expansion from day 5 to 12 
post-infection was decreased by 10-fold. Thus, sCE2/CPT-11 GDEPT 
inhibited CRAd propagation. 
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Figure 4: Construction
and characterization of
Ad5-∆24.E3-sCE2. (A)
Schematic presentation
of the conditionally
replicating adenoviruses
used in this study. (B)
SW1398 cells were
infected with Ad5-
∆24.E3-sCE2 at MOI 0.3
(squares) or mock
treated (diamonds) and
the CE-activity in the
medium was determined
at days 1, 2, 4 and 5 after
infection. (C) Comparison
of the CE-activity in the
medium 5 days after
infection of SW1398 cells
with Ad5-∆24.E3-sCE2 at
MOI 0.3 or with
replication deficient Ad-
sCE2 at various MOI.
Data represent mean
values +/- SD of an
experiment performed in
quintuples. 
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Figure 5: The replication of Ad5-∆24.E3-sCE2 is inhibited by CPT-11 treatment. 
Colo205 and WiDr cells were infected with Ad5-∆24.E3-sCE2 at MOI 0.01 and 
treated with CPT-11. At days 5 and 12 after infection the viral titer was determined. 
 
 
Ad5-∆24.E3-sCE2 exhibits enhanced cytotoxicity against colon cancer 
cell lines when combined with CPT-11 treatment 
To determine the cytotoxic potency of Ad5-∆24.E3-sCE2, human colon cancer 
cell lines were infected with Ad5-∆24.E3-sCE2 or with the parent control virus 
Ad5-∆24.E3 and treated with CPT-11. After six days, viability of the cells was 
determined by WST-1 assay. Figure 6 shows that in the absence of CPT-11, 
sCE2 transgene expression did not change CRAd oncolytic potency on 
Colo205 and SW1398 cells and only slightly enhanced killing of WiDr cells. 
Most importantly, Ad5-∆24.E3-sCE2, but not Ad5-∆24.E3, sensitized colon 
cancer cells to CPT-11. At an MOI at which Ad5-∆24.E3-sCE2 and its parent 
Ad5-∆24.E3 were only mildly toxic, addition of a non-toxic concentration of 1 
µM CPT-11 killed 60-80% of Ad5-∆24.E3-sCE2-infected colon cancer cells.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: CPT-11 increases the anti-tumor effect of Ad5-∆24.E3-sCE2 against colon 
cancer cells. SW1398, WiDr and Colo205 cells were infected with Ad5-∆24.E3 or 
Ad5-∆24.E3-sCE2 at MOI 1 and treated with CPT-11. At non-toxic concentrations, 
CPT-11 enhanced the oncolytic effect of Ad5-∆24.E3-sCE2, but not of the parental 
virus Ad5-∆24.E3. 
1.00E+00
1.00E+01
1.00E+02
1.00E+03
1.00E+04
1.00E+05
1.00E+06
1.00E+07
1.00E+08
1.00E+09
Colo205 WiDr
tit
er
 iu
/m
l Day 5
Day 5 + CPT-11
Day 12
Day 12 + CPT-11
 
0
20
40
60
80
100
120
0.00 0.01 0.10 1.00 10.00
0
20
40
60
80
100
120
0.00 0.01 0.10 1.00 10.00
0 
20 
40 
60 
80 
100 
120 
0.00 0.01 0.10 1.00 10.00 
µ M CPT-11
Vi
ab
ilit
y 
% 
of 
co
ntr
l
Ad5 - ∆ 24.E3
Ad5 - ∆ 24.E3 - sCE2 
uninfected
uninfected 
Ad5 - ∆ 24.E3 
Ad5-∆24.E3
Ad5 - ∆ 24.E3 - sCE2 Ad5-∆24.E3-sCE2
SW1398                  WiDr     Colo205 
uninfected 
Chapter 5 
 114
To study oncolytic replication of the new CRAd Ad5-∆24.E3-sCE2 in the 
continued presence of CPT-11, colon cancer cell lines were infected with Ad5-
∆24.E3-sCE2 at low MOI and cultured in the presence of a non-toxic 
concentration of CPT-11 or in plain medium. At several days post infection, 
cells that had survived the treatment were stained with crystal violet. This 
revealed a progressive destruction of all monolayers by replicating Ad5-
∆24.E3-sCE2. After 11 days, surviving cells were stained with crystal violet. 
Figure 7 shows more prominent plaques indicative of lytic replication in the 
absence of CPT-11, suggesting CRAd propagation inhibition by sCE2/CPT-11 
GDEPT. However, it can also be seen that Ad5-∆24.E3-sCE2 eradicated 
monolayers of all three colon cancer cell lines more effectively in the presence 
of a non-toxic dose of CPT-11. Hence, despite the inhibitory influence of 
sCE2/CPT-11 GDEPT on CRAd propagation, CRAd/GDEPT combination 
therapy was still more effective than either treatment alone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
Combining CRAd virotherapy with GDEPT is under evaluation for effective 
anti-cancer treatment. Previously, HSV-TK/GCV GDEPT has been tested in 
the context of E1B-55kD deleted CRAds 9,10 or wild type adenovirus 11,13,14. In 
general, these studies showed that HSV-TK/GDEPT primarily enhanced the 
oncolytic potency of severely attenuated E1B-55kD deleted CRAds, whereas 
the anti-tumor efficacy of more potent wild type viruses decreased when 
combined with TK/GCV GDEPT. Interestingly, Nanda et al. found that 
although TK/GCV treatment completely abrogated wild type adenovirus 
replication when administered concomitantly, it significantly enhanced the 
oncolytic potency of wild type adenovirus when GCV administration was 
started one or two days after virus injection 21. Virotherapy has also been 
combined with HSV-TK/GCV and cytosine deaminase (CD)/5-FC double 
GDEPT. Freytag et al. showed that an E1B-55kD deleted CRAd expressing a 
fusion gene consisting of CD and TK was quite effective in killing cancer cells 
in vitro when combined with GCV or 5-FC, which effect could be further 
augmented by irradiation 22. Interestingly, these effects occurred at prodrug 
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Figure 7: Ad5-∆24.E3-sCE2
replicates in colon cancer cells
in the continuous presence of
CPT-11. SW1398, Colo205 and
WiDr cells were infected with
Ad5-∆24.E3-sCE2 at the
indicated MOI and cultured with
or without 1 µM CPT-11. At day
11 after infection, attached cells
were stained with crystal violet.
Combination treatment was
more effective than virotherapy
alone. 
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concentrations that inhibited adenovirus replication, suggesting that the CRAd 
acted merely as an effective prodrug-converting gene transfer vector. 
Furthermore, combination therapy of colon cancer cells with an E1B-55kD 
deleted CRAd expressing the enzyme nitroreductase and the prodrug 
CB1954 also demonstrated that prodrug treatment can inhibit viral replication 
15. Recently, Stubdal et al. incorporated the rabbit CE gene into an E1B 
deleted CRAd 12. In vitro, this virus exhibited increased toxicity on a colon 
carcinoma cell line in the presence of CPT-11 compared to control virus.  
However, treatment with CPT-11 did not enhance survival of mice carrying 
CRAd-CE injected subcutaneous colon cancer xenografts. In the aggregate, 
previous results suggest that arming CRAds with transgenes for GDEPT can 
improve their oncolytic potential. However, careful evaluation of CRAd 
efficacy enhancing versus abrogating activities of GDEPT is needed. 
Apparently, in the context of virotherapy, there is a delicate balance between 
GDEPT induced cancer cell death and GDEPT mediated impairment of viral 
replication.  
Since the aim of arming CRAds with therapeutic genes such as those 
encoding prodrug-converting enzymes is to augment their anti-cancer 
potency, studies into combining CRAds and GDEPT are most useful if they 
are performed with the most powerful types of CRAds. Therefore, we studied 
whether the CRAd Ad∆24, which is much more potent than E1B-deleted 
CRAds 17, could be further improved by combinations with HSV-TK/GCV or 
sCE2/CPT-11 GDEPT. To this end, we used an in vitro adenovirus-mixing 
model where cells are transduced with Ad∆24 and a replication deficient 
adenovirus expressing TK or sCE2.  Using this model, we could select a 
suitable CRAd-GDEPT combination prior to actually constructing the CRAd 
expressing the prodrug-converting enzyme. Hence, the mixing model could 
proof useful for quick evaluation of other CRAd-GDEPT systems as well. 
We found that HSV-TK/GCV GDEPT decreased treatment efficacy, 
which was in line with earlier studies showing that HSV-TK/GCV GDEPT did 
also not work in combination with wild type adenovirus 11,13,14. It can thus be 
concluded that GCV/TK GDEPT is not suitable to improve the efficacy of 
potent CRAds. In contrast, expression of sCE2 in the context of Ad∆24 
replication combined with CPT-11 treatment increased the efficacy of 
virotherapy. This was also true for Ad5-∆24.E3, a more potent Ad∆24 variant 
that retains the E3 region 19. Therefore, we constructed Ad5-∆24.E3-sCE2, a 
derivative of Ad5-∆24.E3 expressing sCE2. This new CRAd differs materially 
from the previously described E1B deleted CE-expressing CRAd ONYX-713 
12 in that Ad5-∆24.E3-sCE2 is a derivative from the more potent CRAd Ad∆24 
and that it encodes a secreted form of human CE-2 instead of an intracellular 
form of rabbit CE. 
Ad5-∆24.E3-sCE2 replicated efficiently in human colon cancer cells 
and expressed high levels of functional sCE2 protein. In the presence of CPT-
11, however, Ad5-∆24.E3-sCE2 viral propagation rate was markedly 
decreased. This observation can perhaps be explained by the fact that the 
active drug SN-38 that is produced through sCE2-mediated conversion of 
CPT-11 inhibits topoisomerase I, which has been demonstrated essential for 
viral replication 23,24,25. Nevertheless, sCE2/GCV GDEPT enhanced the 
efficacy of Ad5-∆24.E3 against colon cancer cells. This increased efficacy of 
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combination treatment is probably due to a strong bystander effect of the 
secreted prodrug-converting enzyme causing toxicity of extracellularly 
converted CPT-11 to uninfected neighboring cells.  Such a bystander effect 
will contribute to the observed virus propagation inhibition, as cells already 
affected by SN-38 prior to Ad5-∆24.E3-sCE2 infection will not support CRAd 
replication. Therefore, treatment regimens might perhaps be optimized by 
delayed administration of CPT-11. 
 Several further improvements to CRAd-sCE2/CPT-11 treatment can be 
foreseen. First, double E1A mutant CRAds have been described with a more 
stringent replication pattern than Ad∆24 26,27. The selectivity of the CE-
expressing CRAd might thus be improved by using such viruses as 
backbones. Second, selective expression of the transgene in cancer cells 
could contribute to diminishing GDEPT cytotoxicity to non-malignant cells. 
Such can be accomplished by driving the expression of the prodrug-
converting enzyme by a cancer cell specific promoter or by the endogenous 
adenovirus major late promoter 28. Third, leakage of sCE2 from the tumor, 
potentially causing systemic toxicity, can be prevented by constructing a 
fusion protein consisting of sCE2 and an scFv antibody directed to a tumor 
antigen 29.  
In conclusion, we have demonstrated that, in contrast to HSV-TK/GCV 
GDEPT, sCE2/CPT-11 GDEPT can be used to augment the anticancer 
potency of already very effective Ad∆24-type CRAds. This warrants further 
evaluation of CRAd plus sCE2/CPT-11 GDEPT strategies for colorectal 
cancer.  
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SUMMARY 
 
Standard treatment modalities for colorectal cancer include surgery and 
chemotherapy. Oxaliplatin is a novel platinum-based drug and is approved for 
the treatment of colorectal cancer. However, the success of chemotherapy as 
single treatment modality is still limited and therefore novel combination 
treatment modalities are warranted. Conditionally replicative adenoviruses 
(CRAds) selectively replicate in and thereby kill cancer cells. CRAds have 
shown limited efficacy as single modality treatment in clinical trials. Combining 
CRAds with conventional chemotherapy resulted in synergistic efficacy in a 
range of tumors. Here, we compared the anti tumor efficacy of two different 
CRAds on colon cancer cells, i.e., Ad∆24 that selectively replicates in cancer 
cells with a defective pRb pathway and its p53-expressing derivative Ad∆24-
p53. Furthermore, we investigated combination treatment of these CRAds 
with oxaliplatin. We found that Ad∆24-p53 was more oncolytic than Ad∆24 
against all tested colon cancer cell lines, with Ad∆24-p53 achieving 
comparable effects at a 4-20-fold lower dose. In combination with a sub-toxic 
concentration oxaliplatin, Ad∆24-p53 exhibited a supra-additive killing 
potency. Similar synergistic effects were observed following combination 
treatment of oxaliplatin with Ad∆24 or with the p53-expressing replication 
deficient adenoviral vector Adwtp53. This suggested that the synergy between 
Ad∆24-p53 and oxaliplatin is most likely the result of two complementing 
mechanisms, i.e., chemosensitization by p53 gene therapy and by CRAd 
replication. Combination therapy consisting of Ad∆24-p53 virotherapy and 
oxaliplatin chemotherapy thus appears very promising for the treatment of 
colorectal cancer. 
 
 
INTRODUCTION 
 
Colon cancer is the second leading cause of cancer deaths in Western 
countries. Between 20% and 50% of patients with colorectal cancer will die 
within five years of diagnosis 1, usually as a result of extensive metastatic 
disease. At the time of diagnosis, 20% of patients have metastases in the 
liver, the predominant metastatic site for colorectal cancer. Standard 
treatment for colorectal cancer includes surgery and chemotherapy. Platinum-
based drugs are among the most active anticancer agents and have been 
widely used in the treatment of colon carcinoma.  Over the last 30 years, a 
large number of platinum analogues has been synthesized to enlarge the 
spectrum of activity, overcome cellular resistance and/or reduce the toxicity of 
both first and second generation platinum drugs, like cisplatin and carboplatin 
2. Of these platinum analogues, compounds containing a diaminocyclohexane 
carrier ligand, such as oxaliplatin 3-5, have consistently demonstrated 
antitumor activity in cell lines with acquired cisplatin resistance and appear to 
be active in tumor types that are intrinsically resistant to cisplatin and 
carboplatin 6-8. Like cisplatin, oxaliplatin forms platinum-DNA adducts, but 
these adducts are bulkier and induce a greater deformation of the DNA 
structure 9,10. Consequently, oxaliplatin is more effective in inhibiting DNA 
synthesis 11,12. Despite improvements in the efficacy of chemotherapy for 
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colorectal cancer, its success is still limited by several drawbacks, including 
insufficient drug concentrations in the tumor, systemic toxicity, lack of 
selectivity for tumor cells over normal cells, and the appearance of drug-
resistant tumor cells.  Therefore, there is a need for more effective treatment 
modalities. Gene therapy approaches for colorectal cancer using conditionally 
replicative adenoviruses (CRAds), designed to selectively replicate in tumor 
cells and to destroy these cells by inducing lysis (reviewed in 13,14), have 
demonstrated promising results in preclinical models. However, the primary 
conclusion from cancer gene therapy trials with replication deficient adenoviral 
vectors is that low efficiency of gene transfer to tumor cells remains the key 
factor limiting clinical efficacy. The release of viral progeny from lysed tumor 
cells offers the potential to amplify CRAds at the site of the tumor and to 
achieve lateral spread to neighboring cells. The CRAd Ad∆24, or Addl922-
947, is a potent cytolytic agent that has a deletion of 24 bp in the adenovirus 
E1A gene, resulting in an E1A protein that cannot bind to the cellular 
retinoblastoma protein (pRb) 15,16. pRb modulates the cell cycle by regulating 
progression from G1 into S-phase. Wild type E1A binds to pRb thereby 
releasing the transcription factor E2F that can subsequently activate cell cycle 
regulatory genes. This allows S-phase entry and virus replication in otherwise 
quiescent cells. Because Ad∆24 is defective in sequestering pRb from E2F, 
its replication depends on E2F being released via other mechanisms. In most, 
if not all, cancer cells this is the case through pRb deficiency, pRb 
hyperphosphorylation, or pRb sequestration by cellular or viral proteins 
associated with malignancy 17. Therefore, Ad∆24 should be unable to 
replicate in normal tissues, whereas its replication is not hampered in tumor 
cells. Previously, we constructed a derivative of Ad∆24, Ad∆24-p53 that 
contains a constitutive expression cassette for the tumor suppressor protein 
p53. On most tested cancer cell lines, Ad∆24-p53 exhibited enhanced 
oncolytic potency compared to Ad∆24 18. The superior anti-cancer efficacy of 
Ad∆24-p53 was further corroborated on primary heterogeneous glioma 
specimens and in xenograft animal models 19,20. 
Multimodality treatments are usually more effective against cancer than 
single treatments. Several studies have already been performed combining 
virotherapy with chemotherapy. In lung cancer cell lines and primary cultures 
as well as in prostate cancer cells, CRAds worked synergistically with the 
platinum-based anticancer agent paclitaxel 21,22.  
Therefore, in this study we tested the efficacy of the strong CRAd 
Ad∆24-p53 in combination with the improved platinum-based drug oxaliplatin 
against colon carcinoma cell lines.  
 
 
MATERIALS AND METHODS 
 
Cells and culture conditions 
The colon cancer cell lines SW1398, Colo205 and WiDr were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% Fetal 
Calf Serum (FCS), 50 IU/ml penicillin and 50 µg/ml streptomycin (Invitrogen, 
Breda, The Netherlands), at 37°°C in a 5% CO2 humidified atmosphere.   
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Recombinant adenoviruses 
Ad∆24 and Ad∆24-p53 18 are conditionally replication competent 
adenoviruses that both contain a 24 bp deletion in the E1A region, resulting in 
selective replication in tumor cells. Both viruses lack the E3 region. Ad∆24-
p53 carries an SV40 early promoter driven p53 expression cassette in place 
of the E3 region. The E1/E3 deleted replication deficient adenoviral vector 
Adwtp53 23 carries the same expression cassette in place of E1. The 
replication deficient adenovirus was propagated on the permissive cell line 
293, whereas the CRAds were propagated on the lung cancer cell line A549. 
All viral aliquots were stored at -80°C until use. Adenovirus titers (pfu/ml) were 
determined by limiting dilution assay on 293 cells. 
 
 
In vitro cytotoxicity assays 
Colon carcinoma cells (1.104/well) were plated in a 96-wells microtiter plate 
(Greiner). After 24h, cells were transduced with various multiplicities of 
infection (MOI) of Ad∆24 or Ad∆24-p53 in 100 µl culture medium as indicated. 
Alternatively, cells were transduced with the replication deficient adenovirus 
Adwtp53 at an MOI of 300 pfu/cell. For combination experiments with 
chemotherapy, different concentrations of oxaliplatin were administered to the 
cells simultaneously with the virus. After 6 or 7 days, cell viability was 
determined by WST-1 (Roche Diagnostics, Mannheim, Germany) conversion 
at 37°C. The culture medium was removed and replaced by 100 µl of 10% 
WST-1 in culture medium. After 1h incubation at 37°C, the A450 was 
measured on a Bio-Rad model 550-microplate reader. WST-1 conversion was 
expressed as a percentage of conversion by uninfected, untreated control 
cells, after subtraction of the background values of WST-1 incubated in the 
absence of cells. 
To determine treatment interactions, the values of fraction of cell growth 
affected by drug dosage were subjected to the multiple drug effect analysis of 
Chou and Talalay 24. Using the Calcusyn software, the combination index (CI) 
was determined 25. A CI value below 0.9, between 0.9 and 1.1 or above 1.1, 
indicates synergism, additive effects and antagonistic effects respectively. 
 
 
RESULTS 
 
Ad∆24-p53 has more oncolytic potency than Ad∆24 against colon 
carcinoma cell lines 
To compare the anti-tumor efficacies of Ad∆24 and Ad∆24-p53 on colon 
carcinoma cell lines, cytotoxicity experiments were performed in which 
SW1398, Colo205 or WiDr cells were infected with a dose range of virus (MOI 
0.03 to 100). Seven days later, cell viability was determined by WST-1 
analysis (Figure 1). In all three colon carcinoma cell lines, Ad∆24-p53 caused 
cell death at lower viral dose than Ad∆24, indicating that Ad∆24-p53 
replicated faster in these cells than the control virus lacking p53. Approximate 
IC50 values were used to compare the potencies of the two CRAds. On 
SW1398 and Colo205 cells, the oncolysis enhancement by p53 expression 
was approximately 20-fold, whereas on WiDr cells this was approximately 4-
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fold. Thus, Ad∆24-p53 was more potent than Ad∆24 in killing colon carcinoma 
cell lines in vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Ad∆24-p53 exhibits enhanced oncolytic potency compared to Ad∆24 on 
colon carcinoma cells. SW1398, Colo205 or WiDr cells were infected with Ad∆24 or 
Ad∆24-p53 at the indicated multiplicity of infection. Cell survival was determined by 
WST-1 conversion assay after 6 days. In all colon carcinoma cell lines Ad∆24-p53 
showed greater oncolytic potency achieving comparable effects at an up to 40 fold 
lower viral dose. 
 
 
Ad∆24-p53 and oxaliplatin show synergistic cytotoxicity against colon 
cancer cells 
To study the combined effects of Ad∆24-p53 with the anti-cancer drug 
oxaliplatin, colon cancer cells were infected with Ad∆24-p53 at a low MOI and 
treated with different concentrations of oxaliplatin. After 6 days, cell viability of 
the cells was determined by WST-1 analysis (Figure 2A). Treatment of 
Ad∆24-p53 infected cells with a low dose oxaliplatin increased the efficacy of 
virotherapy against all three cell lines. The toxicity observed after combination 
treatment was larger than the sum of the toxicities of the two separate 
treatments. In order to quantitatively evaluate the effect of combining Ad∆24-
p53 and oxaliplatin, the CI values were calculated using Calcusyn analysis at 
50%, 75% and 90% cell viability. The average CI values for SW1398, Colo205 
and WiDr were 0.8, 0.7 and 0.6, respectively. These values indicate that the 
combination of Ad∆24-p53 and oxaliplatin is synergistic in all three cell lines.  
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Figure 2: The efficacy of Ad∆24-p53 is enhanced by treatment with low dose 
oxaliplatin. SW1398, Colo205 or WiDr cells were infected with Ad∆24-p53 (A), Ad∆24 
(B) or Adwtp53 (C) at the indicated MOI and subsequently treated with oxaliplatin at 
the indicated dose. Cell survival was determined by WST-1 conversion assay after 6 
days. In all cell lines, a non-toxic concentration of oxaliplatin increased the efficacy of 
CRAd virotherapy or p53 gene therapy. 
 
 
Expression of p53 and Ad∆24 replication each sensitize colon cancer 
cells to oxaliplatin 
To investigate which component of Ad∆24-p53, i.e., oncolytic replication of the 
CRAd Ad∆24 or p53 transgene expression, synergized with oxaliplatin 
treatment, these were analyzed separately. To this end, the cells were 
infected with Ad∆24 or with Adwtp53, a replication deficient vector expressing 
p53, and treated with oxaliplatin as described above. As Ad∆24 is less 
effective than Ad∆24-p53 and as Adwtp53 does not replicate, they were used 
at 10 and 100-times higher dose, respectively. As can be seen in figures 2B 
and 2C, both viruses synergized with oxaliplatin. For the combination of 
Ad∆24 with oxaliplatin, CI values of 0.7, 0.7 and 0.5 were obtained for 
SW1398, Colo205 and WiDr respectively, all indicating synergy.  Altogether, 
these observations suggest that the three treatment components Ad∆24 
replication, p53 expression and oxaliplatin each strengthened the effect of 
both other components. 
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DISCUSSION 
 
Oxaliplatin is a new drug for the treatment of colorectal cancer. Despite 
increased efficacy of oxaliplatin compared to conventional cytotoxic drugs for 
the treatment of colorectal cancer, there is still a need for more effective 
treatment modalities. Gene therapy approaches with CRAds in clinical trials 
that administration of these viruses to patients is a safe procedure without 
manifestation of severe side effects 26-30. Unfortunately, no objective 
responses were documented with single agent therapy. Given this degree of 
safety but inadequate efficacy, second generation viruses with greater 
potency had to be developed. To this end, CRAds were armed with various 
transgenes 31-33. Among these, expression of p53 was found to drastically 
augment the oncolytic potency of the CRAd Ad∆24 in preclinical investigations 
18.  
In this study, we confirmed that the p53-expressing derivative of 
Ad∆24, Ad∆24-p53, was more oncolytic than its parent in colon cancer cells. 
We also studied combination treatment consisting of oxaliplatin and Ad∆24-
p53. In all colon cancer cell lines tested, a non-toxic dose of oxaliplatin 
enhanced the efficacy of Ad∆24-p53 virotherapy. All three components of the 
combination treatment, i.e., the CRAd, the transgene and the 
chemotherapeutic drug were found to contribute to the efficacy of the 
treatment. This agrees with previous reports demonstrating that p53 
sensitizes colon cancer cells to chemotherapeutic agents 34,35, including 
cisplatin, and that CRAds synergies with chemotherapy in vitro, in vivo and in 
clinical trials 21,22,36,37. A theoretical explanation for the synergy between 
oxaliplatin and CRAd replication could be that chemotherapeutic drugs 
accelerate viral replication or outburst. We observed, however, that the 
number of adenoviral genomes decreased when Ad∆24 was combined with 
oxaliplatin treatment, compared to cells treated with Ad∆24 only (data not 
shown). Another potential mechanism for the synergy could be that Ad∆24 
augments the antitumor activity of chemotherapy. The adenovirus E1A protein 
is a multifunctional transcription factor believed to be a potent inducer of 
chemosensitivity through both p53-dependent and independent mechanisms 
38. Malignant tumors expressing E1A are very sensitive to treatment with DNA 
damaging agents in vivo 39-41 and this could be an explanation for the 
observed synergy between oxaliplatin and Ad∆24-p53.  
In conclusion, we have demonstrated that in colon cancer cell lines 
Ad∆24-p53 is more oncolytic than the parental control virus Ad∆24. The 
efficacy of Ad∆24-p53 could be further enhanced by combining it with low-
dose oxaliplatin. Hence, combination therapy consisting of Ad∆24-p53 
virotherapy and oxaliplatin chemotherapy might have applicability for the 
treatment of colon cancer. In future experiments, we would like to test 
combination therapy consisting of Ad∆24-p53 and oxaliplatin in subcutaneous 
colon cancer xenografts in nude mice. 
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SUMMARY 
 
One of the most common types of cancer is colorectal cancer, accounting for 
13 percent of all cancer cases in both sexes. This means that each year about 
8000 persons are diagnosed with colorectal cancer in the Netherlands. 
Approximately 30% of all patients with colorectal cancer have metastatic 
disease at the time of diagnosis, additionally, 50% of early-stage patients will 
eventually develop metastatic or advanced disease. Most frequently, 
metastases of colon cancer are found in the liver. The initial treatment of 
colorectal cancer depends on the location of the tumor and its severity at the 
time of detection. The primary therapy for patients whose tumors have not 
spread to the lymph nodes is surgery with the intent to completely remove the 
tumor and cure the patient. In patients in which the cancer is present in the 
lymph nodes or the liver, surgery is combined with chemotherapy. The drug 
most widely used for the treatment of colorectal cancer is 5-Fluorouracil (5-
FU). To increase the efficacy of 5-FU many different schedules of 
administration have been developed and combination therapy of 5-FU and 
several other cytotoxic drugs has been studied. Despite these attempts, no 
survival advantage was established until the development of the newer 
cytotoxic drugs CPT-11 and oxaliplatin. 
CPT-11 (Irinotecan) is a relatively new drug for the treatment of 
colorectal cancer. Initially it was approved as second-line treatment for 
metastatic colorectal cancer, but recently it has been approved for use in 
combination with 5-FU/Leuovorin as first-line treatment for this disease. 
Administration of CPT-11 to patients is, unfortunately, limited by the 
occurrence of side effects, mainly myelosuppression and diarrhea. Since 
CPT-11 is a prodrug and needs to be converted in order to be active, a 
possible way to increase the efficacy and decrease the side effects of 
chemotherapy with CPT-11 is by using GDEPT. In GDEPT with CPT-11 the 
gene encoding the prodrug converting-enzyme carboxylesterase-2 (CE2) is 
specifically expressed by tumor cells and when hereafter the prodrug CPT-11 
is administered, it will specifically be activated in the tumor. In the first part of 
this thesis, we aimed to increase the anti-tumor effects of CPT-11 by GDEPT 
using replication deficient adenoviral vectors to express the prodrug 
converting enzyme CE2. Thereafter, the utility of conditionally replicating 
adenoviruses for the treatment of colorectal cancer combined with GDEPT or 
conventional chemotherapy, was explored. An overview of GDEPT and 
adenoviruses is given in Chapter 1. 
In vivo, for the treatment of colon cancer metastases in the liver, 
administration of adenoviral vectors can be performed via two different routes 
of administration. First, it is possible to directly inject the viral vector in colon 
cancer nodules in the liver, and as an alternative the viral vectors can be 
administered systemically by injection into the portal vein. A limitation of gene 
therapy with adenoviral vectors that express a therapeutic protein is that the 
penetration capacity of replication deficient adenoviral vectors in solid tumor 
masses is hampered. If the adenoviral vector is directly injected in the tumor, 
the virus will only infect tumor cells around the needle tract. On the other side, 
if the viral vector is administered via the portal vein, mainly hepatocytes will be 
transduced. If the gene encoding the prodrug-converting enzyme is an 
intracellular enzyme, like wild type carboxylesterase, it will thus only be 
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expressed in the cells primarily infected by the adenovirus and this will not 
likely increase the efficacy of CPT-11 treatment to a significant level. We 
therefore hypothesized that incorporating a gene encoding a secreted 
prodrug-activating enzyme might increase the efficacy of the therapy by 
enlarging the bystander effect. If the enzyme is secreted by transduced cells it 
will be able to freely diffuse to and through a solid tumor mass. If 
subsequently, the prodrug is administered it will be converted into the active 
drug throughout the whole tumor mass thereby exerting toxicity to 
untransduced tumor cells. The disadvantage of this approach is that 
theoretically the secreted enzyme might be able to diffuse from the tumor to 
the rest of the body, resulting in prodrug activation at other sites than the 
tumor and thus in unwanted side effects. To prevent these side effects, a 
secreted, tumor-targeted prodrug-activating enzyme could be used by 
constructing a fusion protein consisting of the secreted enzyme fused to a 
single chain antibody directed to a tumor antigen. 
In Chapter 2, we describe the construction and characterization of 
plasmids containing the cDNA encoding a secreted form of human liver CE2 
as well as a fully human fusion protein consisting of a single chain antibody 
against the Epithelial Cell Adhesion Molecule (EpCAM) and the secreted form 
of CE2. EpCAM is a highly suitable target antigen, because it is expressed at 
high levels on cells of many solid tumor types including colon cancer and 
tumor selective binding of monoclonal antibodies directed to EpCAM has 
been demonstrated in clinical studies. The secreted and the secreted- 
targeted protein were detected in the supernatant of transfected COS-7 cells 
and exhibited comparable enzymatic activities as determined by conversion of 
pNpAc, a substrate for esterases. Comparing these secreted proteins to 
intracellular wild type CE2, it was observed that the total esterase activity 
detected in the transfected cells plus the activity detected in the supernatant 
was much greater in cells transfected with the secreted proteins than in cells 
transfected with the wild type enzyme. Whether this was due to a greater 
amount of protein or a higher activity of the secreted enzymes is not clear. 
The targeted fusion protein was furthermore capable of specific binding to 
EpCAM expressing cells. Most importantly, both the secreted and the targeted 
form of CE2 were capable of activating CPT-11 resulting in toxicity to 
untransduced cells, which is very important for future in vivo applications.  
We anticipated that both constructs could have potential for adenoviral 
suicide gene therapy. Therefore, we constructed replication deficient 
adenoviral vectors expressing these enzymes and examined their utility. In 
Chapter 3, we describe the construction and characterization of the 
replication deficient adenoviral vector containing the cDNA encoding secreted 
EpCAM-targeted CE2 and we explore the utility of this vector in a spheroid 
model. Spheroids are small nodules of tumor cells growing in a 3-dimensional 
manner and they are of intermediate complexity between in vivo tumors and 
monolayers cell cultures. Diffusion of the fusion protein from transduced cells 
and binding to untransduced neighboring cells was demonstrated in the 
multicellular spheroid model. Furthermore, treatment of colon cancer 
spheroids with this adenovirus, Ad.C28-sCE2, and the prodrug CPT-11 
resulted in growth inhibition comparable to treatment with the active drug SN-
38.  
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In Chapter 4, we describe the construction and characterization of a 
replication deficient adenoviral vector containing the cDNA encoding the 
secreted form of human CE2, Ad-sCE2, and we evaluated the utility of this 
adenoviral vector for the treatment of osteosarcoma, the most common 
primary bone tumor in children and young adults. Ad-sCE2 transduction of 
osteosarcoma cell lines or primary cell cultures that were brought directly into 
culture after the tumor was surgically removed, sensitized the cells to CPT-11 
treatment, despite the fact that osteosarcoma hardly express the adenoviral 
receptor CAR. This suggests a very efficient bystander effect, resulting in 
toxicity to untransduced cells. Growth inhibition of established osteosarcoma 
xenografts was more effective when the tumors were injected with the 
adenovirus vector combined with CPT-11 treatment compared to CPT-11 or 
virus treatment only.  
Another way to overcome the problem of limited penetration of 
adenoviral vectors in solid tumors is using conditionally replicating 
adenoviruses (CRAds). CRAds replicate only in cancer cells and destroy 
these cells through the natural process of adenoviral replication. Via multiple 
cycles of lytic replication and lateral spread, more pronounced anti-tumor 
effect is accomplished. Unfortunately, the efficacy of CRAds as 
monotherapeutic agents in clinical trials has so far been limited. The anti-
cancer efficacy of virotherapy could, however, be synergistically improved by 
combination therapy with conventional chemotherapeutic drugs. This 
observed synergy warranted investigations into combination modalities 
consisting of virotherapy and the tumor specific GDEPT. In Chapter 5, we 
therefore investigated whether the CRAd Ad∆24, a CRAd that selectively 
replicates in cells with a dysfunctional pRb pathway, is compatible with 
carboxylesterase/CPT-11 therapy. With an in vitro adenovirus mixing model it 
was demonstrated that, in contrast to another enzyme prodrug system 
(thymidine kinase/ganciclovir), secreted CE2/CPT-11 treatment increased the 
efficacy of Ad∆24 virotherapy. Also in a more potent Ad∆24 variant, in which 
the adenoviral E3 region was retained, the efficacy of virotherapy was 
ameliorated by secreted CE2/CPT-11 enzyme prodrug therapy. Therefore, we 
constructed Ad5-∆24.E3-sCE2, a derivative of the Ad5-∆24.E3 CRAd 
expressing the secreted form of CE2. This CRAd expressed high levels of 
functional CE2 in human colon cancer cells. Most importantly, compared to its 
parental control Ad5-∆24.E3, Ad5-∆24.E3-sCE2 exhibited enhanced 
cytotoxicity if combined with non-toxic CPT-11 treatment on all colon cancer 
cell lines tested, although in the presence of CPT-11, viral replication of Ad5-
∆24.E3-sCE2 was hampered. This new CRAd, therefore, has potency for the 
treatment of patients with colorectal cancer if combined with conventional 
CPT-11 treatment. 
CRAds can thus be developed into more powerful agents by inserting 
therapeutic genes into their genome. A critical step determining the rate of 
virus replication is the release of newly formed virus from an infected cell 
through the induction of lysis at late stages of infection. A way to enhance the 
lysis is by expressing a pro-apoptotic gene, like p53. Previously, a derivative 
of the CRAd Ad∆24, Ad∆24-p53 was constructed that contains a constitutive 
p53 expression cassette. On the majority of tested cancer cell lines, Ad∆24-
p53 exhibited enhanced oncolytic potency compared to Ad∆24 1. In Chapter 
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6, we investigated whether the efficacy of Ad∆24-p53 could be further 
improved by combination treatment with the promising chemotherapeutic drug 
oxaliplatin that was recently approved for the treatment of colorectal cancer. 
In this study we confirmed that the p53-expressing variant was more oncolytic 
than the parental CRAd on colon cancer cell lines. An even higher anti-tumor 
effect was observed in vitro if Ad∆24-p53 virotherapy was combined with 
administration of non-toxic concentrations of oxaliplatin. Similar synergistic 
effects were demonstrated following combination treatment of oxaliplatin with 
Ad∆24 or with the replication deficient adenoviral vector Adwtp53. This 
suggested that the synergy between Ad∆24-p53 and oxaliplatin is most likely 
the result of two complementing mechanisms, i.e., chemosensitization by p53 
gene therapy and by CRAd replication. However, oxaliplatin did not accelerate 
CRAd replication or viral outburst, so the actual mechanism of the observed 
synergy between CRAds and oxaliplatin remains unclear. In conclusion, the 
findings described in this chapter suggest that combination therapy consisting 
of Ad∆24-p53 virotherapy and oxaliplatin chemotherapy might have 
applicability for the treatment of colon cancer.  
The following overall conclusions can be drawn from the work 
described in this thesis. Secreted or targeted forms of human liver CE2 can 
activate the prodrug CPT-11. Suicide gene therapy using replication deficient 
adenoviral vectors expressing these enzymes combined with CPT-11 
treatment caused profound anticancer effects in in vitro and in vivo models for 
colorectal carcinoma and osteosarcoma. The efficacy of this approach could 
be further improved by combining carboxylesterase/CPT-11 enzyme prodrug 
therapy with the conditionally replicating adenovirus Ad5-∆24.E3. Finally, 
combination therapy consisting of Ad∆24-p53 virotherapy and oxaliplatin 
administration is more effective in inhibiting colon cancer growth than single 
modality treatment.  
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DISCUSSION AND FUTURE PROSPECTS 
 
Colorectal cancer is the second leading cause of cancer-related deaths in the 
Netherlands, following breast cancer. The most common treatment for 
colorectal cancer is surgically removing the tumor. In order to also treat 
distant metastases, other kinds of therapies, such as chemotherapy and 
radiation therapy, are used. Relatively new treatment modalities for these 
tumors include immunotherapy, in which the body’s immune system is used to 
fight cancer. Recent approved immunotherapeutic drugs for the treatment of 
colorectal cancer are Avastin (bevacizumab) and Erbitux (cetuximab). 
Avastatin is a recombinant humanized antibody to Vascular Endothelial 
Growth Factor and is approved for combination treatment with intravenous 5-
FU-based chemotherapy as a treatment for patients with first-line - or 
previously untreated - metastatic cancer of the colon or rectum. Erbitux is a 
chimeric antibody directed to the Epidermal Growth Factor Receptor and is 
approved for combination treatment with CPT-11. Another interesting new 
therapeutic modality for the treatment of cancer is the use of gene therapy 
applications with viral vectors.  
Human gene therapy is one of the new therapeutic approaches 
emerging from molecular biology and biotechnology revolution. The aim of 
human gene therapy is to correct genetic defects or to express gene products 
that are therapeutically useful. The principle of gene therapy for genetic 
diseases has several advantages over existing therapeutic modalities. These 
include correction of the genetic cause of the disease, selective treatment of 
affected cells and tissues and long-term treatment after single application. 
Based on these theoretical principles, at the time of its first introduction a 
decade ago, gene therapy promised to be an effective and safe treatment 
modality, which would soon cure diseases and replace classical therapies. 
Due to several factors it is fair to state that until today, the progress of gene 
therapy has been slower than expected. First of all, gene therapy is a 
pioneering new therapeutic modality based on complex biological systems 
and the incomplete knowledge of the biology of the disease and the used 
vector limit the effectiveness of clinical gene therapy. Secondly, stringent and 
time-consuming safety studies are needed as well as the establishment of 
new regulatory frameworks essential to ensure safety to the patient and the 
population. Furthermore, high costs are involved in the production of clinically 
approved batches of the gene transfer vectors. Finally, if successful, gene 
therapy will be first introduced as part of a combination therapy with other, 
existing therapeutic modalities, making it difficult to prove the efficacy of gene 
therapy.  
In the last couple of years, the development of human gene therapy 
has further been hampered by a lot of negative publicity due to the occurrence 
of two tragedies. In 1999, Jesse Gelsinger died in a phase I gene therapy 
clinical trial and his death could be directly attributed to the vector used – an 
adenoviral vector. Jesse suffered from deficiency of ornithine 
transcarbamylase, a metabolic enzyme required to break down ammonia. The 
phase I trial consisted of a study in which several patients were given 
escalating doses of second-generation adenoviral vectors. Jesse received the 
highest viral dose, up to 6 x 1013 viral particles 2. Within hours of hepatic 
administration, he began to experience severe complications and died two 
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days later. Doctors later explained that, because of a previous infection, Jesse 
had had an acute immune response to the adenovirus. In the months 
following his death, FDA and NIH officials identified a host of procedural 
irregularities and problems that contributed to Jesse’s death.  
The first gene therapy success went hand in hand with the second 
tragedy and was reported in 2000 when a group in Paris succeeded in totally 
correcting children with Severe Combined Immune Deficiency (SCID), a 
disease that is characterized by a total lack of T lymphocytes and natural killer 
cells, which normally defend the body against infections 3. The patient’s blood 
stem cells were incubated with a retroviral vector carrying a normal γc gene 
and the engineered blood cells were reinfused into the patient. Unfortunately, 
about 30 months after treatment, 2 of the 10 patients developed T-cell 
leukemia and these children had to be treated with chemotherapy 4. The FDA 
subsequently halted 27 gene therapy trials. Recent findings explain why these 
two patients developed leukemia after gene therapy treatment 5,6. The γc gene 
was inserted in both patients near LMO2, an oncogene that is activated as a 
result of translocations in acute lymphoblastic leukemia, causing 
overexpression of the LMO2 protein. The data of Davé et al. demonstrate that 
the γc gene can act as an oncogene when under control of a retroviral 
promoter, meaning that insertion of the γc vector near LMO2 represents a 
double hit, and that the transduced cells are only one mutation away from 
tumor development. This implies that the treatment modality could be further 
developed into a safer gene therapy protocol, for example by modifying the 
vector in such way that it is not likely to activate juxtaposed genes. Since 
patients with SCID are forced to live in tightly-controlled, sterile "bubbles" to 
avoid threats to their non-existent immune systems and the gene therapy 
treatment improved the quality of life in such a way that the 10 treated boys in 
France were able to live a normal life, in my opinion it is very worthwhile to 
continue these kinds of gene therapy trials. All together, the latest 
developments in gene transfer research have demonstrated that there have 
been serious failures and some successes. This development may well 
parallel that of monoclonal antibody therapy in its early stages. In 1975, the 
technique to generate monoclonal antibodies was greeted with enthusiasm 
and monoclonal antibodies were predicted to have a profound effect on the 
treatment of human diseases. Indeed, these antibodies quickly became of 
great practical use in basic science and diagnostic analysis, but the early 
promise of monoclonal antibodies as therapeutic agents was slow to 
materialize. Progress in this area was hampered by a number of technical 
hurdles: therapeutically relevant targets were difficult to identify, the cost of 
producing purified biological reagents was very high and the first generation 
antibodies were themselves subject to immune responses that limited the 
efficacy and duration of the therapeutic effect. The past decade, however, has 
seen several major breakthroughs in monoclonal antibody therapeutics for 
cancer as well as other diseases. If the expansion of gene therapy parallels 
the development of monoclonal antibodies into valuable treatment modalities 
there’s still much to be expected of gene therapy. 
By far the largest proportion of gene therapy trials target cancer. For 
cancer gene therapy the basic concept is to introduce a therapeutic gene and 
its encoding product should cure or slow down the progression of the disease. 
This approach requires a technology capable of gene transfer specifically in 
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the diseased cells. To date, viral vectors have been extensively studied and 
modified to optimize them for this approach. Non-integrating viruses, like the 
adenovirus, are mainly used for the treatment of cancer. The adenoviruses 
are a family of DNA viruses that cause benign respiratory tract infections in 
humans. Advantages of adenoviral vectors are that they can transduce 
genetic material into both dividing and non-dividing cells and it is relatively 
easy to generate high-titer commercial-grade recombinant vectors. An 
interesting approach of using gene therapy for the treatment of colorectal 
cancer is to increase the efficacy of conventional cytotoxic drugs by activation 
of the drug at the site of the tumor. This approach is known as GDEPT or 
suicide gene therapy.  
The aim of this thesis was therefore to further improve the efficacy of 
chemotherapy for the treatment of colorectal cancer by combining 
conventional therapy with cytotoxic drugs with adenoviral gene therapy. In the 
first part of this thesis we tried to improve the efficacy of chemotherapy for 
colorectal cancer using GDEPT with replication deficient adenoviral vectors 
containing the cDNA encoding a prodrug-converting enzyme. An interesting 
drug for colorectal cancer is CPT-11, approved for first-line treatment of this 
disease. CPT-11 is a prodrug that needs to be activated by the enzyme 
carboxylesterase (CE). In humans, this occurs rather inefficiently, only about 
5% of the administered prodrug is indeed converted into the toxic drug SN-38. 
The most efficient enzyme to activate CPT-11 known to date is rabbit CE 7,8. 
The disadvantage of a non-human enzyme is, however, that it might elicit an 
immune response in a patient. To prevent the occurrence of an immune 
response, prodrug-converting enzymes of a human origin are used, thereby 
allowing repeated administration of the enzyme. From recent clinical trials with 
GDEPT, it is clear that the responses so far were relatively poor, probably due 
to insufficient gene transfer and limited distribution within a tumor mass 
leading to inefficient prodrug activation. To overcome these problems, 
enhancement of the bystander effect is considered to be very important. 
Therefore, the development of secreted and cell-surface tethered prodrug-
converting enzymes might result in better anti-tumor effects 9-11. The 
disadvantage of a cell surface tethered enzyme is that it will only be 
expressed on the membranes of transduced cells and not on untransduced 
neighboring cells. Secretion of prodrug converting enzymes by transduced 
cells may cause a better tumor distribution, but a potential risk of secreted 
enzymes is leakage of the enzyme into the circulation. This could be 
overcome by using secreted tumor-targeted forms of prodrug-converting 
enzymes 11.  
We indeed demonstrated that the secreted form as well as the EpCAM-
targeted form of CE2 is capable of activating the prodrug CPT-11, thereby 
exerting toxicity to untransduced cells in vitro on monolayers cell cultures as 
well as on colon cancer spheroids. These data were, however, not confirmed 
in in vivo experiments. The problem with experiments in mice to test the 
activation of CPT-11 by selective expression of CE, is that mice have very 
high esterase levels in their plasma and after systemic administration of the 
prodrug CPT-11, most of it will be directly converted in to the toxic drug by 
endogenous esterases. This results in a very small therapeutic window for 
tumor-selective activation of CPT-11. Recently, esterase deficient SCID mice 
were developed by the group of Phil Potter (unpublished results). In these 
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mice, we would like to compare the efficacy of intratumoral injections with the 
replication deficient adenoviral vectors expressing intracellular CE2 with 
secreted CE2 and with secreted EpCAM-targeted CE2 in combination with 
intravenous treatment with CPT-11. With this experiment it is possible to truly 
demonstrate that GDEPT with secreted prodrug-converting enzymes does 
indeed lead to an enlarged bystander effect compared to intracellular prodrug-
converting enzymes. Furthermore, it would then be possible to demonstrate 
that targeting the prodrug-converting enzyme to tumor cells prevents leakage 
of the prodrug-converting enzyme into the circulation and indeed leads to 
fewer side effects compared to secreted prodrug-converting enzymes. A pilot 
study with SW1398 xenografts in these esterase deficient mice demonstrated 
that after intratumoral injection with the adenoviral vector expressing secreted 
CE2, no esterase activity was detectable. Apparently, the SW1398 cell line 
grown as xenografts, is not easily transducable with adenoviruses. Possibly, 
grown as a xenograft, a tumor cell line shows an altered expression of the 
adenoviral receptor CAR. This could possibly be overcome by targeting the 
virus to tumor antigens, as described in Chapter 1. Another explanation for 
the reduced transduction efficiency in vivo could be that mucus secretion or 
the extracellular matrix in the SW1398 xenografts prevents penetration of the 
virus into the solid tumor mass. This could possibly be overcome by pre-
administration of mucin-degrading organic agents, like ethanol or acetone, 
which has been demonstrated to increase the adenoviral transduction 
efficiency in the bladder 12. However, we would first like to repeat the 
experiments in another colon cancer model, to see whether other cell lines 
are infectable in vivo by adenoviruses. In my opinion, the probability of 
generating a bystander effect will be highly increased using a secreted form of 
CE2 instead of an intracellular enzyme. The difference between secreted and 
secreted, targeted enzymes is more difficult to predict. In theory, it is most 
likely that a targeted enzyme will indeed result in a reduction of side effects 
compared to a secreted enzyme, but in the case of the fusion protein 
described in this thesis, C28-sCE2, it is not so clear. First of all, as determined 
by Senter et al., the specific activity of human liver CE2 for CPT-11 is 
insufficient for targeting strategies using conjugates for antigen-specific CPT-
11 activation 13. The fact that this enzyme has proven useful in gene therapy 
studies is most likely attributed to very high expression levels in the 
transduced cells. It is thus not really likely that by leakage of secreted CE2 
throughout the body, prodrug activation occurs resulting in toxicity to normal 
cells. The specific activity of CE2 might be improved, for example by side-
directed mutagenesis, to generate a CE2 variant that has a higher specific 
activity for CPT-11. The opposite is also possible: to develop a prodrug that is 
more suited for activation by CE2, although in my opinion the biggest 
advantage of enzyme prodrug therapy with CE2 and CPT-11 is that the 
prodrug is clinically approved for the treatment of cancer. Furthermore, an 
important point of consideration is the affinity of the targeting moiety, in our 
case the single chain Fv antibody directed to EpCAM, for its antigen. The 
influence of the affinity of an antibody on tumor uptake has been studied 
previously. Adams et al. demonstrated that tumor uptake increased 
proportionally with enhanced affinity 14. In contrast, Kievit et al. showed that 
an antibody with a very high affinity is primarily retained in the perivascular 
regions of a tumor 15. The lower affinity antibody resulted in more effective 
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tumor growth inhibition in an ovarian cancer xenografts model than the higher 
affinity antibody. In GDEPT, the affinity should be high enough to prevent 
leakage of the fusion protein into the circulation, but as low as possible to 
ensure distribution of the fusion protein throughout the whole tumor. It 
remains to be established whether the affinity of the single chain Fv antibody 
used in this study is ideal. 
An appealing way to improve the efficacy of GDEPT is using replication 
competent adenoviral vectors, as explored in the second part of this thesis. By 
arming replication-selective viruses with prodrug converting enzymes the 
therapeutic effect might be increased by a combined effect on the tumor cells 
of oncolysis and increased production of the prodrug-converting enzyme 
leading to augmented prodrug activation. On the other hand, this might also 
lead to a decreased efficacy, because it is well possible that prodrug 
activation could abrogate the viral life cycle. It has already been reported for 
other enzyme prodrug systems that  the efficacy of the therapy is only 
increased when combined with slowly replicating viruses 16-18. In this thesis, it 
is demonstrated that CE2/CPT-11 GDEPT combined with CRAd replication 
led to increased cytotoxicity to colon cancer cells because of increased 
enzyme production and thus augmented CPT-11 activation, although prodrug 
activation hampered viral replication.  
In the last chapter of this thesis the efficacy of combination therapy with 
conditionally replicating viruses and the relatively new drug for colorectal 
cancer, oxaliplatin, was explored. Oxaliplatin is not a prodrug but exerts a 
direct effect on a cell by the formation of platinum-DNA adducts, resulting in 
inhibition of DNA synthesis and finally to cell death. In this thesis it is 
demonstrated that combination therapy was more effective in inhibiting tumor 
growth than single treatment modalities.  
In conclusion, combining new gene therapeutic approaches using 
replication deficient adenoviral vectors or conditionally replicating 
adenoviruses for the treatment of cancer with conventional chemotherapy has 
prospective for further development into a highly effective treatment modality 
for this disease. The studies described in this thesis indicate that gene 
therapy remains a very good candidate to receive attention as therapeutic 
strategy for colorectal cancer. Advances in understanding the pathobiology, 
continuing basic research aimed at improving the selectivity of viral vectors 
and therapeutic genes should ultimately lead to the development of an 
effective treatment strategy for cancer. 
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SAMENVATTING 
 
Kanker ontstaat wanneer een lichaamscel genetisch ontregeld raakt en 
daardoor ongecontroleerd gaat delen. Deze ongecontroleerde celdeling leidt 
tot het ontstaan van een gezwel of tumor. De meest voorkomende vorm van 
kanker is borstkanker gevolgd door kanker aan de dikke darm (colon) en de 
endeldarm (rectum), tezamen colorectale kanker genoemd. Ongeveer 13 
procent van alle kankerpatiënten heeft deze laatste vorm van kanker. Vaak 
wordt een tumor aan de dikke darm of de endeldarm chirurgisch verwijderd. 
Helaas heeft ongeveer 30 procent van de patiënten met colorectale kanker op 
het moment van diagnose uitzaaiingen ofwel metastasen in andere organen 
in het lichaam. Deze uitzaaiingen zijn meestal niet gemakkelijk chirurgisch te 
verwijderen en derhalve worden deze ‘tumoren op afstand’ vaak behandeld 
met bestraling en/of chemotherapie. Chemotherapie houdt in dat de tumoren 
behandeld worden met giftige stoffen (cytostatica) die de groei van de 
tumoren afremmen of zelfs de tumor vernietigen. Vaak gebruikte middelen 
voor de behandeling van colorectale kanker zijn 5-fluorouracil en  leucovorin. 
Recent zijn er twee nieuwe middelen voor de behandeling van colorectale 
kanker beschikbaar gekomen, namelijk oxaliplatin en CPT-11.  
Het gebruik van chemotherapeutische middelen voor de behandeling 
van kanker heeft als nadeel dat ook gezonde cellen in het lichaam door deze 
stoffen kunnen worden aangetast; met andere woorden, ze zijn niet tumor-
specifiek. Bijvoorbeeld haarverlies en misselijkheid kunnen het gevolg zijn van 
behandeling met chemotherapie en deze bijwerkingen beperken de toe te 
dienen dosis van het cytostaticum en daardoor de effectiviteit van de 
behandeling. Een manier om deze bijwerkingen te voorkomen is om in plaats 
van de giftige (toxische) stof een niet-toxische prodrug aan patiënten toe te 
dienen. Deze niet-toxische prodrug kan door een enzym worden omgezet 
naar een actief cytostaticum. Wanneer dit enzym alleen aanwezig is in de 
tumor, zal de prodrug specifiek geactiveerd worden in de tumor en daardoor 
ontstaat lokaal een hoge dosis van het actieve cytostaticum. Dit heeft tot 
gevolg dat de algehele bijwerkingen van de chemotherapie afnemen, terwijl 
de effectiviteit van de therapie toeneemt. 
Een goed voorbeeld van een prodrug is CPT-11, de drug hierboven al 
genoemd voor de behandeling van colorectale kanker. Om actief te zijn moet 
CPT-11 omgezet worden in de drug SN-38 door het enzym carboxylesterase. 
Wanneer CPT-11 wordt toegediend aan patiënten met kanker wordt een klein 
percentage (ongeveer 5%) van het CPT-11 door carboxylesterase in de lever 
en darmen van de patiënt omgezet in de actieve drug SN-38 en dit heeft 
remming van de groei van de tumor tot gevolg. Het SN-38  veroorzaakt echter 
ook bijwerkingen, voornamelijk diarree, die de toediening van CPT-11 
beperken.  
Helaas blijft dus 95% van het toegediende CPT-11 in de prodrug-vorm 
in de patiënt aanwezig. Het hoofddoel van het hier beschreven promotie-
onderzoek richt zich op het verbeteren van de effectiviteit van behandeling 
met CPT-11 door tumorspecifieke omzetting van de 95% van de ‘ongebruikte’ 
prodrug CPT-11. Verhoging van de hoeveelheid prodrug-omzettend enzym 
carboxylesterase in de tumor zou leiden tot verhoogde effectiviteit van de 
therapie  met CPT-11. De hoeveelheid carboxylesterase in de tumor willen we 
vergroten door middel van gentherapie.  
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Een algemeen overzicht van verschillende enzym-prodrug systemen 
en gentherapie benaderingen wordt gegeven in Hoofdstuk 1. Met behulp van 
gentherapie wordt een stukje DNA, in dit geval het DNA dat de genetische 
informatie bevat voor carboxylesterase,  in de tumor afgeleverd. Vervolgens 
gaan de tumorcellen dit stukje DNA vertalen naar een eiwit, het enzym 
carboxylesterase.  Wanneer vervolgens de prodrug CPT-11 wordt 
toegediend, zal dit in de tumor omgezet worden in de drug SN-38 en zullen 
specifiek de tumorcellen dood gaan. Voor het afleveren van het stukje DNA in 
de tumor hebben we gebruik gemaakt van een aangepast (gemodificeerd) 
adenovirus, ofwel een niet gevaarlijk verkoudheidsvirus. Het adenovirus dringt 
cellen binnen via binding aan een membraan-eiwit, zodat het DNA de gastcel, 
de tumorcel, bereikt. In het eerste gedeelte van dit proefschrift gebruiken we 
replicatie-deficiënte adenovirussen. Dit betekent dat bepaalde genen, die 
essentieel zijn voor de vermenigvuldiging (replicatie) van het virus, uit het 
adenovirus gehaald zijn. Zo’n virus is dientengevolge alleen nog maar in staat 
om een cel te infecteren en het DNA af te leveren; het virus is dus nog slechts 
een vervoermiddel voor het DNA. Het probleem met de huidige generatie 
adenovirussen is dat maar een klein percentage van alle cellen in een 
tumormassa wordt bereikt, zodat slechts een klein aantal tumorcellen het 
CPT-11 omzettende enzym carboxylesterase gaat maken. Om de effectiviteit 
van adenovirale enzym-prodrug therapie met carboxylesterase en CPT-11 
nog meer te verhogen kan men denken aan een vorm van carboxylesterase 
die uitgescheiden wordt door cellen waarin het virus met het DNA voor 
carboxylesterase is binnengedrongen. Een uitgescheiden (secretoire) vorm 
kan namelijk diffunderen door een solide tumormassa en wanneer vervolgens 
de niet-toxische prodrug CPT-11 wordt toegediend, zal dit door de hele tumor 
heen geactiveerd worden tot de drug SN-38. Dit zal niet alleen leiden tot de 
dood van de tumorcellen die door het adenovirus geïnfecteerd waren, maar 
ook kunnen de omringende, niet-geïnfecteerde tumorcellen vernietigd worden 
door de gegenereerde drug. Het theoretische nadeel van een secretoir eiwit is 
echter dat het uit de tumor zou kunnen lekken en zodoende via de bloedbaan 
in andere delen van het lichaam terecht kan komen. Wanneer hierna de 
prodrug CPT-11 toegediend wordt, zou dit weer kunnen leiden tot veel 
bijwerkingen omdat de prodrug in het hele lichaam geactiveerd wordt. Om dit 
te voorkomen kan men het secretoire carboxylesterase genetisch koppelen 
aan een stukje van een antilichaam dat specifiek bindt aan een bepaald 
celmembraan eiwit van de tumorcellen. Bij gebruik van dit construct zal het 
geproduceerde fusie-eiwit gesecreteerd worden door geïnfecteerde 
tumorcellen, waarna het fusie-eiwit door de tumor kan diffunderen en binden 
aan de celmembranen van nabij gelegen tumorcellen. Ook dan zal, wanneer 
daarna CPT-11 wordt toegediend, dit leiden tot de dood van meer tumorcellen 
dan alleen de geïnfecteerde cellen.  
In Hoofdstuk 2 hebben we de constructie en karakterisatie van een 
secretoire vorm van carboxylesterase en een fusie-eiwit bestaande uit 
secretoir carboxylesterase en het antilichaam tegen EpCAM dat op 
membranen van tumorcellen aanwezig is, beschreven. In dit hoofdstuk 
hebben we laten zien dat zowel secretoir carboxylesterase als het fusie-eiwit 
worden uitgescheiden wanneer een stukje DNA coderend voor deze eiwitten 
in dikke darmkanker-cellijnen werd ingebracht. Het fusie-eiwit bleek inderdaad 
specifiek te binden aan cellen die het molecuul EpCAM op hun 
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celmembranen hadden. Tenslotte  bleken beide eiwitten nog steeds in staat 
om de prodrug CPT-11 te activeren naar de toxische stof SN-38. 
Uit deze resultaten concludeerden wij dat het  zin heeft om deze 
eiwitten te gebruiken in combinatie met CPT-11 toediening en adenovirale 
gentherapie. Dit onderzoek werd daarom gecontinueerd met de constructie 
van replicatie-deficiënte adenovirussen die of het DNA coderend voor 
secretoir carboxylesterase ofwel secretoir, EpCAM getarget carboxylesterase 
bevatten.  
In Hoofdstuk 3 wordt de constructie en de toepassing van het 
adenovirus met het DNA coderend voor EpCAM getarget carboxylesterase in 
dikke darmkanker spheroiden beschreven. Spheroiden bestaan uit 
tumorcellen die in het laboratorium tot 3-dimensionale klompjes zijn 
uitgegroeid. Dit bleek een ideaal model om de penetratie van virussen en de 
verspreiding van gevormde eiwitten te bestuderen. In deze spheroiden 
hebben we aan kunnen tonen dat het fusie-eiwit inderdaad gemaakt wordt 
door cellen waar het adenovirus naar binnen was gedrongen. Ook konden we 
laten zien dat dit fusie-eiwit na uitscheiding door de geïnfecteerde cellen kon 
binden aan omringende niet-geïnfecteerde cellen. Het meest belangrijke 
experiment liet zien dat, wanneer we zo’n tumorklompje infecteerden met het 
gemodificeerde adenovirus en vervolgens de prodrug CPT-11 toedienden, het 
hele klompje tumorcellen vernietigd werd. 
In Hoofdstuk 4 wordt de constructie beschreven van het replicatie-
deficiënte adenovirus met het DNA coderend voor secretoir carboxylesterase 
en de toepassing van dit virus in combinatie met CPT-11 toediening voor de 
behandeling van osteosarcoma. Osteosarcoma is een zeldzame tumor van 
het bot die voornamelijk bij kinderen voorkomt. Zowel osteosarcoma-cellijnen 
als primair materiaal (dit wil zeggen tumoren die operatief verwijderd zijn uit 
patiënten en direct daarna in het laboratorium getest worden) werden 
gevoelig voor CPT-11 na infectie met het adenovirus met het secretoire 
carboxylesterase. Deze resultaten konden ook bevestigd worden in 
experimenten met zogenaamde ‘naakte’ muizen (dit zijn muizen met een 
verzwakt immuunsysteem) die humane osteosarcoma-tumoren hadden. 
Een andere manier waarop de penetratie van een adenovirus in een 
solide tumormassa verbeterd zou kunnen worden is het gebruik van 
conditioneel replicerende adenovirussen ofwel CRAds en dit wordt 
beschreven in het tweede gedeelte van dit proefschrift. CRAds zijn 
adenovirussen die zich, door genetische aanpassingen, wel in tumorcellen, 
maar niet in normale, gezonde cellen kunnen vermenigvuldigen. Wanneer 
een CRAd een tumorcel infecteert, zal het virus in deze cel gaan repliceren. 
Uiteindelijk gaat de cel dood en vervolgens komen er duizenden nieuwe 
virusdeeltjes vrij die op hun beurt weer nieuwe tumorcellen kunnen 
vernietigen. Dit type adenovirus is al toegepast in klinische trials bij patiënten 
met verschillende soorten kanker. Het bleek dat de effectiviteit van CRAds 
enorm verbeterd kon worden door combinatie-behandeling met conventionele 
chemotherapie. Wij waren daarom zeer geïnteresseerd in de combinatie van 
CRAds met tumor-specifieke chemotherapie met CPT-11 en het enzym 
carboxylesterase.  
In Hoofdstuk 5 wordt de constructie beschreven van een CRAd die 
tevens het DNA bevat voor het secretoire carboxylesterase. Dikke 
darmkanker-cellijnen die geïnfecteerd werden met dit virus bleken hoge 
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hoeveelheden carboxylesterase te maken. Wanneer de cellijnen vervolgens 
ook behandeld werden met de prodrug CPT-11, zagen we dat dit de 
effectiviteit van de therapie nog meer vergrootte.  
Alle bovenstaande virussen, zowel de replicatie-deficiënte als de 
conditioneel replicerende, zouden dus mogelijk van toepassing kunnen zijn bij 
de behandeling van dikke darmkanker in combinatie met toediening van de 
prodrug CPT-11. 
De effectiviteit van CRAds bleek dus te verbeteren door er genen in te 
brengen die een extra therapeutisch effect hebben. Een kritische stap die de 
effectiviteit van virus-therapie bepaalt, is het snel vrijkomen van nieuwe 
virusdeeltjes. Hoe langer dit duurt, hoe lager de effectiviteit van de therapie 
zal zijn, omdat er snel na toediening van het virus een immuunrespons in de 
patiënt  op gang komt, die het virus elimineert. Een manier om het vrijkomen 
van nieuwe virusdeeltjes te versnellen is door een gen in te brengen in de 
CRAd die dit proces versnelt, bijvoorbeeld het eiwit p53. Het eiwit p53, dat 
ook wel ‘bewaker van het  genoom’ genoemd wordt, kan een cel zelfmoord 
laten plegen wanneer dit nodig is, bijvoorbeeld bij schade aan het DNA. 
Vrijwel alle tumorcellen hebben dit eiwit niet meer, waardoor ze constant door 
blijven groeien. In het laboratorium is een CRAd gemaakt die het eiwit p53 tot 
expressie brengt. Uit onderzoek in het laboratorium bleek dat de CRAd met 
het gen coderend voor p53 inderdaad effectiever is dan de CRAd zonder p53 
op vele verschillende soorten kankercellijnen, waaronder dikke darmkanker 
cellijnen. In Hoofdstuk 6 hebben we gekeken of de effectiviteit van de CRAd 
met p53 op dikke darmkanker-cellijnen nog meer te verbeteren viel door 
combinatie-behandeling met het nieuwe cytostaticum oxaliplatin. Dikke 
darmkanker-cellijnen bleken gebaat bij toevoeging van oxaliplatin aan 
behandeling met dit virus. Verrassend genoeg werden ook vergelijkbare 
effecten op cellijnen geobserveerd wanneer we de CRAd zonder p53 
gebruikten en ook wanneer we het replicatie-deficiënte virus met p53 
gebruikten. Dit suggereert dat de positieve effecten van behandeling met de 
CRAd met p53 in combinatie met oxaliplatin het resultaat zijn van 2 
mechanismen, namelijk enerzijds dat dikke darmkanker-cellijnen gevoeliger 
worden voor oxaliplatin wanneer ze positief zijn voor het eiwit p53 en 
anderzijds dat oxaliplatin een effect heeft op de replicatie van het adenovirus. 
Ook deze combinatie zou in de toekomst gebruikt kunnen worden voor de 
behandeling van patiënten met kanker aan de dikke darm.  
Kort samenvattend: secretoire en tumor-bindende vormen van 
carboxylesterase kunnen de prodrug CPT-11 activeren. Gentherapie met 
replicatie-deficiënte adenovirussen die het DNA coderend voor deze enzymen 
bevatten, resulteert in verhoogde effectiviteit bij de behandeling van 
osteosarcoma en dikke darmkanker wanneer deze gecombineerd wordt met 
CPT-11 toediening. Dit effect was te verbeteren door combinatie met 
conditioneel replicerende adenovirussen. Tenslotte hebben we aangetoond 
dat de effectiviteit van conditioneel replicerende virussen te verhogen is door 
deze te combineren met behandeling met oxaliplatin. In conclusie, 
adenovirale gentherapie gecombineerd met (selectieve) chemotherapie lijkt 
veelbelovend voor behandeling van kanker. Nader preklinisch onderzoek is 
echter noodzakelijk om deze verworven resultaten verder te ontwikkelen in 
een hopelijk succesvolle, meer tumor-specifieke therapie, om zodoende de 
levensduur en de kwaliteit van leven van kankerpatiënten te verbeteren.  
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